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Bioactive peptides are short (2-50 residues) sequences of amino acids that exhibit a single or multiple 
activities that can have an impact on biological systems.  They can be derived from a variety of sources 
that include dietary proteins, which release peptides during digestion via digestive proteases in-vivo, or 
they can be isolated from various sources ex vivo such as plant-based proteins, animal proteins, or 
generated as a waste by-product from the meat industry.  Many peptide sequences that could be 
bioactive are found in inactive states in larger proteins. 
 
The objectives of this study were twofold; firstly, the physicochemical properties and bioactivity of 
porcine liver and placenta hydrolysates derived from waste material generated from the meat industry 
were investigated.  The hydrolysates were manufactured and supplied by Biofac A/C (Denmark).  
Secondly, a method was developed to predict the presence of bioactive peptides, which was used in the 
generation of novel synthetic peptides, using the Biofac hydrolysates as the source.   
 
The introduction and literature review (chapter 1) begins with general background information on 
bioactive peptides, including how peptides have been developed as pharmaceutical agents, nutraceutical 
peptides, and the types of bioactivities that can be demonstrated in peptides.    Bioactive peptides that 
have been investigated in the literature generally are isolated from hydrolysates of proteins from the 
above sources, and analysed for activities such as antioxidant activity, regulation of blood pressure, 
wound healing, antimicrobial, and immunomodulation.  Chapter 1 discusses the use of in silico methods 
used in the literature to characterise bioactive peptides that have been isolated.  The use of online 
resources such as databases of known bioactive peptides, and where they were isolated from, is widely 
used in the literature.  These databases, used in conjunction with in silico enzyme digestion tools, can 
be used to generate lists of peptides that theoretically exhibit bioactivity, which can then be run through 
algorithms that predict the likelihood of any given sequence being bioactive.  Finally, the source of the 
hydrolysates used in this study, and how the work undertaken can be used by Biofac to increase the 
value of their product is discussed. 
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The first results chapter (chapter 3) investigated the physicochemical properties of the Biofac 
hydrolysates.  These factors were analysed to provide information that could be utilised in the 
manufacturing process, and on how the product could be further processed, such as formulation.  The 
morphology and flow properties of the powders were analysed using microscopy, particle size analysis, 
and particle flow analysis.  Information on the molecular properties and composition of the powders 
were studied by analysing the solubility and saturation point, and the determination of the amount of 
carbohydrates present in the samples.  Finally, the molecular weight (MW) of the constituent peptides 
were investigated using SEC-MALS.  The placenta (P1) demonstrated much greater solubility than liver 
(L1), followed by the heart hydrolysate (H1).  The composition of L2 hydrolysate showed the highest 
proportion of carbohydrate (4.32%), and P1 demonstrated the least (0.62). 
 
Chapter 4 focused on the bioactivity of the hydrolysates (L1, L2, L3, P1, and P2), and the activity of 
fractions derived from the L2 sample after preparative HPLC.  The bioactivities investigated in this 
chapter were antioxidant activity (using the DPPH assay, ORAC assay, lipid peroxidation assay, and a 
cellular antioxidant activity assay), cell proliferation (cell counts and MTT assay) and wound healing 
(scratch wound assay), and an ACE inhibition assay.  It was found that the liver hydrolysates performed 
better overall as antioxidants, while placenta performed better as anti-ACE agents.  Neither sets of 
hydrolysates were found to influence cell proliferation or wound healing.  Furthermore, the peptides, 
which constitute the hydrolysates, were assessed using HPLC and an MTT assay  over a seven-day 
period and found to be stable in solution. 
 
The final results chapter (chapter 5) addressed the development of a high throughput screening method 
for bioactive peptides primarily using the online resources presented by the BIOPEP database, and the 
bioactivity prediction algorithm, Peptide Ranker.  This set of work involved the isolation of individual 
peptides from the hydrolysates (L2 and P2) using reverse-phase HPLC so the amino acid sequence 
could be discovered using tandem mass spectrometry with de-novo sequencing.  The sequences 
generated from this process were then used to discover the host protein they were from.  These proteins 
were digested in silico using the enzyme papain, with the resulting peptides crosschecked against 
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databases of known bioactive peptides.  Unreported peptides were then analysed using Peptide Ranker, 
and subsequently, four peptides that indicated a high probability of activity were selected to be 
synthesised.  The synthesised peptides (FWG, MFLF, FFNDA, and SDPPLVFVG) were analysed using 
the same techniques as in chapter 4.  It was found that FWG exhibited the greatest antioxidant activity 
followed by MFLG with FFNDA and SDPPLVFVG not demonstrating antioxidant activity at 
detectable levels.  MFLG was found to be the most potent ACE inhibitor, followed by FWG, then 
FFNDA and SDPPLVFVG.  None of the peptides exhibited any wound healing or cell proliferation 
activity. 
 
Chapter 6 covers the general conclusions, and future work related to the study as well as analysing the 
usefulness of the screening method as a tool in predicting the presence of bioactive peptides before, and 
after the production of hydrolysates.  The use of different enzymes to generate the peptides was explored 
along with utilising different algorithms for the prediction of specific bioactivity to increase the chance 
of identifying a peptide, and characterising the bioactivity.  The future work section incorporates the 






The common amino acids, the single and three letter codes, and notes on their structure are represented 
in Table IV-1. 
Table IV-1 Amino acid single, and three letter codes with a general description for each amino acid 
Amino acid One letter code Three letter code Structure 
Alanine A Ala Neutral, nonpolar side 
chain 
Arginine R Arg Basic, polar side chain 
Asparagine N Asn Neutral, polar side 
chain 
Aspartate D Asp Acidic, polar side 
chain 
Cysteine C Cys Neutral, polar side 
chain 
Glutamate E Glu Acidic, polar side 
chain 
Glutamine Q Gln Neutral, polar side 
chain 
Glycine G Gly Neutral, nonpolar side 
chain 
Histidine H His Basic, polar side chain 
Isoleucine I Ile Neutral, nonpolar side 
chain 
Leucine L Leu Neutral, nonpolar side 
chain 
Lysine K Lys Basic, polar side chain 
Methionine M Met Neutral, nonpolar side 
chain 
Phenylalanine F Phe Neutral, nonpolar side 
chain, aromatic 
Proline P Pro Neutral, nonpolar side 
chain 
Serine S Ser Neutral, polar side 
chain 
Threonine T Thr Neutral, polar side 
chain 
Tryptophan W Trp Neutral, polar side 
chain, aromatic 
Tyrosine Y Tyr Neutral, polar side 
chain, aromatic 





AAPH  - 2,2′-Azobis(2-Methylpropionamidine) Dihydrochloride 
Abs  - Absorbance 
ABTS  - 2,2'-Azino-Bis(3-Ethylbenzothiazoline-6-Sulphonic Acid 
ACE   - Angiotensin Converting Enzyme 
AUC  - Area Under the Curve 
BSEI  - Back Scattered Electron Image 
CAA  - Cellular Antioxidant Activity 
CEC  - Capillary Endothelial Cells 
CGM  - Complete Growth Media 
CID  - Collision Induced Dissociation 
DCF  - 2′, 7′-Dichlorofluorescein 
DCFD  - 2′, 7′-Dichlorofluorescein Diacetate 
DCFDA - 2′, 7′-Dichlorodihydrofluorescein Diacetate 
DMEM  - Dulbecco’s Modified Eagle Medium 
DMSO  - Dimethyl Sulfoxide 
DPPH  - 1, 1-Diphenyl-2-Picrylhydrazyl (α,α-Diphenyl-β-Picrylhydrazyl 
DT  - Doubling Time 
ECM  - Extra Cellular Matrix 
ETD  - Everheart Thornley Detector 
FBS  - Foetal Bovine Serum 
FFC  - Flow Function 
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FPLC  - Fast Protein Liquid Chromatography 
FRAP  - Ferric Ion Reducing Antioxidant Parameter Assay 
FTC  - Ferric Thiocyanate 
GI  - Gastrointestinal 
HA  - Hippuric Acid 
HAT  - Hydrogen Atom Transfer 
HBSS  - Hank’s Balanced Salt Solution 
HCl  - Hydrochloric Acid 
HEPES  - (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
HHL  - Hippuryl Histidyl Leucine 
HPLC  - High Performance Liquid Chromatography 
IC50  - Inhibitory Concentration at 50 % 
LDL  - Low Density Lipoprotein 
LM  - Light Microscopy 
MW  - Molecular Weight 
MS  - Mass Spectrometry 
MS/MS  - Tandem Mass Spectrometry 
MTT  - 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NADPH - Nicotinamide Adenine Dinucleotide Phosphate 
LC-MS/MS - Liquid Chromatography with Tandem Mass Spectrometry 
ORAC  - Oxygen Radical Absorbance Capacity 
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PBS  - Phosphate Buffered Saline 
PDL  - Population Doubling Level 
PenStrep - Penicillin-Streptomycin 
Prep HPLC - Preparative HPLC 
RCF  - Relative Centrifugal Force 
ROO+  - Peroxide Radical 
RSA  - Radical Scavenging Activity (RSA) 
RP-HPLC - Reverse Phase High Performance Liquid Chromatography 
RNS  - Reactive Nitrogen Species 
ROS  - Reactive Oxygen Species 
SET  - Single Electron Transfer 
SEC  - Size Exclusion Chromatography 
SEC- MALS - Size Exclusion Chromatography Multi-Angle Light Scattering 
SEM  - Scanning Electron Microscopy 
SHR  - Spontaneously Hypertensive Rats 
TE  - Trolox Equivalence 
TFA  - Trifluoroacetic Acid 
TRIS  - Tris(Hydroxymethyl)Aminomethane 
UV  - Ultra-Violet 
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 Introduction and Literature Review 
1.1 Project Aim and Background 
Recent trends in pharmaceutical development have seen an increased emphasis on biomolecules with 
regards to novel therapeutics.  These biomolecules include proteins, monoclonal antibodies, and 
peptides (Prueksaritanont and Tang, 2012).  With the increasing average age of the population, there is 
an ever-growing market for natural bioactive compounds with nutritional, functional and biological 
activities that are scientifically proven. Such compounds could be used as potential ingredients of 
health-promoting foods, nutraceuticals and other health supplements. Peptides are one class of 
compounds that have been shown to have a range of beneficial bioactive effects (Sánchez and Vázquez, 
2017, Danquah and Agyei, 2012 ).  In tandem with the discovery of novel compounds that exhibit 
bioactivities, the source is also of interest, specifically whether valuable compounds can be extracted 
from material that otherwise would be considered waste. 
 
The aim of this research project was to evaluate hydrolysates derived from meat waste material for 
bioactivity.  This project covers three major areas of investigation: the physicochemical structure of 
crude hydrolysates, the bioactivity demonstrated by the samples, and the analysis of the structure of the 
hydrolysates leading to the generation of novel synthetic peptides.  This work was funded by Biofac 
A/C (Denmark), the manufacturer of the hydrolysates. 
1.2 General Protein Structure 
Proteins are organised into four levels of structure, primary, secondary, tertiary, and quaternary.  
Primary structure is the sequence of amino acids connected through covalent bonds known as peptide 
bonds.  These chains of amino acids, or polypeptides, form into alpha helixes and beta sheets; these 
formations are termed secondary structure.  The three-dimensional structures that result from the folding 
of a single polypeptide chain are called tertiary structures.  The conformation of secondary and tertiary 
structures is bound together with bonds such as covalent disulphide bridges, hydrogen bonds, and van 
der Waals forces.  The final level of structure is termed quaternary.  Quaternary structures are the results 
25 
 
of multiple protein subunits (separate polypeptide chains) forming a complex.  An example of a protein 
constituted in this fashion is haemoglobin, a protein that is made up of four globular protein subunits, 
and four haem groups (iron containing molecule that bind to oxygen) (Lukin et al., 2003, Alberts et al., 
2008). 
 
Proteins that constitute soft and connective tissues are of internet concerning this project because they 
are a common source of bioactive peptides (Mora et al., 2014).  Skeletal, and cardiac muscle are both 
examples of striated muscle, which is composed of sarcomere.  The main proteins that make up 
sarcomere are myosin and actin; these proteins form the filaments that allow the muscle tissue to 
contract (shorten) and to relax (lengthen).  Collagen is the most abundant protein type in mammals, 
making up approximately 30% (Ricard-Blum, 2011).  Collagen is constructed of polypeptide chains in 
a triple helix and is found in abundance in skin, tendons, and ligaments, but is also found in significant 
amounts in muscle tissue.  The abundance of collagen in vertebrate tissue means that it is a likely source 
for bioactive peptides (Gómez-Guillén et al., 2011, Howell and Kasase, 2010) 
1.3 Biologically Active Peptides 
Peptides are short (2-50 residues) sequences of amino acids (Banga, 2015).  Generally, amino acid 
sequences that are under 10 residues long are termed oligopeptides; sequences over 50 residues long 
are regarded as proteins.  Many peptide sequences that are bioactive are found in larger proteins, but in 
an inactive state (Capriotti et al., 2015). 
 
Bioactive peptides can be derived from a variety of sources; these could be from dietary proteins that 
are then broken down in the gastrointestinal tract to release bioactive peptides, or they can be isolated 
from various sources ex vivo. Sources include plant-based proteins such as soy, and chickpeas, and 
animal proteins such as from waste from the meat industry and fish skin (Himaya et al., 2012, Lassoued 
et al., 2015, Di Bernardini et al., 2011, Fu et al., 2017, Beermann et al., 2009, Capriotti et al., 2015, Xue 
et al., 2015, Xue et al., 2012, Howell and Kasase, 2010).  Many studies have been carried out on 
bioactive peptides and their uses.  Areas of greatest interest however, are where bioactive peptides can 
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be used in either treatment of a condition or aid in a biological process.  Bioactivities that are of 
particular interest to this study are antioxidant activity, cell proliferation and wound healing, and 
regulation of blood pressure.   
1.4 Pharmaceutical Peptides 
There are three major groups of compounds that are routinely used in the treatment of diseases, small 
molecules, proteins, and peptides, with small molecules accounting for the majority of these 
therapeutics.  That being said there has been a rise in the development of peptides as drug candidates in 
recent years (Otvos, 2008).  Peptides have been used as pharmaceuticals for many years; peptide based 
vaccines against viral, and bacterial pathogens for example, were some of the earlier developed peptide 
based therapeutics. More recently, different types of conditions have subsequently been targeted with 
peptides (Otvos, 2008). 
 
For the most part, small molecules have dominated drug development, with peptides regarded as a 
poorer target, due to their susceptibility to the large array of proteases found in the human body.  The 
lack of oral availability of peptides is one of the major hurdles in development of drugs based on 
peptides and proteins, resulting in a more severe route of administration. Insulin for example, is injected 
instead of being delivered orally (Lau and Dunn, 2018).  However, peptides and proteins are integral to 
many biological processes in the body including signalling between cells and within individual cells 
(de Mejia and Dia, 2010), and it has been noted that peptides that are naturally found in biological 
systems do exhibit greater stability than would be expected for this type of molecule (Uhlig et al., 2014).  
Nonetheless, altering a peptide chemically to remove certain disadvantages is an approach taken by 
researchers in drug discovery. This process is known as peptidomimetics, the rationale behind this is 
that while peptides may be potent active compounds in their own right, their structure leads them to 
have poor bioavailability.  Thus, if an active peptide cannot reach the desired target site then it cannot 




Peptidomimetics involves the designing of molecules that mimic the active parts of peptides (in both 
structure and conformation), but removes or adds elements that lead to improved pharmacokinetics 
(Mizuno et al., 2017).  An example of changes that can be made to peptides to improve their 
pharmacokinetics is the hydrocarbon stapling method that is used to improve the ability of a peptide to 
cross lipid bilayers (Chandrudu et al., 2013).  The availability of peptide-based pharmaceuticals due to 
the advancements in development methods, and increasing limitations in the pursuit of small molecule 
candidates has therefore increased.  Examples of commercially available peptide based drugs are 
Zoladex® (goserelin acetate), which targets breast, and prostate cancer, and Fuzeon® (enfuvirtide), 
which is used in the treatment of HIV (Chandrudu et al., 2013).  The interest in therapeutic peptides has 
led to the investigations into other sources of active peptides, notably bioactive peptides found in 
proteins derived from food (Danquah and Agyei, 2012 ). 
1.5 Nutraceutical Peptides 
Bioactive peptides that are derived from proteins present in food are generally termed nutraceuticals.  
The term ‘nutraceutical’ is defined as food, or components of food that confer benefits to health as well 
as nutrition (de Mejia and Dia, 2010).  The role of nutraceuticals in health is the subject of multiple 
studies that have investigated either the composition of peptides derived from food sources, or the 
effects certain diets or supplements have on certain conditions. 
 
An example of the possible effects of a certain diet on health can be seen in the prevention of 
cardiovascular disease (Minuz et al., 2017).  An example is the prevalence of extra virgin olive oil in 
the Mediterranean diet.  Extra virgin olive oil has been shown to down regulate the enzyme nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase 2, the activity of which leads to the production of 
reactive oxygen species (ROS) (Carnevale et al., 2014).  The production of ROS through NADPH 
oxidase 2 has been linked to atherosclerosis (caused by the build-up of plaque in the blood vessels); the 
down regulation of NADPH oxidase 2 therefore can help reduce the damage that leads to cardiovascular 




The role of bioactive peptides as nutraceuticals has been extensively investigated.  In fact, peptides have 
been shown to be the most versatile group of molecules with regards to health benefits.  Activities that 
have been demonstrated in nutraceutical peptides include antioxidant, antihypertensive, antimicrobial, 
anticancer, and anti-inflammatory (Girija, 2018).  This wide variety of activities attributed to bioactive 
peptides found in nutraceuticals, and the fact that single peptides have been shown to convey more than 
one type of activity make them an interesting group of molecules to study.  The study by Himaya et al 
(2012) is an example of an investigation where the authors discovered numerous types of activity that 
could be attributed to a peptide that they were researching.  As well as angiotensin converting enzyme 
(ACE) inhibitory properties, they also investigated the protective effects of the peptide on cell 
membrane lipid peroxidation, cell membrane protein oxidation, and on cellular DNA oxidation.  They 
also investigated the effects on cell viability using MRC-5, and RAW264.7 cells using the 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  The study indicated that the 
peptide was involved in the upregulation of mRNA expression for cellular antioxidative enzymes.  This 
indicated that multiple effects can be attributed either to the same peptide, or from peptides extracted 
from one source. 
1.6 Bioactive Peptides derived from Food Proteins and Meat Waste 
There is a significant amount of literature on the benefits of bioactive peptides when used as dietary 
supplements.  Much of this focuses on bioactive peptides derived from milk and soy proteins.  These 
studies show that bioactive peptides are present in proteins found in foods, and via hydrolysis in the 
gastrointestinal tract, they are released from this non-functional state. 
 
Two studies into bioactive peptides derived from food protein were carried out by Ahmed, et al (2015), 
and Corrêa, et al (2014).  Both of these groups investigated bioactive peptides derived from milk 
proteins, with the former focusing on the release of bioactive peptides from the hydrolysis of goat milk 
proteins (specifically caseins and whey proteins) by digestive enzymes found in the gastrointestinal 
tract.  The proteins were digested with pepsin, and then lyophilised.  The protein digests were further 
processed using fast protein liquid chromatography (FPLC) and the fractions collected were assayed 
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for any antioxidant activity.  Fractions that showed good antioxidant activities were separated using 
high performance liquid chromatography (HPLC), and analysed for sequence data using mass 
spectrometry. 
 
Data from the study carried out by Ahmed, et al (2015) indicated that short peptides were found to be 
more antioxidant than longer chains, and that amphiphilic peptides seem to enhance antioxidant activity.  
It was suggested that amphiphilic peptides were more antioxidant because the hydrophobic residues 
within the peptide have high antioxidant activity, with the polar residues allowing greater solubility, 
therefore increasing the availability of the peptides in the assays.  It is noted in the study that most of 
the isolated peptides are rich in hydrophobic residues, therefore the specific sequence in the more active 
peptides is directly related to their bioactivity (Ahmed et al., 2015). 
 
The study carried out by Corrêa, et al (2014), investigated hydrolysates derived from whey produced as 
a by-product of cheese making, they hydrolysed the whey proteins using a protease isolated from 
bacteria (Bacillus sp. P7). The results showed that hydrolysed whey protein had an increased radical 
scavenging activity when compared to the non-hydrolysed protein when measured using the 2,2'-azino-
bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) assay, a greater Fe2+-chelating ability, along with 
an increase in hydrophobicity.  The data in this study relates to other studies such as the one carried out 
by Ahmed, et al. (2015), because hydrolysis time was shown to be proportional to antioxidant activity 
(up to and including 6 hours), suggesting that smaller peptides are more active.  One of the sequences 
discovered that displayed high antioxidant activity (isolated after 4 hours hydrolysis) was 
LAFNPTQLEGQCHV.  Leu (1), Ala (2), and Phe (3) at the N-terminus are all hydrophobic residues.  
The sequence also contains four more hydrophobic residues (Pro (5), Thr (6), Leu (8), and Val (13)).  
The authors highlight the presence of Val at the C-terminus as being significant because radical 
scavenging activity of bioactive peptides could be related to the availability of non-polar amino acids.  
Structural data suggests that the hydrophobic residues (LAF) at the N-terminus are exposed, and 
therefore can contribute to radical scavenging activity.  They also indicate that the CH at the C-terminus 
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are not hidden, and therefore contribute antioxidant activity due to these residues redox and metal 
chelating properties (Corrêa et al., 2014). 
 
The two studies discussed both indicate that short peptide chains, when liberated from larger proteins, 
can have significant antioxidant properties.  Furthermore, Ahmed, et al. (2015), used pepsin, an enzyme 
found in the gastrointestinal (GI) tract.  This indicates that the bioactive peptides found within proteins 
in goats’ milk can be liberated through digestion. 
 
The study carried out by Jang and Lee (2005) investigated peptides isolated from hydrolysates derived 
from beef.  They were particularly interested in peptides that could act as ACE inhibitors.  Hydrolysates 
were extracted from sarcoplasmic proteins using the enzymes thermolysin, protease A, and protease 
type XIII.  The homogenised meat samples were incubated with the enzymes over 24 hours, with time 
points for sampling at 0, 4, 8, 12, and 24 hours.  The peptides were isolated using ultrafiltration, gel 
filtration, and reverse-phase HPLC.  The purified peptide with the greatest ACE inhibition was 
sequenced using Edman degradation. 
 
The study found that the peptides with the most potent ACE inhibitory activity were from the 4-hour 
time point of the hydrolysis, with thermolysin and protease A.  The sequence of the peptide that was 
found to have the greatest ACE inhibitory activity was VLAQYK.  The authors suggest that their 
peptide shows similar properties to another study, where the hydrophobic/aliphatic V at the N-terminus 
is important to ACE inhibitory activity (other examples of aliphatic amino acids are glycine (G), alanine 
(A), leucine (L), and isoleucine (I)).  The same group evaluated their peptide in spontaneously 
hypertensive rats (SHR).  They found that groups fed the peptide showed lower concentrations of total 
cholesterol, and low-density lipoprotein (LDL) cholesterol than the control groups.  Systolic blood 





An example of bioactive peptides discovered in plant-based material is an investigation carried out by 
Capriotti, et al (2015).  This group looked at the release of bioactive peptides from simulated 
gastrointestinal digestion of proteins derived from soybeans.  Proteins were isolated from different 
sources derived from soy, which were then sequenced using nano-liquid chromatography in conjunction 
with tandem mass spectrometry (nano-LC-MS/MS).  The sequences generated from this process were 
then cross-referenced against databases of known peptides that show bioactivity.  They were 
particularly interested in bioactive peptides that were predicted to demonstrate antimicrobial properties.  
The results indicated that bioactive peptides can be generated from simulated gastrointestinal digestion 
of proteins, and that three of the sequences they had found had been reported in previous studies.  They 
also identified known bioactive peptide sequences that were contained in larger peptides.  The three 
bioactive peptides identified that were present in the databases showed ACE inhibition, and antioxidant 
properties. The bioactive peptides that were identified to be contained in longer precursor sequences 
had been shown to have either ACE inhibition, or antioxidant properties, with one having 
immunomodulating activity (Capriotti et al., 2015).  This study used bioinformatics to assess the 
peptides released from the digests.  The authors tabled the most likely candidates that had predicted 
antimicrobial activity using the online database CAMP, which uses  four machine-learning algorithms 
to analyse the peptides (Random Forests, Support Vector Machines, Artificial Neural Network, and 
Discriminant Analysis) (Thomas et al., 2010). 
 
It was noted that nine of the peptides found with predicted antimicrobial activity were derived from the 
precursor proteins glycinin, and beta-conglycinin; these proteins have been previously reported to 
reduce the growth of three pathogenic bacteria that had been inoculated into raw milk.  Gycinin was 
shown to significantly reduce the growth of the bacteria (Osman et al., 2013).  
Another interesting point that this study made was that the peptide sequences generated from the soy 
products were slightly longer than those extracted from animal sources using similar digestion methods.  
It was suggested that the presence of protease inhibitors that can be found in plant seeds could be the 




The papers discussed here investigated the generation of bioactive peptides from longer amino acid 
sequences by simulating digestion of food derived proteins in vitro, using proteases.  While the bioactive 
peptides were from different sources (dairy, meat, and plant), they all identified certain properties that 
were related.  It is therefore, reasonable to assume that bioactive peptides found in Biofac hydrolysates 
may have antioxidant activity, ACE inhibition, and even antimicrobial activity. An important 
consideration when releasing bioactive peptides from protein samples is the choice of enzyme used for 
the hydrolysis.  It has been demonstrated that the type of protease used in processing samples is related 
to the peptides produced. An example of this was highlighted by Arihara et al (2001), where they found 
that fractions produced from the digestion of porcine skeletal muscle by the enzyme thermolysin 
showed the greatest ACE inhibitory activity of the eight enzymes investigated (trypsin, alpha-
chymotrypsin, pronase E, proteinase K, thermolysin ficin, papain, and pepsin) (Arihara et al., 2001, 
Toldrá et al., 2012, Di Bernardini et al., 2011). 
 
This study is based on the analysis of hydrolysates derived from waste produced from the meat industry, 
and if any value can be extracted from such material.  The approach to producing and analysing 
hydrolysates from meat waste is similar to that of projects looking at other sources.  Typical by-products 
of meat production are meat trimmings, mechanically recovered meat, collagen, and blood.  All of these 
are constituted of proteins, which can therefore be hydrolysed using proteases to release peptides (Mora 
et al., 2014).  Regardless of the source of the proteins, the methods to extract them, and the resulting 
peptides should be the same whether they are extracted from waste, or food grade material.  The 
difference should be from the method of hydrolysis, recovery of the hydrolysate, and the isolation of 
peptides. 
1.7 Generation/isolation/identification of bioactive peptides 
Bioactive peptides can be generated by processing raw materials that contain proteins, producing 
hydrolysates that contain peptides of various size and sequence (Sánchez and Vázquez, 2017).  One of 
the more prevalent methods reported for generating bioactive peptides is the use of proteases to 
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hydrolyse lager proteins (Mora et al., 2014); this leads to peptides of differing length and structural 
conformations, that are related to their activity (Himaya et al., 2012).  Different structures, that can alter 
activity, can form in peptides of sufficient length, for example, secondary structures forming where 
hydrophobic residues move to the centre of a structure, or hydrogen bonds can form between two non-
adjacent amino acids (Möhle and Hofmann, 1998).  Different proteases will cleave peptides at different 
sites therefore, by using a specific enzyme in a single digestion (or multiple), various peptide fragments 
can be generated that have varying bioactivity (Jang and Lee, 2005). 
 
It is common for bioactive peptides to be generated from precursor proteins by enzymes that can be 
found in the gastrointestinal tract such as pepsin and trypsin, but proteases from other sources can also 
be used (such as cysteine proteases like papain).  Peptides can be isolated from the protein digests using 
a number of methods either singularly or in combination with various methods of chromatography being 
widely used.  Size exclusion chromatography (SEC) is often used as the first step in isolating peptides 
from their crude hydrolysates, the fractions generated from SEC can then be further processed using 
FPLC, and reverse phase high performance liquid chromatography (RP-HPLC).  Fractions collected 
from chromatography can then be assayed for any bioactive properties.  Fractions that show activity 
can then be further separated using HPLC, and sequenced by using mass spectrometry (MS) (Ahmed 
et al., 2015, Corrêa et al., 2014). 
 
An example of using tandem mass spectrometry (MS/MS) for the characterisation of bioactive peptides 
in the literature is the study undertaken by Jang and Lee (2005). They used SEC to separate hydrolysates 
from the marine bivalve Mactra veneriformis (using sephadex G-25 gel filtration column).  Five 
fractions were collected from the column and each were assayed for antioxidant activty.  The two most 
active fractions were then sequenced using ultra high pressure liquid chromatography, linked to 
MS/MS, using positve electrospray ionisation and collision induced dissociation (CID) mode.  From 
these two fractions, twenty one sequences were identified and the information used to synthesise these 
peptides.  The synthetic sequences were then assayed to determine their hydroxyl radical scavenging 
activies.  Using this method the authors were able to isolate, and identify specfifc bioactive peptides 
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that were antioxidants, they also highlighted that peptides rich in proton donor amino acids and 
hydrophobic amino acids can act as potent antioxidants (Jang and Lee, 2005). 
 
Sequencing bioactive peptides that have been generated by the hydrolysis of larger peptides/proteins is 
a powerful tool in identifying the molecular mechanism of activity of bioactive peptides.  Using 
chromatographic techniques, fractions of the hydrolysate can be generated, which contain peptides.  
These fractions can then be assayed for bioactivity, with active fractions undergoing MS/MS, and de 
novo sequencing to identify the sequence of the active peptide.  This structural information can then be 
used to understand peptide bioactivity (Liu et al., 2015).    
1.8 Assays used in the Analysis of Bioactive Peptides 
Fractions generated using chromatography will normally be assayed for bioactivity to assess whether 
they are suitable candidates for further investigation through sequencing.  To investigate bioactivity in 
these fractions, certain simple assays can be used.  Fractions that display good activity can therefore be 
further explored.  Once sequences are identified the peptides can be crosschecked with databases of 
known bioactive peptides and identify known bioactive peptide sequences that are contained in larger 
peptides.  Examples of activities of bioactive peptides researched in this fashion are ACE inhibition, 
antioxidant activity, immunomodulating activity, and antimicrobial activity (Capriotti et al., 2015).  The 
examples of assays discussed in this section represent the most common types of bioactivity 
investigated in relation to peptides in the literature.  
 Antioxidant activities of bioactive peptides 
Oxidative stress in biological systems is a major factor relating to cellular damage. It is caused by ROS, 
which are by-products of some of the most important biological reactions, including respiration (Gagné, 
2014).  The reduction in oxidative stress induced damage is therefore an important consideration in 




Antioxidant activity is one of the most prevalent bioactivities exhibited by peptides generated through 
hydrolysis of protein rich materials with proteases.  Antioxidant assays can be divided into two major 
types, in vitro, and in vivo.  The use of in vitro assays is useful for high throughput assays, but to 
discover if the samples being analysed are biologically available, an in vivo assay is required.  A specific 
sample may show excellent antioxidant activity in vitro, but if it cannot interact with the biological 
target, it will not be effective (Vermeirssen et al., 2007).  That being said, in-vitro assays are an 
important tool because they can screen potential targets using relatively inexpensive procedures before 
being analysed with more expensive and complex in-vivo methods.  In vitro antioxidant assays can be 
further separated into hydrogen atom transfer (HAT), and single electron transfer (SET) assays 
depending on the type of chemical reaction involved (Figure 1-1) (Huang et al., 2005).  Examples of 
antioxidant assays commonly used that involve the HAT pathway are the oxygen radical absorbance 
capacity assay (ORAC), and the lipid peroxidation assay. Examples of ET assays are the 1, 1-diphenyl-
2-picrylhydrazyl (α,α-diphenyl-β-picrylhydrazyl (DPPH) radical scavenging assay, and the ferric ion 
reducing antioxidant parameter assay (FRAP). 
 
Figure 1-1 Mechanisms of hydrogen atom transfer (HAT), and single electron transfer (SET)antioxidant pathways.  In SET an 
electron is transferred to the radical from the antioxidant, generating a radical cation, which can then form a radical.  In the 
HAT pathway a hydrogen atom is donated from the antioxidant producing a radical. 
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The antioxidant properties of various bioactive peptides have been analysed in numerous studies.  These 
studies use multiple assays to determine the antioxidative potential of different bioactive peptides.  The 
studies by Corrêa et al (2014) and Ahmed et al (2015) that have previously been discussed here 
determined that small peptides hydrolysed form larger proteins could exhibit antioxidant properties. 
 
Antioxidant properties of bioactive peptides can be assessed through various assays, some of which 
have been noted as being biologically significant to mammals.  However, some antioxidant activities 
noted in certain papers were generated using assays that have been described as not being biologically 
relevant.  In their review, Lopez-Alarcon and Denicola (2012) suggest that to thoroughly evaluate 
antioxidant ability of natural products, multiple chemical in vitro methods should be used including 
cell-based assays.  It was found that there is not a strong correlation between chemical and cellular 
assays.  The authors’ stress that it is important to assess the samples in cellular based assays after initial 
screening has been carried out to evaluate their bioavailability.  Antioxidant activity is not just related 
to the ability of a compound to scavenge ROS, and reactive nitrogen species (RNS), the up regulation 
of antioxidant enzymes is also important (López-Alarcón and Denicola, 2013).  It is therefore important 
when investigating the antioxidant activity exhibited by peptides, to cover a broad range of antioxidant 
mechanisms by performing assays that utilise different pathways. 
 
The information on antioxidant assays used to assess the capacity of peptides to reduce oxidative stress 
gathered from the literature suggests that to analyse the antioxidant activity of peptides requires the use 
of multiple assays. To reflect this, a selection of different antioxidant assays were used in this research.  
These will be discussed in section 2.26. 
 Blood pressure regulation 
Hypertension is a condition that is of growing concern in modern global healthcare.  It is the most 
important factor in relation to cardiovascular disease, with over 60% of adults over 60 years of age 
being affected (Delacroix, 2014).  Angiotensin II is a peptide that is connected with common conditions 
associated with the cardiovascular system including hypertension, and coronary heart disease (Dostal 
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and Baker, 1999).  The active form of angiotensin II, which causes the constriction of blood vessels, is 
generated by the action of ACE on angiotensin I.  The inhibition of ACE is therefore an important 
therapeutic target (Figure 1-2).   
 
ACE inhibitors were developed after the discovery of the antihypertensive effects of snake venom in 
the 1960s.  Captopril, which was discovered in the 1970s, and its subsequent approval by regulatory 
bodies in the 1980s was the first commercially available ACE inhibitor (Cushman and Ondetti, 1991).  
In the following years, numerous ACE inhibitory peptides were isolated and derived from snake venom 
(Captopril being a prominent example), that have been developed into ACE inhibitors that improved 
upon Captopril in terms of selectivity and side effects.  ACE inhibitory peptides have subsequently been 
found in food proteins (both animal and plant derived) and have been isolated by means of hydrolysis 
by proteases, and identified using HPLC and mass spectrometry(Himaya et al., 2012, Vercruysse et al., 
2005, Hong et al., 2008). 
 
 
Figure 1-2 Simplified renin/angiotensin pathway.  The active form of angiotensin II is generated by the action of angiotensin 
II converting enzyme (ACE) on angiotensin I.  The inhibition of ACE prevents the activation of angiotensin II receptors of 
vascular smooth muscles, preventing contraction. 
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A number of studies have been performed on the ability of certain peptides to inhibit ACE in vitro.  As 
discussed previously, Correa et al (2014), investigated hydrolysates derived from whey produced as a 
by-product of cheese making.  One of the aspects of the peptides they assayed was their ability to inhibit 
ACE.  Himaya et al (2012), and Jang and Lee (2005) investigated ACE inhibition caused by bioactive 
peptides. 
 
Himaya et al (2012) isolated an active peptide from Pacific cod skin gelatin, a waste product of the 
fisheries industry, using gastrointestinal enzymes (pepsin, trypsin, and alpha-chymotrypsin) to 
hydrolyse the protein.  The isolated peptide sequence was LLMLDNDLPP, which was shown to have 
potent non-competitive ACE inhibition, and showed antioxidant properties (Himaya et al., 2012).  Their 
findings relate to other studies discussed previously in that peptides generated by hydrolysis using 
gastrointestinal enzymes contain hydrophobic residues at specific positions in the sequence.  They 
highlight that the presence of branched chain aliphatic amino acids at the N-terminus (leucine and 
methionine), and that the proline and leucine residues at the C-terminus are what enables the peptide to 
be a potent ACE inhibitor.  It is suggested that the lower molecular weight of digested peptides not only 
ensure that bioactive sequences are exposed, but that they are also more biologically available because 
they can easily be absorbed into the body (Himaya et al., 2012). 
 
The findings of Himaya et al (2012) echo that of the one carried out by Jang and Lee (2005), analysing 
peptides derived from meat waste, discussed previously.  They found that the sequence of the peptide 
with the greatest ACE inhibitory activity was VLAQYK, with the valine (a branched chain aliphatic 
amino acid) at the N-terminus enabling the ACE inhibitory activity of the peptide (Jang and Lee, 2005).  
The fact that the peptides isolated in each study end in hydrophobic residues appears to be the significant 
factor in activity.  The large aromatic side chain of tyrosine could also cause steric interference, if the 
smaller aliphatic valine binds to the ACE. 
 
The ACE inhibitory activity assessed by the two studies discussed here was determined using the 
Cheung and Cushman (1971) method, which utilises he ACE specific substrate hippuryl histidyl leucine 
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(HHL).  The hydrolysis of HHL results in the product hippuric acid (HA) by ACE, is used to measure 
the activity of the enzyme by detecting the amounts of HA in relation to HHL by ultra-violet (UV) 
spectrophotometry.  Reduction in HA production when the reaction mixture contains ACE inhibitors is 
used to assess their functional ability (Cushman and Cheung, 1971).  Improvements to this assay have 
been undertaken in other studies, such as the use HPLC as the method of detection, increasing the 
sensitivity of the assay (Meng et al., 1995). 
 
The study carried out by Lassoued et al (2015), investigated hydrolysates from thornback ray skin.  
Directing their research towards ACE inhibition and antioxidant activity, sequences isolated were 
assayed before being synthesised to confirm their activity in vitro.  They found the most active ACE 
inhibitor to be GIPGAP (Lassoued et al., 2015).   
 
The three peptides discussed here (LLMLDNDLPP, VLAQYK, GIPGAP) while appearing to be 
different in structure do show some similarities to each other that may determine their activity.  
LLMLDNDLPP and VLAQYK both have residues with hydrophobic sidechains at the N-terminus 
(LLML, and VLA), and LLMLDNDLPP and GIPGAP both have proline at the C-terminus.  Proline is 
the particular amino acid is that conveys the activity of Captopril and has been noted to be important in 
the inhibition of ACE (Bhuyan and Mugesh, 2011).  ACE has also been noted to preferably bind to 
peptides with hydrophobic residues at the C-terminus (Segura Campos et al., 2013). While VLAQYK 
ends in lysine, it does contain tyrosine next to the C-terminus, and considering the size of the peptide, 
the sidechain of tyrosine is likely to be available. This method of synthesising peptides derived from 
hydrolysates was adopted in work presented in chapter 5 of this thesis.  
 Wound healing 
A prominent area of research involving bioactive peptides is that of wound healing.  The process of 
repairing damage to tissues is performed, and controlled by various cell types, extracellular matrix 
molecules, mediators, and cytokines found at the site of the wound.  Wound healing can be separated 
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into three distinct, but overlapping phases: Inflammation, tissue formation, and tissue remodelling 
(Figure 1-3).   
 
Figure 1-3  The three stages of wound healing after the initial damage (a) include inflammation where cells migrate into the 
wound area (b), tissue formation where granulation tissue forms, which is reinforced with collagen deposited by fibroblasts 
(c), and the remodelling phase where the wound is healed (d).  
The inflammation stage involves the initial response to the trauma, including the aggregation of platelets 
to form a clot, the release of cytokines, and the arrival of leukocytes to the region.  Tissue is then 
produced to cover over the wound site; this tissue is mainly made up of endothelial cells and fibroblasts.  
The tissue then undergoes remodelling to repair the wound (Eming et al., 2007). 
 
Demidova-Rice et al (2011) derived bioactive peptides from vascular endothelial cell extracellular 
matrices (ECM).  They proposed that the degradation of the ECM released bioactive peptides that 
stimulate cellular response to damage, and promote angiogenesis.  ECM was degraded using 
collagenase from C. histolyticum.  Peptides isolated from the hydrolysates were then synthesised, and 
assayed for their ability to stimulate the proliferation of capillary endothelial cells (CEC) in culture.  
They found that bioactive peptides derived from ECM could stimulate endothelial cell proliferation, 




A major factor involved in inflammation and tissue repair is the protease thrombin.  This protein is part 
of a cascade that causes blood to clot.  Prothrombin is cleaved to thrombin, which in turn cleaves 
fribrinogin to form fribin, an insoluble protein that forms the fibrous matrixes that limit the flow of 
blood (Brummel et al., 2002).  Thrombin has also been shown to catalyse other important processes 
involved in wound healing (Stiernberg et al., 2000).  In their study investigating the synthetic thrombin 
peptide, TP508 (AGYKPDEGKRGDACEGDSGGPFV), Stiernberg et al. (2000), demonstrated that the 
peptide accelerated wound closure (37% more than negative controls by day 7); importantly, the peptide 
does not promote the recruitment of platelets or cleave fibrinogin.  The authors showed that wounds not 
only healed at a faster rate than the control, but they also had a greater breaking strength at the same 
point post treatment.  The authors suggest that the mode of action of TP508 is related to how thrombin 
acts in the process of wound healing.  In normal wound healing, products of thrombin degradation are 
released from the fibrin clots a few days after the injury, thus initiating a cascade.  In this case, the 
application of TP508 would seem to initiate this cascade sooner.   
The peptide (TP508) was assessed using an in vivo full thickness model.  Adult male Harlan Sprague-
Dawley rats had two full thickness dermal circles (2 cm) excised (down to the skeletal muscle).  The 
wounds were treated either with saline or with saline containing TP508.  The wounds were then left 
uncovered.  The wounds were checked periodically to track wound closing.  After the wounds had 
closed, the new tissue was excised and tested for breaking strength.  Analysis of photomicrographs of 
the wound area indicated that the density of functional blood vessels was the same for each group; 
however, the number of larger vessels found in the TP508 treated groups were significantly greater than 
that of the control group.  The authors suggest that the increased rate of wound closure is due to the 
increased early inflammatory cell recruitment, and the presence of blood vessels that are significantly 
larger than in the un-treated control group.  The structure of the peptide is not discussed in this paper.  
They do state however, that the peptide binds to high-affinity thrombin receptors, and that in doing so 
mimics the natural activity of thrombin (Stiernberg et al., 2000).  This indicates that the structure is 
specific to the receptor, and that during natural wound healing this part of the thrombin molecule will 
bind to the same receptors.  The study by Stiernberg et al, 2000 highlights a useful in vivo wound healing 
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assay that could be used with active peptides derived from the Biofac samples if preliminary wound 
healing assays such as the scratch wound assay provide positive results.  The fact that TP508 (though 
synthetic) is a fragment of a larger protein is interesting because it follows the precedent that active 
peptide sequences are located in longer inactive peptides.  The discovery of active peptides by 
degradation of larger molecules in-vitro can therefore be linked with processes occurring in-vivo such 
as blood clotting.  In comparison to the other sequences mentioned in this review, TP508 has affinity 
for a specific receptor so will not necessarily have similar sequence and structure. 
 Antimicrobial 
Peptides can act as potent antimicrobial agents, many of which are large peptide sequences that can 
form into secondary structures, and have been shown to have a net negative charge with approximately 
50% of the sequence being hydrophobic residues.  The prevalence of the hydrophobic residues can lead 
to the peptide conforming into amphiphilic structures when interacting with cell membranes.  Peptides 
that demonstrate antimicrobial activity contain alpha helical or beta sheet structures that are essential to 
function (Daoud et al., 2005, Marr et al., 2006, Powers and Hancock, 2003, Andreu and Rivas, 1998).  
The characteristics that make these peptides antimicrobial also account for toxicity towards eukaryotic 
cells (Chen et al., 2005). 
Only two new classes of antibiotics have been developed, and approved in the past 20 years, neither of 
which are active on Gram-negative bacteria.  While there are numerous targets still in development, 
only 15 out of 44 show any activity towards Gram-negative bacteria (Tacconelli et al., 2018).  The 
systemic, pharmacodynamic and pharmacokinetic issues with peptides have not been overcome to date.  
Common issues arising include; in vivo half-life, susceptibility to mammalian proteases, dosing, and 
aggregation of peptides (Marr et al., 2006). 
 
Daoud et al (2005) used hydrolysis to generate antimicrobial peptides derived from bovine 
haemoglobin.  The antimicrobial activity was measured by the disc-diffusion method where activity is 
deduced from the diameter of the cleared area around the inoculation site in relation to a positive, and 
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a negative control.  The peptide was shown to have antimicrobial activity against four species of 
bacteria, and was shown to not be haemolytic at relatively high concentrations (Daoud et al., 2005).   
 
Antimicrobial properties of the Biofac samples could be evaluated in a similar way.  However, sequence 
data of peptides contained in the samples would be important here because only sequences that can 
potentially form into the secondary structures are likely to confer antimicrobial activity, and would have 
to be released as a single peptide to become active. 
 Immune modulation/adjuvants/innate immune response 
Immunomodulation is the process of modifying the immune system. Modification can be achieved 
either by the use of prophylactics (e.g. vaccines) or therapeutics (Gea-Banacloche, 2006).  Many 
antimicrobial peptides found in a wide selection of organisms show direct antimicrobial action.  There 
is evidence that these peptides also play an important role in modulating the innate immune response, 
can act as adjuvants, and promote wound healing (Brown and Hancock, 2006). 
 
Cationic amphipathic peptides can be defined as peptides with between 12 and 50 residues.  Within this 
sequence, between 2 and 9 will be a positively charged residues (either lysine or arginine), and up to 
half will be hydrophobic residues (Brown and Hancock, 2006).  Cationic host defence peptides have 
been shown to be active against microbial infection and have immune modulating effect on the innate 
immune response.  These peptides are one of the most conserved aspects of innate immunity in 
organisms and are expressed by either a response to pathogen associated molecular pattern molecules, 
or in response to inflammatory mediators, such as certain cytokines (Bowdish et al., 2005).  LL-37 is 
an example of a human cationic host defence peptide that has been demonstrated to have a potent 
immunomodulating activity. 
1.9 In Silico Analysis 
Bioinformatics is a powerful tool in the analysis of peptides released from protein digests because of 
the great number of sequences that can be isolated from peptides. Thus in silico analysis of peptides 
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can therefore, lead to the more rapid discovery of novel bioactive peptides.  A number of online tools 
are available that predict possible cleavage sites, for example the BIOPEP database (Minkiewicz et al., 
2008) can be used to predict the peptides released from proteins after digestion with a selected enzyme.  
This information can be used in conjunction with experimental data, to predict the type of sequences 
that are in a particular hydrolysate. Therefore, an in silico approach to selecting the enzyme to hydrolyse 
precursor proteins can be a useful tool (Cheung et al., 2009).  The predicted peptides that are generated 
by the in silico digests can then be further analysed by online tools that can predict bioactivity.  The 
example of the resource used in the present study was the Peptide Ranker tool by Bioware (Mooney et 
al., 2012).  This program assigns a rank to the likelihood of a peptide sequence being bioactive (0.0 
being highly unlikely, 1.0 being highly likely).  Further details on how the Peptide Ranker tool works 
is presented in chapter 5. 
 
An example where peptide databases were used in the discovery of bioactive peptides was the study 
performed by Cheung et al. (2009).  This group utilised the BIOPEP database to predict which enzyme 
would produce the most bioactive peptides from oat proteins that could inhibit ACE.  The group then 
used the information gathered to compare with experimental data to validate their method.  The results 
indicated that an in silico approach to selecting the enzyme to hydrolyse precursor proteins can be a 
useful tool.  Another group that utilised the BIOPEP database was that of Lafarga et al (2014).  The 
group used in silico techniques to predict the release of bioactive peptides from proteins derived from 
haemoglobin, collagen, and serum albumin.  Peptides that were identified to be bioactive (in this case 
antihypertensive) were synthesised and assayed in vitro (Lafarga et al., 2014). 
1.10 Biofac Hydrolysates 
This project was based on investigating the bioactive properties of hydrolysates of porcine liver, and 
placenta provided by the company Biofac.  These were produced by processing the raw material (liver 
or placenta) before hydrolysis is carried out with the cysteine protease papain.  The procedure used to 
produce the hydrolysates is described in Figure 1-4.  Briefly, the raw material generated from meat 
waste was homogenised before the addition of water and heating to 85°C.  Hydrogen peroxide was then 
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added to the mix, and the batch was heated to 63-68°C, at this point papain was added and the reaction 
mixture was left for 10-14 hours.  The temperature was then increased to 85°C for 30 minutes to 
inactivate the enzyme, after which several filtration steps were undertaken to purify the sample.  The 
sample was then dried through evaporation, and spray dried before the final sieving process. 
 
Figure 1-4 Biofac procedure for the production of porcine hydrolysates. 
The use of papain as the proteolytic enzyme results in multiple peptides of varying length (Storer and 
Ménard, 2013).  Papain preferentially hydrolyses polypeptides as illustrated in Figure 1-5 with the 
resulting peptides having a structure as shown Figure 1-6.  The enzyme however, can also cleave at 
the carboxyl side of a number of different residues that can exhibit basic, acidic, and neutral 
characteristic, along with aliphatic and aromatic residues (Kimmel, 1954).  These factors indicate that 




Figure 1-5 Preferential cleavage site for papain 
 
Figure 1-6 Possible structure of peptide resulting from hydrolysation of a polypeptide by papain 
Because papain is not a highly specific protease, the peptides that result from papain hydrolysis are 
likely to be diverse.  However, there are a number of statements that can be made about peptides 
generated from papain: 
• Valine will not be at the N-terminus or the C-terminus:  If valine is present in the peptide it will 
be mid sequence.  Valine is hydrophobic so it can be next to the C-terminus. 
• Arginine and lysine are likely to be at the C-terminus; other amino acids that may be at the C-
terminus are glutamic acid, histidine, glycine, tyrosine, and alanine. 
• The amino acid immediately upstream of the C-terminus will be a hydrophobic residue 
1.11 Rationale of Study 
The methodology of the studies that look into the bioactivity of peptides generally follow a similar 
trajectorary:  Separate the hydrolysate; assay the fractions; isolate indivdual peptides in active fractions; 
synthesise the peptides, and repeat the assay.  The aims of this project were, 1) to identify the host 
proteins that were hydrolysed to produce the peptides and 2) to identify, using in silico methods, 
peptides that would likely be produced by the particular enzyme used in the hydrolysis.  The resultant 
peptides could then be anaylsed for the likelyhood of bioactivity, then manufactured and used in assays.  
The method described by Cheung et al. could also be applied to different enzymes, in doing so it would 
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be possible to identify peptides before hydrolysis. For this project however, papain was the target 
enzyme because of its use by Biofac in the manufacture of its products. 
 
The data from the studies discussed in this review indicates the possibilities for the Biofac peptides to 
show bioactivity.  Some of the studies discussed have made direct links to the structure and sequence 
of peptides to their bioactivity while looking at derivatives of larger proteins (Himaya et al., 2012, Jang 
and Lee, 2005, Lassoued et al., 2015).  It is clear that the amino acid sequence is important to the relative 
bioactivity. Moreover, if similar sequences can be identified within peptides from different sources, 
such as meat waste, and plants, it suggests that there are a many potential bioactive peptides in the 




 Materials and General Methods 
2.1 Materials 
 Biofac hydrolysates 
The hydrolysates were produced by Biofac at their manufacturing site in Copenhagen, Denmark.  Over 
the course of the study a number of batches, of each type of hydrolysate were used.  This study was an 
industrially funded project, which meant that the changing requirements of the company had to be taken 
into account.  The products that they produce changed over this period, and so their interests in some 
of the hydrolysates lessened.  An important factor relating to this was the introduction of an additional 
filtration step in the production of the liver, and placenta hydrolysates.  Another change was that after 
the first stage of the project, the heart hydrolysate was deemed to be less of a priority.  It is for this 
reason the investigation focused on the liver and placenta hydrolysates, and that not all the batches were 
analysed using the same techniques.  Throughout this thesis the hydrolysates are referred to the 
abbreviations reported in Table 2-1. 
Table 2-1 Description, batch number, and abbreviated form for the Biofac hydrolysates used in this study 
Description Batch number Abbreviation 
Heart hydrolysate 150601-1000 H1 
Liver hydrolysate 150615-1900 L1 
Liver hydrolysate 160126-0700 L2 
Liver hydrolysate 170127-0815 L3 
Placenta hydrolysate 0-150625-1700 P1 
Placenta hydrolysate 0-160330-1500 P2 
 
 Synthetic peptides 
The synthetic peptides that were used in this project (Table 2-2) are referred to as their sequence of 
amino acids (single letter code).  The peptides were synthesised by Peptide Protein Research, 10 mg 
of each peptide were provided. 
Table 2-2 Sequences of the synthetic peptides derived from amino acid sequences found in the Biofac hydrolysates 
Description Supplier 
FFNDA Peptide Protein Research Ltd (Fareham, UK) 
FWG Peptide Protein Research Ltd (Fareham, UK) 
SDPPLVFVG Peptide Protein Research Ltd (Fareham, UK) 
MFLG Peptide Protein Research Ltd (Fareham, UK) 





The specialist equipment used to analyse the hydrolysates, and the synthetic peptides for this project 
are listed in Table 2-3. 
Table 2-3 Specialist Equipment 
Description Name Supplier 
Analytical column Ascentis® Express Peptide ES-
C18 
Sigma Aldrich (Gillingham, 
UK) 
Prep column Dynamax C18 -60A Agilent (Cheadle, UK) 
HPLC pumps System Gold 125 Solvent 
Module 
Beckman Coulter (Palo Alta, 
USA) 
HPLC detector System Gold Programmable 
Detector Module 166 
Beckman Coulter (High 
Wycombe, UK) 
Prep HPLC pumps Model 303, and Model 305 Gilson (Dunstable, UK) 
Prep HPLC detector HM Holodrone UV-Vis Gilson (Dunstable, UK) 
Prep HPLC printer Kipp and Zonen BD40 Gilson (Dunstable, UK) 
Fluorescent microplate reader Fluostar Optima microplate 
reader 
BMG Labtech (Aylsbury, UK) 
Microplate reader Infinite F50 Tecan (Männedorf, He) 
Wet laser diffraction particle 
size analyser 
Mastersizer Malvern Panlytical (Malvern, 
UK) 
Dry powder laser diffraction 
particle size analyser 
Helos Sympatec (Bury, UK) 
SECMALS (Size Exclusion 
Chromatography coupled to 
Multi-Angle Laser Light 
Scattering 
DAWN HELIOS-II (light 
scattering detector) & rEX 
(refactive index detector) 
Wyatt Technologies (Santa 
Barbara, USA) 
Shear cell apparatus RST-XS Dietmar Schulze (Wolfenbüttel 
Germany) 
SEM Quanta250 FEG FEI Instruments (Hillsboro, 
USA) 
Light microscope E24 HD Leica (Wetzlar, Germany) 
 
 General materials 
All general laboratory reagents and materials used in this project were supplied by Sigma Aldrich 
(Gillingham, UK), Sarsedt (Nümbrecht, Germany), and Thermo Scientific (Loughborough, UK).  
Specific materials and reagents are recorded in Table 2-4. 
Table 2-4 Specific materials and reagents 
Description Supplier 
FluoroNunc™/LumiNunc™ 96-Well Plate Thermo Scientific 
Nunc™ F96 MicroWell™ Black Thermo Scientific 
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 Cell line 
The cell line used for the entirety of the cell culture for this project was mouse 3T3 fibroblasts (p12) 
(NIH 3t3 cells, LGC, Middlesex, UK). 
2.2 General Methods 
The analytical methods used in this project were used over multiple chapters, with slightly different 
procedures.  This section describes the basic mechanisms of the methods, and rationale behind their 
use.  For more detailed procedures, see the methods sections in the results chapters (3, 4, and 5). 
 Microscopy 
Microscopy was used to analyse the physical structure of the hydrolysate particles.  This information 
was used to build up a profile on each sample, which could provide information on how the hydrolysate 
powders flow. 
2.2.1.1 Light Microscopy 
Light microscopy (LM) was used to investigate the structure of the particles under visible light, thus 
allowing the colour of the samples to be analysed.  A Leica E24 HD was used for LM; samples were 
taken from P1, L1, and H1, and pictures taken. 
2.2.1.2 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was used to analyse the structure of the particles to a greater 
magnification than is possible using LM.  Samples were analysed using a FEI Instruments, Quanta250 
FEG SEM (full details in section 3.2.1). 
 Particle Size Analysis 
The particle size distributions of the hydrolysates were analysed using three methods.  Pharmaceutical 
sieves were used to separate the powders into fractions of different sizes.  The fractions generated were 
used in the particle flow analysis to understand how the different sizes of particles, and their distribution 
influenced the flow of the product.  Alongside the sieves, two methods of laser diffraction were used to 
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analyse the particle size distribution, wet laser diffraction using a Malvern Mastersizer 2000, and dry 
laser diffraction using a HELOS (Hi209) laser diffraction sensor with RODOS dispersion unit.  The 
laser diffraction methods are useful to analyse particles that are rounded, and are able to separate 
particles that are agglomerated (a limitation with the pharmaceutical sieves).  
 Particle Flow Analysis 
The ability of the particles, that make up the hydrolysate, to flow is an important factor to consider in 
the manufacturing process.  To analyse the flow properties of the hydrolysates, a RST-XS shear cell 
apparatus was used.  The data outputted from this device indicates how well the samples flow as a flow 
function (10 is free flowing and 1 is cohesive).  The fractions generated through the molecular sieving 
were used, alongside the full hydrolysates in the flow analysis. 
 Size Exclusion Chromatography Multi-Angle Light Scattering 
The hydrolysates were analysed using Size Exclusion Chromatography Multi-Angle Light Scattering 
(SEC-MALS) to assess the molecular weight profile of the peptides.  SEC-MALS is a method that 
separates the molecules in a sample by size, before analysing them using multi-angle light scattering, 
which is used to determine the molecular weight of the molecules in solution. 
 Phenol-Sulphuric Acid Assay 
The production method used to make the hydrolysates is intended to produce a powder that is made up 
of peptides derived from the specific starting material.  The analysis of the bioactivity of the 
hydrolysates is directed towards bioactive peptides, however, there could be other active molecules 
within the samples.  Therefore, the total carbohydrate content of the hydrolysates was assessed using 
the phenol-sulphuric acid assay.  This colourimetric assay can determine the concentration of reducing 
sugars in solution, when mixed with phenol and sulphuric acid, by measuring the optical density at 490 
nm (orange/red) (DuBois et al., 1956).  This assay can be used to estimate the carbohydrate content of 
a sample in relation to a standard.  In this case, glucose was used as the standard. 
52 
 
 Antioxidant Assays 
2.2.6.1 DPPH Radical Scavenging Activity (RSA) 
1, 1-Diphenyl-2-Picrylhydrazyl (α,α-Diphenyl-β-Picrylhydrazyl (DPPH) is a stable free radical that is 
utilised in a simple assay that can be used to determine the radical scavenging capacity of an antioxidant.  
When mixed with a proton donating substance, DPPH is reduced from the purple radical to produce the 
pale yellow to clear non-radical form.  The change in colour is used to evaluate the ability of an 
antioxidant to scavenge radicals through proton donation (Alam et al., 2013).  The inexpensive, and 
simple nature of this assay makes it an ideal method to rapidly screen antioxidants.  The limitations of 
this assay are that the test sample solutions must be miscible with alcohol, and that the mechanism of 
reduction demonstrated is not limited to antioxidants; other substances that exhibit no antioxidant 
activity, such as hydrogen peroxide, can reduce the radical form of DPPH to the non-radical form 
(Amorati and Valgimigli, 2015). 
2.2.6.2 Oxygen Radical Absorbance Capacity Assay (ORAC) 
The ORAC assay, is one of the more prevalent methods in the literature to determine the level of activity 
of antioxidants.  The ORAC method is an example of an assay that utilises a fluorescent probe that can 
be oxidised by free radical generating compounds such as 2,2′-Azobis(2-methylpropionamidine) 
dihydrochloride (AAPH) (Amorati and Valgimigli, 2015).  The assay measures the ability of 
antioxidants to protect the probe by absorbing oxygen radicals, and is detected by measuring the 
fluorescence of the probe at specific time points over a set period of time.  The antioxidant capacity is 
measured by comparing the area under the curve of the experimental samples to that of a known 
antioxidant standard, in this case the vitamin E analogue Trolox, and is reported as Trolox equivalence 
(TE) (where a TE of 1 indicates that 1 g of the experimental sample is equivalent to 1 g of Trolox). 
2.2.6.3 Lipid Peroxidation Inhibition  
To assess the ability of the hydrolysates to reduce or inhibit lipid peroxidation, the linoleic acid/ ferric 
thiocyannate assay (FTC) method was used.  This assay is based on the production of lipid peroxyl fatty 
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acid radicals through autoxidation.  The linoleic acid model is used as an approximation of phospholipid 
bilayers that make up cell membranes.  This assay is an inexpensive, and relatively rapid (in comparison 
to cell culture assays) method to determine the effect of antioxidants on oxidative stress caused through 
the autoxidation of non-conjugated polyunsaturated lipids (Nazeer et al., 2013). 
2.2.6.4 Cellular Antioxidant Activity Assay 
While the use of chemical in-vitro assays to assess the antioxidant capacity compounds is an important 
element in antioxidant screening, there are a number of issues associated with these methods.  Some of 
these methods are not carried out under biologically relevant conditions, such as pH, and they do not 
account for the biological mechanisms in-vivo, that could affect the compounds such as them being 
metabolised, and their bioavailability.  They also use molecules that are not found in-vivo such radicals 
like DPPH, or oxygen radical generators like AAPH (Liu and Finley, 2005).  The most relevant assays 
would therefore be in-vivo methods that use animal models, and detect the effects of the antioxidant 
through experiments on serum samples (Onoja et al., 2014), however, the cost and ethical considerations 
make these methods less attractive.  Cell-based assays are therefore a viable alternative to both chemical 
in-vitro, and in-vivo assays because they take into account physiological conditions.  The method used 
in this study exploited the intracellular oxidation of 2′, 7′-dichlorodihydrofluorescein (DCFH) into the 
fluorescent dichlorfluorescein (DCF).  In the case of the assay, AAPH is used as a source of oxygen 
radicals, to differentiate from oxidative stress that would occur naturally with the cells.  The ability of 
antioxidant to reduce the oxidation of DCFH to DCF (and therefore produce lower fluorescence) is 
measured by comparing the experimental groups with that of a negative control.  The percentage 
reduction in oxidation can be calculated from this data (Wolfe and Liu, 2007). 
 Cell Proliferation 
The ability of the hydrolysates to influence cell proliferation (negativity or positively) were analysed to 
assess if the samples could have an impact on wound healing.  Two methods were used to determine 
the level of proliferation of treated cells in relation to a control group of untreated cells. 
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2.2.7.1 Cell Counting 
This method used cell counts derived from a haemocytometer to determine the number of cells in culture 
for each test sample, and to generate population doubling level (PDL), and doubling time (DT) data.  
PDL is a measure of how many times a population of cells have doubled over the time that they have 
been in culture, while DT measures the average time taken for the population to double.  These two 
figures are an important measure of the health of cells in culture.  A greater PDL indicates that the cells 
are proliferating a higher rate, while a lower PDL indicates that the teat samples are having a negative 
effect on the cells. 
2.2.7.2 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is a yellow tetrazole that when 
reduced by enzymes present in mitochondria, forms purple formazan crystals that are soluble in organic 
solvents.  Measuring the absorbance of the dissolved formazan crystals is used to determine metabolic 
activity of the cell population.  This can be used as an indirect measure of cell viability and proliferation 
(Liu et al., 1997).  In this study, the MTT assay is used by generating standard curves with known 
numbers of cells, which the test samples were measured against.  In this way the assay could be used to 
estimate cell number directly. 
 Wound Healing Assay (Scratch Assay) 
The scratch wound assay is a convenient method to test the ability of the peptides in aiding cell 
migration.  The simulation of a wound on a confluent monolayer, by creating a ‘scratch’ is easy to 
prepare, quick, and is low cost; this makes it an ideal preliminary assay for wound healing (Liang et al., 
2007).  This method is used as a measure of cytotaxis, therefore the antimitotic compound Mitomycin 
C was added to the cell culture media to arrest cell proliferation. 
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 High Performance Liquid Chromatography (HPLC) 
2.2.9.1 Analytical HPLC 
Reverse phase HPLC was used to analyse the composition of the hydrolysates, to isolate individual 
peaks for use in identification, and to test the purity of the collected fractions.  All HPLC used in this 
study used an analytical C18 column specifically designed for peptides and small proteins 
(Ascentis® Express Peptide ES-C18 (length 100 mm, ID 4.6 mm). All HPLC used UV at 220 nm for 
detection except HPLC used in the ACE assay (228 nm). 
2.2.9.2 Preparative HPLC 
Preparative HPLC (prep HPLC) was used to fractionate the hydrolysates, which could then be recovered 
by lyophilisation.  The recovered fractions were then analysed for physical appearance, and bioactivity 
using the assays established for the analysis of the full hydrolysates.  The method used to fractionate 
the hydrolysates with the preparative column was produced by scaling up the method used for the 
analytical HPLC. 
 Lyophilisation 
Peptides in the fractions generated from preparative HPLC were recovered by lyophilisation.  This 
method was used because it is relatively simple, and because the method is unlikely to alter the 
molecular compositions of the peptides, because it does not use high temperatures as the drying method.  
The powders resulting from the freeze drying process were then reconstituted in the appropriate buffers 
for the required assay. 
 ACE Inhibition Assay 
The prevalence of bioactive peptides, which have been reported to inhibit ACE was the reason the 
hydrolysates anti-ACE activity were assessed.  The method used in this study uses the substrate HHL, 
which ACE will metabolise to produce HA.  The digestions were separated by HPLC using UV to detect 
the levels of HHL, and HA (detection at 228 nm).  Inhibition of ACE would lead to a reduction in the 
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levels of HA.  This method was selected because HPLC is able to separate the product from the 
substrate, leading to a sensitive detection method. 
 De-Novo Peptide Sequencing Using MS/MS 
De-Novo peptide sequencing was outsourced to the Metabolomics & Proteomics Lab at the University 
of York.  This method was used to determine the sequences of the isolated peptides derived from the 
hydrolysates.  These sequences were used to identify the probable host protein from in which the 
peptides originated. 
 In silico Analysis of Bioactive Peptides 
In silico analysis was used to analyse the likelihood of certain peptides being present in the hydrolysates, 
and the possibility of those sequences being bioactive.  The digestion of the host proteins derived from 
the De-Novo sequencing, and their comparison to known bioactive peptides were performed using tools 
on the BIOPEP website (Minkiewicz et al., 2008).  The likelihood of the peptides being bioactive were 




 Physicochemical analysis of possible bioactive 
hydrolysates derived from porcine hydrolysates 
3.1 Introduction 
The initial work carried out on the evaluation of the three Biofac hydrolysates (liver (L1), placenta (P1), 
and heart (H1)) supplied, was focused on their physicochemical properties. This included the 
morphological characteristics of the peptide samples, the particle size distribution, and their solubility.  
The rationale for investigating these properties at the beginning of the project was that these data are 
important parameters, which may provide useful information with regards manufacturing processes.  
The physicochemical properties of the individual hydrolysates will be affected by both their molecular 
composition, and the manufacturing process used to produce them.  An example of a property that can 
be affected is flowability.  For instance, lyophilised samples will demonstrate a reduced ability to flow 
because of their planer morphology, compared to spray dried samples which produces more spherical 
particles (Singh et al., 2013, Febriyenti et al., 2014).  The drying process therefore, will alter the final 
physical make-up (size and shape of the particles) of the powders, which in turn, will affect certain 
physical properties. These include flowability, compaction behaviour, and dissolution (Rajinikanth et 
al., 2012), therefore identifying the basic morphology of the powders was an important first step as this  
also affects how the hydrolysates are further processed into formats that can be consumed, such as 
tableting and capsule filling.  The solubility of the hydrolysates is important to the bioavailability of 
any potential bioactive peptides within the powder.  Solubility is the ability of a substance to dissolve 
into solution.  The fundamental parameters of solubility are dependent on the molecular composition of 
the solute, and therefore not necessarily affected by the drying process, however, if the temperature 
used in a process such as spray drying is too high, then this could have an effect on the molecular 
composition of peptides in the hydrolysates (Mujumdar et al., 2014). 
 
The average molecular mass of the peptides within the hydrolysates was analysed using size exclusion 
chromatography coupled with multi-angle light scattering detection (SEC-MALS).  This procedure was 
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used on the original hydrolysates (L1, P1, and H1) as well as further batches received from Biofac (L2, 
and P2). L2 and P2 were produced in a similar fashion to L1 and P1, but with an added filtration step 
to remove particles with a molecular weight (MW) greater than 5 kDa. 
 
The hydrolysates were analysed using a phenol-sulphuric acid assay.  This was used to determine the 
concentration of reducing sugars in the hydrolysates, when mixed with phenol and sulphuric acid, by 
measuring the optical density at 490 nm.  A series of glucose standards were prepared and assayed 
alongside the hydrolysates.  Carbohydrates can also illicit bioactivity, so it was important to assess the 
proportion of carbohydrates in each sample (Hu et al., 2016).  All liver, and placenta hydrolysates used 
in this project were analysed using this method (L1, L2, L3, P1, and P2). 
 
This section of the study is dedicated to the physical properties of the hydrolysates.  This information 
was gathered to gain an understanding of how the individual products behave as solids and in solution.  
This information was aimed at the producing data that can be used in the optimisation of the production 
process for Biofac.  
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3.2 Materials and methods 
 Microscopy of peptide samples 
The size and shape the particles from each sample were analysed using LM (Leica E24 HD), and SEM 
(FEI Instruments, Quanta250 FEG).  The samples were prepared for SEM by coating in a gold and 
platinum alloy (3 nm) using a 7920 Sputter coater (Quorum Instruments) for a period of 45 seconds.  
The samples were mounted on an aluminium stub (50 nm diameter).  The SEM was operated in high 
vacuum mode with an accelerating voltage of 20 kV.  The images were taken using Back Scattered 
Electron Image (BSEI), and an Everheart Thornley Detector (ETD) for secondary electrons.  The 
images generated by SEM were used to compare the microstructure of the samples and the light 
microscopy provided information regarding the macroscopic size and shape. 
 Particle size analysis 
To determine the particle size distribution of the samples three methods were used:  Wet laser 
diffraction, dry powder laser diffraction, and pharmaceutical sieving.  The hydrolysate samples were 
analysed by wet laser diffraction using a Malvern Mastersizer 2000.  The samples were dispersed in 
hexane and particle size distribution was measured. Individual samples were measured four times to 
assess the reproducibility of the data. 
The hydrolysate samples were analysed in the dry powder form using a HELOS (Hi209) laser 
diffraction sensor with RODOS dispersion unit, this method of sizing is particularly beneficial for 
moisture-sensitive materials. 
 
To assess the range of particles present and to assess a cheap and simple approach to sizing 
pharmaceutical sieves were used. The samples were passed through a series of sieves with an aperture 
range of 250-180 µm, 180-125 µm, 125-75 µm, 75-38 µm, and less than 38 µm. Particles that were 
retained by each sieve were collected and weighed as a percentage of the total weight (assuming that 
the density was equal) of the hydrolysates added to the sieves.  The mass of each hydrolysate loaded 
onto the sieves were, 135 g of H1, 85 g of L1, and 78 g P1. 
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 Particle flow analysis 
To assess the followability of each of the crude hydrolysate, and the fractions generated by 
pharmaceutical sieving, a RST-XS shear cell apparatus was used.  The flowability of each fraction was 
expressed as a flow function (FFC), where 10 is free flowing and 1 is cohesive.  The individual fractions 
were loaded into the annular shear cell.  Vertical force (measured as vertical load FN) was applied to the 
sample through a loading rod connected to the annular lid.  Torque (measured as shear forces F1 and 
F2) was then applied to the cell through horizontal tie and push rods.  Torque was applied until the 
powder contained in the cell began to shear.  The forces applied to the cell were computer-controlled 
through a program with pre-set parameters (RST-CONTROL 95).  The flow properties were calculated 
from multiple measurements. 
 Solubility and saturation point 
The saturation point over a pH range between 1.2 and 7.2, for each hydrolysate was investigated as this 
information can potentially relate to the bioavailability of the hydrolysates if taken orally.  The 
saturation point for each hydrolysate was obtained by adding the samples to 10 mM phosphate buffer 
(at pH 1.2, 5.8, and 7.2) at room temperature until the solution was saturated (powder remained in 
suspension, which was 1.5 g in 5 mL of buffer for L1, and 1 g in 5 mL for P1).  The samples were 
placed in a shaking water bath, at 37 °C and 100 oscillations per minute, and left for 24 hours.  The 
samples were then centrifuged at 3.0 x g for 6 minutes, and the supernatant removed.  The supernatant 
was then filtered through filter paper to remove any residual particulates.  The samples were then diluted 
accordingly with the relevant buffer to enable analysis by UV-Vis (ultra violet/visible light 
spectrophotometry).  The concentration of the hydrolysate in solution was calculated from a standard 
curve derived from known concentrations (0 – 80 µg/mL) of the same hydrolysate (Figure 3-1, and 
Figure 3-2); the concentrations calculated for each sample were then multiplied by the relevant dilution 




Figure 3-1 Standard curve using different concentrations of liver 150615-1900 (L1) to determine the concentration of 150615-




Figure 3-2 Standard curve using different concentrations of heart 150615-1900 (H1) to determine the concentration of heart 
150615-1900 (H1) at the saturation point at pH 1.2 (a), pH 5.8 (b), and pH 7.2 (c) 
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The standard curves were generated by preparing a stock solution for each individual hydrolysate, (1.0 
mg/mL).  This was prepared by adding the relevant hydrolysate (100 mg) to a 100 mL buffer solution 
in a volumetric flask. A series of dilutions was then prepared in triplicate for all samples. 
 
The dilutions were analysed by UV-Vis to determine the absorbance of each concentration.  The 
wavelength range used was 300 nm to 190 nm because peptide bonds absorb UV between 190-230 nm, 
and the UV active amino acids (tryptophan, tyrosine, and phenylalanine) absorb UV between 257 and 
280 nm.  The samples were analysed in silica cuvettes, and run on a fast scan mode.  The average  peak 
absorption (λmax) of each sample was plotted against concentration to produce standard curves. Standard 
curves were not produced for placenta peptide at pH 5.8, and pH 1.2.  This was because of the high 
solubility of this peptide at pH 7.2. 
  SEC MALS analysis 
SEC-MALS was used to determine the molecular weight of the hydrolysates.  Heart (H1), two batches 
of liver (L1, and L2) and two batches of placenta (P1, and P2) hydrolysates were analysed.  The 
hydrolysates were first dissolved in 0.1 M sodium nitrate before being passed through a 0.2 µm 
(polyrthersulphone) filter.  High performance size exclusion chromatography (HPSEC) was performed 
at room temperature on a system consisting of a PL aquagel guard column (Polymer Labs, Amherst, 
U.S.A.) followed by in series (PL aquagel-OH 60, PL aquagel-OH 50 and PL aquagel-OH 40) eluted 
with 0.1 M sodium nitrate containing 0.02 % sodium azide as an antibacterial agent at a flow rate of 0.7 
mL/min.  The eluent was detected on-line by a DAWN EOS light scattering (LS) detector and a rEX 
differential refractometer (RI) (both supplied by Wyatt Technology, Santa Barbara, U.S.A.). The 
refractive index increment, dn/dc was taken to be 0.185 mL/g. 
 Determination of Total Sugars Using the Phenol-Sulphuric Acid Assay 
Calibration solutions were prepared (D-glucose in deionised water) at the following concentrations: 200 
µg/mL, 160 µg/mL, 120 µg/mL, 80 µg/mL, 40 µg/mL, and 20 µg/mL. The final concentrations, when 
combined with the 5% phenol in 0.1 M HCl were 100 µg/mL, 80 µg/mL, 60 µg/mL, 40 µg/mL, 20 
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µg/mL, and 10 µg/mL).  The test samples were prepared in triplicate at a concentration of 1 mg/mL in 
deionised water.  5% phenol in 0.1 M hydrochloric acid (HCl) was prepared by adding phenol (0.5 g) 
to 0.1 M HCl (9.5 mL).  The assay was performed by combining the glucose calibration solution or test 
samples (0.5 mL) with 5% phenol in 0.1 M HCl (0.5 mL), and concentrated sulphuric acid (2.5 mL).  
The vials were shaken vigorously then left at room temperature for 10 minutes.  A blank solution was 
also prepared in a similar fashion that replaced the sample solution with deionised water.  The vials 
were then placed in a water bath set at 25-30C for 20 minutes.  The absorbance of the samples was 
measured at a wavelength of 490 nm using a UV-Vis spectrophotometer.  A standard curve was 
generated (Figure 3-3) from the glucose standards (0 - 100 µg/mL) which was then used to calculate 
the carbohydrate contents of the peptide hydrolysates (Table 3-2). 
 
Figure 3-3 Standard curve using different concentrations of glucose (0 - 100 µg/mL) to determine the carbohydrate content 
of the peptide hydrolysates 
 Statistical analysis 
Data were analysed using ANOVA, and t-tests.  The ANOVA was single factor, where the null 
hypothesis stating that there is no significant difference in the data points analysed.  The t-tests used 
were one-tailed t-tests with equal variances assumed.  Statistical analyses were performed on data (n = 
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6) using Microsoft Excel. A p value of < 0.05 was considered significant and standard deviation derived 




 Microscopy of peptide samples  
The LM, and SEM images (Figure 3-4) indicate that there is a major difference in morphology between 
the H1 hydrolysate, and the L1 and P1 hydrolysates.  The LM and SEM images of the H1 sample 
(Figure 3-4 a and d) are more angular and in general smaller than the images for the L1 and placenta 
samples (Figure 3-4 b and e, and c and f).  The particles that make up the P1, and the L1 samples 
are also appear to be more uniform in their size distribution. 
 
Figure 3-4 :  Microscopy images of hydrolysates heart 150615-1900 (H1) (A and D), liver 150615-1900 (L1) (B and E), and 
placenta 0-150625-1700 (P1) (C and F) by light microscopy A-C and scanning electron microscopy (SEM) D-F 
 Particle size and distribution 
The three methods used for the size distribution (wet laser diffraction, dry laser diffraction and 
pharmaceutical sieves) were compared by converting the data ranges to be similar to the sieves.  The 
mass of the fractions generated from sieving the hydrolysate are shown in table Table 3-1.  The 
percentages of particle sizes for each method are shown in Figure 3-7.  The percentages of particle 
size distribution were calculated by identifying the fractions that fall within the size range of each of 
the sieves and then working out the value as a percentage of the total.  The particle size distribution 
generated using the Malvern Mastersizer (Figure 3-5), and the HELOS (Hi209) (Figure 3-6) show a 
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similar pattern of size distribution.  The heart hydrolysate had the greatest uniformity in particle size 
(the majority of the particles were under 75 µm) while the liver, and placenta samples had similar size 
distribution.  The most uniform distribution of particle size groups was observed in the liver hydrolysate. 
Table 3-1:  Mass of fractions generated from sieving the hydrolysates heart 150615-1900 (H1), liver 150615-1900 (L1) and 









>250  0.00 1.02 1.01 
250-180 0.95 6.12 3.98 
180-125 4.05 25.59 20.98 
125-75 11.07 25.59 22.00 
75-38 61.43 22.53 29.02 
≤38 57.38 4.08 1.01 
 
 
Figure 3-5 Particle size distributions using wet laser diffraction for heart 150615-1900 (H1), liver 150615-1900 (L1) and 0-




Figure 3-6 Particle size distributions using dry powder laser diffraction for heart 150615-1900 (H1), liver 150615-1900 (L1) 
and placenta 0-150625-1700 (P1) hydrolysate samples.  Where the distribution density is represented on the right y-axis and 
the cumulative distribution is represented on the left y-axis 
In general, the data for the pharmaceutical sieves shows a similar size distribution pattern as the laser 
diffraction methods, however, it was apparent that smaller particle sizes resulted in less uniform data.  
The data does indicate that there is a greater proportion of smaller particles in the heart hydrolysate than 




Figure 3-7 Comparison of the three methods of particle size analysis, wet laser diffraction, dry powder laser diffraction, and 
sieve fractionation for heart 150615-1900 (H1), liver 150615-1900 (L1) and placenta 0-150625-1700 (P1) hydrolysate samples   
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 Particle flow analysis 
The fractions generated from the mechanical sieving, along with the crude peptide samples were used 
in flowability analysis using a RST-XS shear cell apparatus.  The ability of each peptide sample to flow 
was first assessed, before the fractions generated from the sieving were analysed.  The FFC values 
obtained from the shear cell are represented in Figure 3-8.  The data is incomplete for the particle flow 
analysis because some of the fractions generated for the liver and placenta hydrolysates, and all the 
fractions generated from the heart hydrolysates became too compact and therefore adhesive when the 
force required for this method was applied to the samples.  The results that were gathered indicated that 
the placenta hydrolysate (FFC ~ 8.5) had a greater flowability than the liver (FFC < 3).  Both were 
greater than the heart, which could not be successfully analysed using this method. 
 
Figure 3-8 Flow factor values for fractions generated from pharmaceutical sieves.  Data could not be generated for the heart 
150615-1900 (H1) peptide fractions 
 Saturation point 
The solubility of the hydrolysates was measured at varying pH levels to simulate the conditions of 
various parts of the gastrointestinal tract.  The calculated saturation points of each peptide tested are 
shown in Figure 3-9.  The calculated saturation point presented represents the mean of 6 readings ± 
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SD.  The placenta hydrolysate did not reach saturation using this method.  This hydrolysate was highly 
soluble, which resulted in a viscous solution at high concentrations.  This in turn hindered the 
dissolution of more peptide to reach the saturation point.  The liver hydrolysate was more soluble than 
the heart over the full pH range.  The pattern of solubility for the two hydrolysates tested were similar 
in that they were both more soluble at pH 5.8.  The reduced solubility of the heart hydrolysate at pH 7.2 
was significantly different to the heart samples tested at pH 1.2, and 5.8 (p = 0.068, and 0.055 
respectively). 
 
Figure 3-9 Mean saturation point concentrations for hydrolysate samples heart 150615-1900 (H1), and liver 150615-1900 
(L1) (n=6) 
 SEC MALS analysis 
The variability of the data generated from SEC MALS (Figure 3-10, and Figure 3-11was judged too 
great to assign an accurate MW, but all the samples fell in between 2 and 14 kDa, which is what would 




Figure 3-10 Chromatograms for the size exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) for 
heart 150615-1900 (H1) (a), liver 150615-1900 (L1) and liver 160126-0700 (L2) (b being L2) (b), placenta 0-150625-1700 (P1) 
and placenta 0-160330-1500 (P2) (b being P2) (c), and the combined graphs (d). 
 
Figure 3-11 Molecular weight for the size exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) for 




 Determination of Total Sugars Using the Phenol-Sulphuric Acid Assay 
The data generated from the phenol-sulphuric acid assay indicated that while there was carbohydrate 
present in all of the hydrolysates, the concentrations were low.  The greatest proportion of total 
carbohydrate was found in L1 (4.32%) followed by L3 (3.62%) (no significant difference between the 
two p = 0.13).  P2 and L2 (p = 0.49) showed similar amounts of sugars (2.53% and 2.51% respectively).  
P1 had the lowest amounts of carbohydrate of all hydrolysates tested (0.62%) (significantly less than 
all other hydrolysates except P2, p = 0.051) (Table 3-2) 
Table 3-2 Total carbohydrate content (in relation to glucose) for the peptide hydrolysates 
 P1 P2 L1 L2 L3 
Abs 0.12 0.28 0.43 0.27 0.37 
µg 3.09 12.64 21.58 12.55 18.11 
mg/g 6.19 25.28 43.15 25.10 36.23 
% total 0.62 2.53 4.32 2.51 3.62 
 
 





The most striking difference between the samples was the morphology of the heart hydrolysate (H1) in 
comparison with the liver (L1) and placenta (P1) hydrolysates.  The heart hydrolysate appears much 
smaller than the liver and placenta hydrolysates, which have a similar size range to each other (Figure 
3-4 A-C). The heart sample (H1) also had irregular shaped particles unlike the liver and placenta 
samples, which were uniform and spherical. The SEM images (Figure 3-4 D-E) highlight further 
differences on a microstructural level as the liver and placenta hydrolysates appeared to contain large 
porosities within the particles and H1 showed flattened plate-like structures with the smaller particles 
forming aggregates.  The holes on the surface of the particles are likely to have arisen from the vacuum 
applied during the SEM analysis.  The morphology of the heart hydrolysate is noticeably different, 
being more irregular, with the general particle size being smaller.  The spherical honeycomb like 
structures of the spray-dried liver, and placenta hydrolysates contrasted with the angular crystalline 
structures of the freeze-dried heart hydrolysate. The images generated from these methods indicated 
that the morphology of the particles was determined by the production method used to generate the 
hydrolysates.  The methods of production are also likely to have had an effect on the particle size 
distribution of each sample.  L1 and P1 samples had a similar size distribution with the majority of 
particles between 10 and 300 µm, whereas the heart peptide sample had a size range between 5 and 100 
µm in addition to a significant population of particles below 3 µm (Figure 3-5 and Figure 3-6).  
Examining the heart peptide hydrolysate SEM and light microscopy images show the particles to have 
planar layers, and rough edges. Again, this is likely down to the particle preparation method. 
Importantly however, this may affect the flowability and tableting behaviour of the heart peptide 
sample.  An interesting feature of the hydrolysate samples was the variation in colour (Figure 3-4 A-
C).  
The fact that the sieve data was different to the laser diffraction data is not too surprising after the 
fractions were analysed under microscopy, which provides shape information.  All three hydrolysate 
samples showed that there was a lower proportion of particles < 38 µm, collected from the sieves than 
what was measured in the other two methods.  Analysis of the images of the heart hydrolysate (Figure 
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3-4 A and D) suggests that the smaller particles aggregated.  Particles less than 100 m become more 
cohesive and below 10 m resist flow under gravity and are extremely cohesive, and therefore are 
unable to pass through smaller meshes (Lu et al., 2015).  This property was also observed for the liver, 
and placenta hydrolysates (figures not shown).  
 
The differences between the wet laser diffraction (Mastersizer) and the dry powder laser diffraction 
(HELOS) appear to be comparable with one another considering the polydisperse nature of the samples.  
The shear cell method used to determine the flowability of the hydrolysates was unable to determine 
the FFC for all the fractions.  Some of the samples reported FFC values well above 10 (placenta 180-
125 µm, and 125-75 µm), whereas the FFC could not be calculated for other samples (all liver fractions 
less than 125 µm, and all heart samples).  The lack of results for the heart samples can be explained by 
the extremely cohesive nature of the particles.  The SEM images clearly show irregular crystalline 
structures that are generally small.  The smaller liver fractions seem to have been affected by the ‘sticky’ 
nature of the particles. The results of the placenta fractions do show that the shape of the particle has 
had a direct effect on the flowability of the hydrolysates.  The placenta fractions were also significantly 
less ‘sticky’ than the liver peptide fractions. 
 
The flowability of the hydrolysates was not further investigated in an attempt to attain a complete data 
set because this data was not deemed vital to the investigations on bioactivity.  The flowability of the 
hydrolysates could however, have an impact on the further processing and manufacturing procedures.  
Because the initial aim of this study was to evaluate the peptide hydrolysates for bioactive properties, 
the solubility in physiological conditions is important for this activity to be translated in vivo (Savjani 
et al., 2012).  The solubility of each peptide sample at different pH levels was therefore investigated to 
evaluate the limits of solubility.  The method used in this study calculated the saturation point of each 




The data shown in Figure 3-9 indicated that both H1, and L1 were more soluble at pH 5.8 than pH 1.2 
and pH 7.2, and that the liver hydrolysate is more soluble than the heart hydrolysate.  The placenta 
hydrolysate was not analysed using this method because the saturation point could not be reached.  The 
extremely high solubility of the placenta peptide is an interesting property that could be utilised by 
potential customers of Biofac.  The ability of the hydrolysate to produce viscous solutions could be 
exploited in the production of topical formulations for example.  These could either be a method of 
administering the hydrolysate as it is, or with other active compound mixed in with it. 
 
Statistical analysis using ANOVA (single factor, null hypothesis being that there is no difference in 
solubility at different pH levels) indicated that there was a significant difference in solubility at different 
pH levels in the heart hydrolysate (p-value < 0.02), but not for the liver hydrolysate (p-value > 0.05).  
Further statistical analysis of the H1 hydrolysate solubility data using t-tests identified that the data 
point at pH 7.2 was significantly different to the data points at pH 1.2, and pH 5.8.  There was no 
significant difference between the data points at pH 1.2, and pH 5.8. 
 
Concerning the total carbohydrate assay, the proportion of carbohydrate in each hydrolysate sample 
was measured using glucose as a reference.  Glucose was selected as the standard because of its 
importance to biological systems, and therefore may be present in the samples.  It is interesting that 
there was a difference between the placenta samples (Figure 3-12).  P1 (no filtration) gave a value of 
0.62%; P2 (< 5 kDa) gave a value of 2.53%.  There was also a difference between the values for the 
liver samples; here L1 (no filtration) gave a value of 4.32%, L2 (< 5 kDa) gave a value of 2.51%, and 
L3 (< 5 kDa) batch 2 gave a value of 3.62%.  The fact that there are differences in total carbohydrate 
content between samples from the same source material indicates that there are differences between the 
batches.  However, the differences are small, and considering the source of the material, the presence 




The investigation into the physicochemical properties of the Biofac hydrolysates highlighted that the 
production method has an important impact on their physical properties.  The size distribution and 
morphology of the particles were directly linked to the method of drying (either lyophilisation or spray 
drying). This subsequently, affects properties such as flowability, the lyophilised H1 for example did 
not flow at all compared to the spray-dried L1and P1 samples.  In contrast to the size distribution and 
morphology, the solubility is not directly linked to the production method (although dissolution rate 
may be linked).  Solubility is dependent upon the molecular composition of the hydrolysates, though 
the high temperatures used in spray drying could be responsible for the differences between the spray 




 Bioactive properties of whole and fractionated 
hydrolysates 
4.1 Introduction 
The investigation into the hydrolysates supplied by Biofac initially centred on the analysis of the 
physicochemical properties of the hydrolysates L1, P1, and H1 (see chapter 3).  This work highlighted 
how the manufacturing process had a major impact on the physical properties.  With regards to 
bioactivity, the physical properties of the hydrolysates relate to the bioavailability of the peptides within 
the samples.  The solubility at various pH levels is an example where the physical properties affect the 
bioactivity; if the hydrolysates do not dissolve easily at biologically relevant buffers at certain pH levels, 
then they will not be biologically available. 
The hydrolysates that were analysed in the bulk of the physicochemical study (chapter 3) were the 
original samples from Biofac, these were liver 150615-1900 (L1), placenta 0-150625-1700 (P1), and 
heart 150615-1900 (H1) (All hydrolysates were analysed using the total carbohydrate assay, and L2 
and P2 were analysed along with H1, L1, and P1 using SEC-MALS).  It was decided that the work 
would concentrate on the placenta and liver hydrolysates because these were more interesting to Biofac.  
As well as the original placenta (P1), and liver (L1) hydrolysates, newer batches were supplied by 
Biofac. These were generated using similar processes but with an added step to remove particles with 
a greater molecular weight than 5 kDa.  The majority of the data generated was from these newer batches 
denoted as L2 (liver 160126-0700), L3 (liver 170127-0815), and P2 (placenta 0-160330-1500). 
The specific examples of bioactivity used to assay the Biofac hydrolysates for this study were selected 
because they were commonly used in relatable studies on bioactive peptides found in the literature.  The 
main areas of interest for this study were antioxidant activity, cell proliferation and wound healing, and 
anti-hypertension.  Of these three bioactivities, antioxidant, and anti-hypertension activity have been 
researched extensively in relation to peptides, whereas cell proliferation and wound healing properties 
of peptides have not been investigated to the same extent, but there are examples of studies into these 
properties (Ryaby et al., 2006, Demidova-Rice, 2011). 
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The antioxidant assays used to assess the hydrolysates were the DPPH assay, ORAC assay, the linoleic 
acid/ FTC assay, and the CAA assay.  The DPPH assay is a radical scavenging assay that assesses to 
what degree a compound can protonate the stable radical DPPH· to the non-radical DPPH.  The ORAC 
assay is a relatively simple assay, and is widely used in similar studies that investigate the antioxidant 
activity of bioactive peptides.  The mechanism of the ORAC assay is the degradation of the fluorescent 
probe sodium fluorescein when exposed to reactive oxygen species generating compound (in this case 
AAPH).  The antioxidant activity of compounds is assessed by their ability to reduce or stop the 
degradation of the fluorescent probe.  The DPPH, and ORAC assays are two non-cell based assays that 
are used to investigate two different mechanisms of antioxidant activity. While they are widely used in 
the literature, they have faced criticism on their lack of biological relevance (Wolfe and Liu, 2007).  For 
this reason, the linoleic acid/FTC assay was used to investigate the ability of the hydrolysates to reduce 
autoxidation in lipids.  The final assay used was the CAA assay.  This assay was used to assess how 
well the hydrolysates could reduce the oxidative stress to a cell when external oxidative stress is applied, 
in this case with the application of AAPH to the cells.  This assay was selected because of its biological 
relevance (Wolfe and Liu, 2007).  Antioxidant assays that use cells are performed under physiological 
pH and temperature, but most importantly, they take metabolism and intracellular transport under 
consideration. 
The effects on cell proliferation were investigated using a simple cell counting method, with the data 
generated used to calculate cell DT, and PDL, and using the MTT assay.  The potential effect of the 
hydrolysates on wound healing was assayed using the scratch wound assay.  Using PDL and DT to 
analyse the effects of the hydrolysates on the cells is a good way to gather initial data related to the 
health of the cell population.  Healthy cells will routinely divide within a certain time range depending 
on the cell line.  If the cells are affected either positively (increased proliferation) or negatively, the 
number of times the population doubles (PDL) and the doubling time (DT) will differ from that of the 
control group.  Major deviations from a normal DT is an indication that the cells have been affected by 
the sample being tested.  The PDT is measured against the control group.  If a sample group PDL is 
significantly different to the control, the compound being tested is likely to be the cause.  These assays 
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are preliminary tests; if significant results are generated then a more in depth, investigation can be 
undertaken. 
Bioactivity of peptides is directly linked to their structure (Nardo et al., 2018).  Understanding the 
structure activity relationships of compounds is a powerful tool in the analysis of bioactivity.  Analysis 
of the composition of the hydrolysates is therefore an interesting, and important element of this study.  
The first steps in analysing the composition of the hydrolysates were carried out using RP-HPLC with 
a C-18 analytical column specifically designed for peptide analysis. The L2 hydrolysate was also 
selected to be further analysed using prep HPLC.  The fractions generated from the prep HPLC were 
recovered by lyophilisation before reconstitution in relevant buffers.  This work led onto the 
investigation into peptide sequencing (using de novo sequencing), which was used to create novel 
synthetic peptides (described in chapter 5).   
The possible effects of peptide degradation on the bioactivity of the hydrolysates was also investigated 
in this section of the study.  It was noted in chapter 1, that bioactive peptide sequences can be found in 
longer peptide chains, or within host proteins.  With this in mind, the stability of the hydrolysates in 
solution was investigated over a seven-day period.  This was undertaken using HPLC, with the activity 
of the samples tested using the MTT assay. 
The aim of this section of work was to discover if the Biofac hydrolysates demonstrate certain 
bioactivities, namely antioxidant activity, cell proliferation and chemotaxis, and to assess fractions of 
the hydrolysates generated from HPLC, for bioactivity.  The information on the crude hydrolysates are 
of particular importance to Biofac because the data generated can be used in the promotion of their 
products.   
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4.2 Materials and methods 
 DPPH Radical Scavenging Activity (RSA) 
4.2.1.1 DPPH Method 1 
The DPPH assay is an inexpensive, and relatively simple assay that can be used to ascertain the 
antioxidant capacity of a given substance.  The assay is based on the stable radical DPPH·, which is 
purple in colour, being converted to the pale yellow DPPH.  This requires molecules that act as proton 
donators (Figure 4-1).  The method used in this assay was developed from various protocols used in 
the literature (Ahmed et al., 2015, Shen et al., 2010, Romano et al., 2009, Szabo et al., 2007). 
 
Figure 4-1 Conversion of the purple 1, 1-diphenyl-2-picrylhydrazyl (α,α-diphenyl-β-picrylhydrazyl radicl (DPPH·) to the yellow 
1, 1-diphenyl-2-picrylhydrazyl (α,α-diphenyl-β-picrylhydrazyl (DPPH) by protonation 
DPPH (0.1 mM) in 100 % ethanol was prepared immediately before use.  DPPH (3.9 mg) was added to 
a 10 mL volumetric flask then made up to 10 mL with 100 % ethanol to produce a stock solution.  The 
working solution was prepared by diluting the stock DPPH solution (3 mL) with 100% ethanol (27 mL).  
Both DPPH solutions were wrapped in foil and stored at 3-8 °C until required. 
 
Hydrolysates and L-Ascorbic acid (control) solutions (500 µg/mL) were prepared by adding 50 mg of 
sample to deionised water in a 100 mL volumetric flask. All samples were prepared in triplicate and 
wrapped in foil.  Each sample was shaken vigorously before being left to incubate at room temperature 
for 30 minutes.  Blank solutions were prepared for each sample by adding 100 % ethanol (0.75 mL) to 
the sample (2.25 mL).  A negative control was prepared by combining DPPH working solution (0.75 
82 
 
mL) with deionised water (2.25 mL).  Hydrolysate samples and positive controls were prepared by 
combining DPPH working solution (0.75 mL) with the relative sample solution (2.25 mL).  The samples 
were measured using a UV-VIS spectrophotometer at 517 nm.  The UV-VIS spectrophotometer had the 
baseline adjusted, and blanked by the relative blank solution prior to use. Antioxidant activity of the 
samples were determined using equation 4.1: 
RSA (%) = [1-(Abs1 ÷ Abs0)] x 100   (Eq. 4.1) 
Where RSA is Radical Scavenging Activity, Abs1 is the absorbance of the sample at 517 nm and Abs0 
is the absorbance of negative control at 517 nm  
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4.2.1.2 DPPH Method 2:  96 well plate DPPH RSA assay 
A DPPH assay using 96 well plates was developed to increase the throughput, and to make the assay 
more statistically robust.  DPPH solution was prepared as stated previously in section 4.2.1.1.  
Hydrolysate solutions were prepared by adding the relevant sample to 10 mM potassium phosphate 
buffer in a volumetric flask (buffer at a higher concentration forms precipitation with the addition of 
ethanol). 
 
The hydrolysate solutions (225 µL) were added to the relevant wells in row b of the plates, and the 
relative solvent (112.5 µL) being added to the other wells.  A 1:1 dilution series was created by 
removing 112.5 µL of the peptide solution and mixing with the next row, this was continued until the 
lowest concentration.  The negative control was 112.5 µL of the relevant solvent.  For each dilution, a 
blank was also prepared in the same manner.  To each of the sample wells, DPPH solution (37.5 µL) 
was added.  To each of the blank wells ethanol (37.5 µL) was added.  The plates were covered with a 
plate cover, and incubated in the dark at room temperature for 30 minutes. 
 
The plates were read using a Tecan Infinite F50 plate reader.  The wavelength was set to 540 nm (this 
is the closest wavelength possible to 517 nm on this apparatus; DPPH still absorbs well at this 
wavelength).  The results were generated form the plate reader data by subtracting the mean blank value 
of a particular concentration form the individual values of the samples.  The RSA was calculated using 
equation 1. 
 ORAC Assay  
The Oxygen Radical Absorbance Capacity of the Biofac hydrolysates were analysed using the ORAC 
assay.  The assay was based on work carried out by Boxin et al (2001), and Huang et al (2002) with 
minor changes (Boxin Ou 2001, Huang et al., 2002). 
 
AAPH solution (153 mM) was prepared fresh by adding AAPH (0.414 g) to 10 mM potassium 
phosphate buffer (pH 7.4) (made up to 10 mL). 
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Sodium fluorescein stock solution (4 µM) was prepared by adding sodium fluorescein (15 mg) to 10 
mM potassium phosphate buffer (pH 7.4) (made up to 100 mL) to produce a concentration of 0.4 mM.  
This was then diluted with 75 mM potassium phosphate buffer (pH 7.4) 1:1000 to reach the required 
concentration.  The stock solution was stored at 2-5°C.  Working sodium fluorescein solution (4 µM) 
was prepared fresh by diluting the stock with buffer 1:1000. 
 
The synthetic vitamin E analogue Trolox is a widely used standard for antioxidant assays.  Trolox was 
used to generate a standard curve against which the experimental samples could be measured.  The 
Trolox standard solution (200 µM) was prepared by adding 10 mg of Trolox to 10 mM potassium 
phosphate buffer (pH 7.4) (made up to 50 mL).  Trolox was dissolved using a magnetic stirring hot 
plate set to 50°C and left until the Trolox had fully dissolved. 
 
Hydrolysate samples (800 µg/mL) were prepared by dissolving the specific sample in 10 mM potassium 
phosphate buffer (pH 7.4).  The stock solutions were used to prepare a concentration gradient ranging 
from 100 µg/mL to 0.78 µg/mL. 
 
Black 96 well plates (Thermo Scientific™ Nunc™ FluoroNunc™/LumiNunc™ 96-Well Plate) were 
set up with the outside wells (rows A and H, and columns 1 and 12), and wells in columns 9, 10, and 
11, rows b to g, filled with deionised water (200 µL).  The plates were covered and warmed to 37°C.  
Sample dilution series were created by adding sodium fluorescein working solution (300 µL) to sample 
wells with either a sample stock solution, or the Trolox standard (50 µL) in a single row.  Sodium 
fluorescein working solution (175 µL) was added to all other sample wells.  175 µL was removed from 
the first set of wells and added to the next, and so on until the final well after which the 175 µL removed 
was discarded.  A negative control was prepared with buffer replacing the sample.  Blanks were 
prepared by adding 10 mM potassium phosphate buffer (pH 7.4) (175 µL) to the plate in triplicate.  The 
plates were incubated at 37°C for 30 minutes. 
Following incubation, the plates were placed in the Fluostar Optima microplate reader using the plate 
mode for slow kinetics.  The fluorescence was measured every minute for 5 cycles. After 5 cycles, the 
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plate was removed and 153 mM AAPH solution (25 µL) was added to each experimental well.  The 
plate was returned to the plate reader where the fluorescence was measured every minute for 115 
minutes.  The fluorescence of each sample, at each time point were blank corrected to remove 
background fluorescence.  The data from the plate reader were plotted onto graphs so that the area under 
the curve (AUC) could be calculated.  The ORAC value (equation 4.3) was calculated from the (AUC) 
(equation 4.2).   
AUC = ∑ [(a + b) ÷ 2] + [(b + c) ÷ 2] ……………+ [(y + z) ÷ 2]   (Eq. 4.2)
   
Relative ORAC value = [(AUCsample – AUCblank) ÷ (AUCTrolox – AUCblank)] X (molTrolox ÷ 
molsample)]          (Eq. 4.3)  
 Lipid peroxidation inhibition  
Lipid peroxidation inhibition followed the method used in previous studies with some modifications 
(Nazeer et al., 2013, Chen et al., 1996, Osawa and Namiki, 1985). Linoleic acid emulsion was used as 
the lipid peroxidation model with the FTC assay used to quantify the peroxidation.  All samples were 
prepared in triplicate as follows:  Solution A:  Test samples (Trolox/hydrolysates) were dissolved in 0.1 
M pH 7.0 phosphate buffer (1.0 mL).  The negative control was prepared with buffer alone.  Deionised 
water (0.5 mL) was added to bring final volume to 1.5 mL.  Solution B:  50 mM linoleic acid (16 µL) 
was added to 1.0 mL 100 % ethanol.  Solutions A and B were then combined to produce an emulsion. 
A 50 µL aliquot was removed immediately for the first time point of the FTC assay.  The vial was then 
sealed and placed in an incubator at 40°C and 50 µL samples were taken every 24 hours and analysed 
using the FTC assay. 
 
FTC solution was prepared by adding 30% ammonium thiocyanate (50 µL), and 20 mM ferrous chloride 
solution in 3.5% HCl (50 µL) to 75% ethanol (2.35 mL).  The linoleic acid emulsion system (50 µL) 
was added to the FTC preparation and left to incubate at room temperature for 3 minutes. The 
absorbance was read at 500 nm to determine the level of peroxidation. To obey the Beer-Lambert law 




The last FTC assay was performed 24 hours after the negative control exceeded 2.0 on the absorbance 
scale; the end-point of the assay was taken at the time point before the absorbance reached 2.0.  The 
level of peroxidation inhibition is relative to the negative control. Equation 4.4 was used to calculate 
percentage of inhibition of lipid peroxidation: 
Inhibition (%) = (1 – Abs. of sample ÷ Abs. of negative control) X 100 % (Eq. 4.4) 
 Cellular antioxidant activity assay (CAA) 
The CAA assay was based on the method developed by (Wolfe and Liu, 2007).  The other antioxidant 
assays performed for this project are directed at specific mechanisms (one for each assay); they also do 
not involve biological systems.  The CAA assay performed in this research used 3T3 fibroblasts.  The 
mechanism for the assay is described in Figure 4-2, and Figure 4-3. 
 
Figure 4-2 Mechanism for the cellular antioxidant assay. 2’-7’ dichloro-dihydro-fluorescein diacetate (DCFH-DA) (non-polar) 
crosses the cell membrane where it is cleaved to form the more polar 2’-7’ dichloro-dihydro-fluorescein (DCFH); DCFH 
cannot then diffuse out of the cell.   
Briefly, the non-polar DCFH-DA crosses the cell membrane where it is cleaved into the polar DCFH; 
DCFH cannot then diffuse out of the cell.  AAPH can diffuses into the cell where it generates peroxide 
radicals (ROO+) by spontaneously decomposing; these radicals can also attack the cell membrane, 
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which in turn generates other radical (ROS+).  The radicals oxidise the DCFH to the fluorescent DCF.  
The introduction of antioxidants to the system will reduce the levels of DCF in the cell by interacting 
with the ROO+ and ROS+, and by preventing the generation of ROS+ from the breakdown of the 
membrane. 
 
Figure 4-3 The nonpolar 2’-7’ dichloro-dihydro-fluorescein diacetate (DCFH-DA) is converted into the polar 2’-7’ dichloro-
dihydro-fluorescein (DCFH) by cellular esterases.  DCFH can then be oxidised into the fluorescent form of 2’-7’ dichloro-
dihydro-fluorescein (DCF) by (reactive oxygen species (ROS+) and peroxide radicals (ROO+). 
3T3 fibroblast cells were seeded in triplicate at cell density of 3 x 104/well on a 96 well plate (3 x 
105/mL) using Dulbecco’s Modified Eagle Medium (DMEM) supplemented with L-glutamine, HEPES 
buffer, and PenSrep.  The cells were incubated for 24 hours at 37°C, 5% CO2.  After 24 hours the media 
was aspirated and the cells washed with PBS (0.01 M).  To the relevant wells, hydrolysates dissolved 
in 100 µL of supplemented DMEM (containing DCFH-DA (5 µM)) were added.  The concentrations 
of hydrolysates in the sample media were 8, 4, and 2 mg/mL.  The plates were returned to the incubator 
for a further 1 hour.  After 1 hour the sample media was removed and the cells were washed with PBS 
(0.01 M).  AAPH (120 µM) in Hank’s balanced salt solution (HBSS) (100 µL) was added to each 
experimental well before the plate was placed into the Fluostar Optima microplate reader (set to 37ºC, 
excitation at 485 nm, emission at 520 nm, readings taken every 5 minutes for 45 minutes).  All plates 
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included control, and blank wells.  Control wells contained no experimental sample and blank wells 
contained no AAPH and no sample. 
 
The values from the blank wells were subtracted from the experimental, and control wells.  The 
fluorescence was plotted against time, and the AUC (equation 4.2) for each sample was calculated.  
The AUC of the control (no sample) was used to calculate the cellular CAA (equation 4.5.), which was 
expressed as a percentage.  Positive figures indicated that a particular sample showed antioxidant 
properties in relation to this assay, whereas negative figures would suggest that the sample increased 
the production of DCF, and therefore were causing oxidative stress. 
CAA unit = 100 – (∫ SA ÷ ∫ CA) x 100   (Eq. 4.5) 
∫SA is the integrated area under the curve of the sample fluorescence versus time and ∫CA is the 
integrated area from the control curve. 
 Cell proliferation 
The hydrolysates were assayed for potential wound healing properties.  One aspect of wound healing is 
cell proliferation (Gonzalez et al., 2016).  Two methods were used to discover if the hydrolysates had 
an effect on the proliferation of fibroblasts in vitro. 
4.2.5.1 Cell counting method 
Hydrolysate solutions were prepared by dissolving 360 mg in 30 mL of PBS (pH 7.4).  This was then 
sterile filtered, and used to produce the following dilutions:  12 mg/mL, 6 mg/mL, and 3 mg/mL.  Six 
well plates were seeded with 3T3 fibroblasts at 3 x 105 cells/well (2.95 mL) in DMEM supplemented 
with FBS (10%), 1 M HEPES (2%), 220 mM L-glutamine (2%), and penicillin-streptomycin (1%).  50 
µL of the relevant dilutions were added to make the total volume 3 mL. The plates were incubated for 
48 hours at 37 °C, 5 % CO2.  The cells were counted using a haemocytometer and staining with trypan 
blue to evaluate cell proliferation.  From the cell count data, the average PDL (equation 4.6 (Roth, 
1974)), and DT (equation 4.7) were calculated.  Any significant effect of the peptides on the cells 
would be indicated by a deviation in the PDL and DT when compared to the control. 
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PDL = 3.321 x log (b ÷ c)   (Eq. 4.6) 
DT = T x log2 ÷ log (b ÷ c)   (Eq. 4.7) 
Where T = time in culture (hours), b = end cell number (total), and c = start cell number (total) 
4.2.5.2 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
To identify and quantify cell proliferation an MTT assay was performed, whereby the tetrazolium ring 
of MTT is cleaved by the mitochondrial dehydrogenases in living cells, producing purple formazan 
crystals. Dissolving these crystals and measuring the absorbance is an indication of the cell population 
metabolic activity.  A growth curve was generated by seeding 3T3 cells at various densities (5 x 102 to 
1 x 105 cells) in a 96 well plate.  They were left for 22 hours before a MTT assay was performed.  The 
resultant absorbance data was then used to generate growth curves, which were used to calculate cell 
number.  A 96 well plate was seeded at 2 x 103 cells/well with 3T3 cells and left to incubate overnight 
to allow cell adhesion.  A dilution series was produced from the hydrolysate solutions prepared for the 
cell counting assay.  The range was from 600 µg/mL to 25 µg/mL.  50 µL of each dilution was added 
to the relevant wells in triplicate.  The final concentrations of each ranged from 200 µg/mL to 8.3 
µg/mL.  The plate was then returned to the incubator and after 48 hours, the cells were assayed using 
MTT. The subsequent absorbance values were used to calculate the proliferation of the cells by using 
equation 4.8. 
 Percentage proliferation = [(a ÷ b) x 100) -100]    Eq. 4.8 
Where a = mean absorbance of control group, and b = absorbance of experimental sample. 
 HPLC analysis of hydrolysates and fractionation of liver hydrolysate 
The hydrolysates were analysed using HPLC to gather information on the composition of the 
hydrolysates.  The hydrolysates were first analysed using analytical HPLC, which was then scaled up 





4.2.6.1 Reverse phase HPLC  
The initial chromatography work on the samples utilised HPLC using an analytical C18 column 
specifically designed for peptides and small proteins (Ascentis® Express Peptide ES-C18 (length 100 
mm, ID 4.6 mm).  Hydrolysate samples were dissolved in the aqueous mobile phase (acetonitrile 
(0.2%), TFA (0.01%), made up to required volume using HPLC grade water) and then 100 µL of the 
reconstituted hydrolysates were injected onto C18 column for analysis using a flow rate of 1 mL/min.  
The concentration gradient of acetonitrile for all samples went from 5% to 29% in the first 10 minutes 
followed by from 29% to 95% in the following 5 minutes. 
4.2.6.2 Preparative HPLC  
To accurately quantify the activity of each fraction generated by HPLC, a greater mass was required. 
To generate more of the fractionated samples a Gilson prep HPLC system was used with a Dynamax-
60A C18 (length 250 mm, ID 21.4 mm) column. The difference in size between the analytical column 
and the prep column has to be taken into account.  Equation 4.9, and Equation 4.10 were used to alter 
the method used for the analytical column, to scale up for the prep column: 
Fp = [Fa x (D2p÷D2a)] ÷ (PSp ÷ PSa)  (Eq. 4.9) 
Vp = Va x [(D2p ÷ D2a) x (Lp ÷La)]  (Eq. 4.10) 
Where Fp = Flow rate of prep column (13.5 mL/min), Fa = Flow rate of analytical column (1 mL/min), 
D2p = Internal diameter of column squared of prep column (457.96 mm), D2a = Internal diameter of 
column squared of analytical column (21.16 mm), PSp = Particle size of prep column (0.008 mm), PSa 
= Particle size of analytical column (0.0027 mm), Vp = injection volume for prep column (2.2 mL), Va 
= injection volume for analytical column (0.04 mL), Lp = Length of prep column (250 mm), and La = 
Length of analytical column (100 mm). 
 
The prep HPLC was only carried out on the <5 kDa liver hydrolysate (L2).  For each run 1 mL of 
dissolved hydrolysate (50 mg/mL) was loaded onto the column. 
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4.2.6.3 Freeze drying fractions 
The collated fractions were divided up into smaller aliquots for freeze-drying (approximately 10 mL 
into 50 mL tubes).  The aliquots were covered with Parafilm then flash frozen using liquid nitrogen so 
that the samples coated the sides of the tubes (to increase the surface area of the frozen sample).  The 
aliquots were stored on dry ice until required.  The samples were freeze dried for 25 hours. Freeze dried 
samples of the same fractions were combined then stored at -20°C. 
4.2.6.4 HPLC analysis of fractions generated form prep HPLC 
The fractions generated from the prep HPLC were further analysed using an analytical C18 column 
(Ascentis® Express Peptide ES-C18).  The parameters were the same as described in section 4.2.6. 
 Assays performed on prep HPLC fractions 
The lyophilised samples generated from the HPLC fractions were assayed along with the full liver 
hydrolysate (L2) to test for bioactivity.  The assays performed were the MTT assay, to identify any 
increase or decrease in cell proliferation, a scratch assay to identify any increase or decrease in 
chemotaxis, and a radical scavenging assay utilising DPPH. 
4.2.7.1 MTT assay 
The cell plates for the MTT assay were prepared according to section 4.2.5.2.  Liver hydrolysate fraction 
preparations (concentration gradient from 200 – 50 µg/mL) were added to the plate and incubated at 
37°C at 5% CO2 for 46 hours.  20 µL of MTT in PBS (5 mg/mL) was then added to each well and the 
plate was then incubated at 37°C at 5% CO2 for 4 hours after which, the media was aspirated and 150 
µL of dimethyl sulfoxide (DMSO) was added.  The plate was read at 540 nm on a plate reader utilising 
a 5 second shake.  The data was generated using equation 4.8. 
4.2.7.2 Scratch Assay 
The scratch assay was adapted from the method used by Travan et al (2016) (Travan et al., 2016). 12 
well plates were seeded with 3T3 fibroblasts at a cell density of 1.5 x 105 cells/mL (2.25 x 105 cells/well) 
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two days prior to the assay and were cultured until confluent.  Peptide fractions were weighed out, and 
used to produce sample preparations using complete growth media (CGM).  Each sample preparation 
was then sterile filtered using 0.22 µM syringe filters.  The target concentration for the preparations 
was 400 µg/mL.  It should be noted that there was not enough of sample F2R1 to produce a 
concentration of 400 µg/mL in the volume required (the maximum concentration of this sample was 50 
µg/mL).  Mitomycin C in PBS (1mg/mL) was added to each preparation along with control media 
(CGM only) to achieve a concentration of 15 µg/mL.  Mitomycin C was added to inhibit mitosis 
therefore, preventing the proliferation of cells without inhibiting chemotaxis (Schreier et al., 1993). 
 
Using sterile 20 µL pipette tips, a scratch was made in the confluent monolayer of each well to produce 
a wound.  The wells were then washed using PBS before the sample preparations were added.  Each 
well was marked in a suitable place and micrographs were taken to record the area of each wound.  This 
was repeated until the wounds were healed. 
 
The first micrograph taken was assigned as 0% closed (Figure 4-4 a) and the area of the wound was 
used as a reference for all other micrograph images taken at the proceeding time points to calculate the 
percentage of wound closure.  The assay ended when the cells had migrated to fill in the wound gap 
(Figure 4-4 b).  The area of each wound was calculated using Image J (version 1.51j8, National 
Institute of Health Bethesda, U.S.A.) (Schindelin et al., 2012).  Wound closure rate (μm2/h) was 
calculated using Equation 4.11:  Percentage wound closure was calculated using equation 4.12. 
Wound closure rate (μm2/h) = (Wn - W0) ÷ Tn   (Eq. 4.11) 
% wound closure = [1 - (Wn ÷ W0)] × 100   (Eq. 4.12) 
Where Wn = Area of wound at the end time point, W0 = Area of wound at time zero, and Tn is the 




Figure 4-4 An example of a wound created in a confluent monolayer of 3T3 fibroblasts (a), and the ‘healed’ wound (b) 
4.2.7.3 DPPH Radical Scavenging Assay 
The collated liver hydrolysate fractions from the prep HPLC were used in a quantitative DPPH assay 
using the 96 well format that was previously described in section 4.2.1.  The samples were prepared in 
pH 7.4 potassium phosphate buffer to a concentration of 0.8 mg/mL. A serial dilution was then 
performed on the plate to produce a concentration gradient. 
 Stability studies 
Whole hydrolysates were prepared in supplemented DMEM to the concentrations of 0.8, 0.4, and 0.2 
mg/mL.  The specific media were then separated into eight aliquots each, before being stored at -20°C 
for 24 hours.  After 24 hours one of each of the placenta (P2), and liver hydrolysate (L2) media were 
removed from the freezer and stored at 5°C.  This was performed every 24 hours until all aliquots had 
been removed.  The thawed aliquots were then used in MTT assays (set up described in section 4.2.5.2, 
concentrations as in 4.2.10.1), and analysed using HPLC (parameters described in 4.2.6) to determine 
whether the peptides contained in the hydrolysates were stable at 5°C.  The aliquot taken for the 0 h 
sample was used immediately after it had thawed. 
 ACE inhibition assay 
ACE from rabbit lung was (purchased form Sigma Aldrich 2U equal to 1 mg of protein) reconstituted 
in milli-q water (1 mL) to produce the ACE stock solution (1 U/mL, 500 µg/mL of protein).  ACE 
working solution (200 mU/mL, 100 µg/mL of protein) was prepared by diluting the stock solution 1:5.  
ACE stock solution was stored at -20°C and the ACE working solution was prepared when required, 
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and stored at -20°C.  HHL solution was prepared by adding HHL (2.15 mg) to TRIS buffer (pH 8.3) 
(10 mL) containing NaCl (300 mM), and ZnSO4 (10 µM) (10 mL).  Peptide hydrolysate preparations 
were prepared by dissolving either liver 57061850 (L1), liver 58063636 (L2) or placenta 5338 3617 
(P1) hydrolysates into milli-q water.  Milli-q water or experimental sample (40 µL) and 0.5 mM HHL 
(145 µL) were added to 1.5 mL micro-centrifuge tubes and incubated in a water bath at 37°C for 3 
minutes then 200 mU/mL ACE (15 µL) was added to each tube, which were then incubated in a water 
bath at 37°C for 30 minutes.  After 30 minutes 1 M HCl (200 µL) was added to the tubes to stop the 
reaction.  Table 4-1 represents how the samples were set up, where column A indicates experimental 
samples, column B control 1, and column C control 2.  Captopril was used as a known ACE inhibitor. 
Table 4-1 Sample preparation for angiotensin II converting enzyme (ACE) inhibition assay 
 
The samples were analysed by HPLC (Beckman Coulter) using an Ascentis® Express Peptide ES-C18, 
2.7 µm column, to determine the anti-ACE activity of the analytes.  The HPLC was setup as follows:  
0.4 mL/min flow rate, isocratic (mobile phase 50% methanol, 50% water containing trifluoroacetic acid 
(TFA) (0.2%).  The substrate and the product were detected using UV at 228 nm.  The ability of each 
peptide to inhibit ACE was measured by comparing the reduction of HA (the product of ACE digested 
HHL) in relation to the positive control (no inhibitor or peptide present).  Equation 4.13 was used to 
calculate the inhibition. 
ACE inhibition (%) = (1-(B ÷ A)) X 100   (Eq. 4.13) 




 DPPH Radical Scavenging Activity (RSA) 
Data generated is represented in (Figure 4-5 a). Due to the very low levels of activity of P1 at 375 
µg/mL the activity was retested at 5 mg/mL and 50 mg/mL (Figure 4-5 b) 
 
Figure 4-5 Radical scavenging activity (RSA) of 0-150625-1700 (P1) hydrolysate, liver 150615-1900 (L1) hydrolysate, and heart 
150615-1900 (H1) hydrolysate compared with the positive control ascorbic acid at 375 µg/mL (a) 0-150625-1700 (P1) 
hydrolysate at 5 mg/mL, and 50 mg/mL (b) 
The DPPH assay method used here was a useful way to assess whether the hydrolysate samples showed 
activity and it was shown that the activity related to the quantity of proton donors in the peptide and 
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followed the trend Liver > Heart > Placenta. As a quantitative measure of activity however, the method 
was not robust.  The assay was therefore developed into a 96 well plate format, with the absorbance of 




Figure 4-6 Radical scavenging activity (RSA) of heart 150615-1900 (H1) (a), liver 150615-1900 (L1) (b), and 0-150625-1700 
(P1) (c) hydrolysates at different concentrations for 96 well plate assay 
The results presented in Figure 4-6 indicate that L1 has the higher radical scavenging activity, followed 
by H1, and then P1.  This activity is also dependant on the concentration of the hydrolysate.  It should 
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be noted that this activity is applicable to the mechanism of the DPPH assay only.  The data generated 
from the 96 well plate assay was comparable to the data generated from the original method (Figure 
4-5).  The same trend was also observed in the assay performed on the samples L2, and P2 Figure 4-7. 
 




 ORAC Assay  
The ORAC activities calculated for the first batch of hydrolysates (L1, and P1) were calculated from 
the data shown in Figure 4-8, and presented as trolox equivalents (TE) (Table 4-2), which represent 
the relative quantity of analyte required to achieve equivalent ORAC activity.  The TE were calculated 
from the AUC of the Trolox standard curve (Figure 4-9). 
 
Figure 4-8 Data plots generated from the fluorescent plate reader used to calculate the area under the curve (AUC) of 




Figure 4-9 area under the curve (AUC) against the concentration of Trolox (run in conjunction with liver 150615-1900 (L1), 
and 0-150625-1700 (P1) hydrolysates) plotted to form a standard curve to calculate Trolox equivalents (TE) 
The hydrolysates from the original batch (L1, P1) demonstrated markedly different ORAC activity.  
The TE for L1 was 30.5 (30.5 g of L1 wold be needed to achieve the same ORAC value as 1 g of 
Trolox), and the TE for P1 was 277.8. 
Table 4-2 Trolox equivalents for liver 150615-1900 (L1), and placenta 0-150625-1700 (P1) 
Trolox Equivalents (TE) 
L1 P1 
30.5 277.8  
The ORAC activities calculated for the L2, L3, and P2 were calculated from the data shown in Figure 
4-10, and presented as Trolox equivalents (TE) (Table 4-3).  The TE were calculated from the AUC 




Figure 4-10 Data plots generated from the fluorescent plate reader used to calculate the area under the curve (AUC) of Trolox 




Figure 4-11 area under the curve (AUC) against the concentration of Trolox (run in conjunction with liver 160126-0700 (L2), 
liver 170127-0815 (L3), and placenta 0-160330-1500 (P2) hydrolysates) plotted to form a standard curve to calculate Trolox 
equivalents (TE) 
The hydrolysates L1, and L2 demonstrated slightly different ORAC activity to L1, with L3 (TE = 50) 
requiring 40% more than L1 to achieve a similar TE, and L2 (TE = 38.3) 22% more.  The TE for P2 
was 71.4, this was approximately 75% less than the TE for P1. 
Table 4-3 Trolox equivalents (TE) for liver 160126-0700 (L2), liver 170127-0815 (L3), and placenta 0-160330-1500 (P2) 
Trolox Equivalents (TE) 
L2 L3 P2 
38.3 50 71.4 
 
 Lipid peroxidation inhibition assay 
The ability of the hydrolysates (L1, P1, and H1) to reduce lipid peroxidation was assessed using the 
lipid peroxidation assay.  The assay measures the level of peroxidation by using the FTC assay, where 
an increase in peroxidation is by visualised by an increase in absorbance at 500 nm (Figure 4-12).  The 
end-point of the assay was selected to be the time point before the absorbance of the negative control 
exceeded 2 AU. 
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The results showed that all the samples significantly reduced autoxidation in the linoleic acid system 
(Figure 4-13).  There was no significant difference between the hydrolysates in this assay. 
 
Figure 4-12 Absorbance at 500 nm as a result of the ferric thiocyannate assay (FTC) for liver 150615-1900 (L1), 0-150625-
1700 (P1), and heart 150615-1900 (H1) plus ascorbic acid (positive control), and the negative control (a), with the traces for 





Figure 4-13 Percentage inhibition of lipid peroxidation at the reaction endpoint (48 h) 
 Cellular antioxidant activity assay (CAA) 
The fluorescence of each sample at each time point was plotted to show the change in fluorescence over 
time.  The CAA (percentage) (Figure 4-15) was calculated from the subsequent plots (Figure 4-14).  
Single factor Anova tests were carried out on the data to determine whether the results were significant.  
The data indicates that both peptide samples display antioxidant activity for most of the conditions 
assayed with values of 12.8% for liver, and 8% for placenta at 8 mg/mL, 8.7% for liver, and 13.8% for 
placenta at 4 mg/mL, and -2.9% for liver, and 14.3% for placenta at 2 mg/mL.  The CAA (percentage) 
for Trolox were greater than the hydrolysates for all conditions.  The statistical analysis of the data 
indicated that there was a significant difference (p < 0.05) between Trolox samples and the hydrolysates. 
There was no significant difference between the liver, and placenta samples at 8 and 4 mg/mL, a 
significant difference between liver, and placenta samples at 2 mg/mL, and that the data over the 
concentration gradient were not significant for the Trolox, and the placenta samples, but they were 




Figure 4-14 Fluorescence traces showing fluorescence against time (a-c) for liver 160126-0700 (L2) peptides (8 mg/mL, 4 
mg/mL, and 2 mg/mL) (a), placenta 0-150625-1700 (P1) peptides (8 mg/mL, 4 mg/mL, and 2 mg/mL) (b), and Trolox (8 




Figure 4-15 Cellular antioxidant activity (percentage) derived from the traces shown in figure 4-13 
 Cell proliferation 
4.3.5.1 Cell counting method 
The data for the cell counting method (Figure 4-16) indicates that there is no significant difference in 
cell proliferation between cells that were treated with L1, and P1 hydrolysates, and the control group 
(no hydrolysate). 
4.3.5.2 MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
The MTT assay indicated that in higher concentrations, the hydrolysates (L1, and P1) caused cell 
proliferation to be drastically reduced.  However, at lower concentrations, both hydrolysates increased 




Figure 4-16 Cell doubling time (DT), and population doubling level (PDL) measured using cell counts for liver 150615-1900 (L1) 




Figure 4-17 Cell number (bars), and cell proliferation (dots) using (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide) (MTT) assay in comparison to the control for cells treated with liver 150615-1900 (L1) (a) and placenta 0-150625-




 HPLC analysis of hydrolysates and fractionation of liver hydrolysate 
4.3.6.1 Reverse phase HPLC  
The hydrolysates L2, and P2 were analysed using an Ascentis® Express Peptide ES-C18 column.  The 
chromatograms for both hydrolysates both indicate that they are composed of multiple peptides, of 
varying sizes.  The hydrolysate L2 (Figure 4-18) appears to be composed of peptides that fall into three 
different size ranges.  The peaks between 1 and 3 minutes (Figure 4-18 b) are likely to consist of short 
peptides, and single amino acids.  There is a significant peak at 5.6 minutes (Figure 4-18 b), which 
probably is made up of a group of similar longer peptides.  The third significant group is between 22 
and 28 minutes, which was likely to be aggregated product and therefore discounted (Figure 4-18 d). 
The hydrolysate P2 (Figure 4-19), like L2 is also composed of peptides that fall into three different 
size ranges.  The peaks between 1 and 3 minutes (Figure 4-19 b) are likely to be made up of short 
peptides, and single amino acids.  There are more peaks in this range than found in L2.  There is a peak 
in a similar range as found in L2 at 5.78 minutes (Figure 4-19 b); this is also probably made up of a 
group of similar longer peptides.  This peak is much smaller than found in L2.  The third group of peak 






Figure 4-18 Analytical high performance liquid chromatography (HPLC) traces for liver 160126-0700 (L2) full chromatogram (a), with 0 – 8 minutes magnified (b), 8 – 18 minutes magnified (c), 




Figure 4-19 Analytical high performance liquid chromatography (HPLC) traces for placenta 0-160330-1500 (P2) full chromatogram (a), with 0 – 8 minutes magnified (b), 8 – 18 minutes magnified 
(c), and 18 – 28 minutes magnified (d) 
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4.3.6.2 Preparative HPLC (pHPLC) of liver hydrolysate 
The liver hydrolysate (L2) was selected to be fractionated using preparative HPLC.  The fractions that 
were collected (Table 4-4) over five runs were combined and retrieved by freeze-drying the fractions 
for reconstitution in different buffers for further analysis. 
Table 4-4 Times at which each fraction was taken for runs 1 to 5 using liver 160126-0700(L2).  Fractions from run 2 to 5 were 
collated.  Fraction from run 1 were kept separate 
  Run 1 Run 2 Run 3 Run 4 Run 5 
Fraction 1 2.8-4.3 min 2.9-4.0 min 2.7-4.1 min 2.8-4.2 min 2.7-4.3 min 
Fraction 2 4.3-5.6 min 4.0-5.8 min 4.1-5.6 min 4.2-5.8 min 4.3-6.2 min 
Fraction 3 5.6-9.1 min 5.8-9.2 min 5.6-9.4 min 5.8-9.3 min 6.2-9.9 min 
Fraction 4 9.1-13 min 9.2-13.2 min 9.4-13.3 min 9.3-13.5 min 9.9-13.5 min 
Fraction 5 n/a n/a 15-18 min 15-18 min 15.3-18.3 min 
 
The chromatograms produced from the prep HPLC of the L2 hydrolysate (Figure 4-20) are quite 
different to the ones produced by the analytical HPLC column.  The fractions obtained from run 2 to 
run 5 were collated (these were denoted as R2 fractions, e.g. F2R2 was a mixture of fraction 2 from run 
2 to run 5).  Fractions from run 1 were not mixed with other runs.  The samples collected from the prep 
HPLC were labelled F1R1, F1R2, F2R1, F2R2, and F4R1.  After freeze-drying, there was very little 
sample recovered from all F3, F5 fractions, or F4 fractions from run 2 - 5.  Therefore, no analysis was 




Figure 4-20 High performance liquid chromatography (HPLC) chromatograms derived from preparative HPLC of liver 160126-
0700 (L2).  Run 1-4 (a - d) were loaded with 50 mg/mL peptide sample (2.2 mL), run 5 (e) was loaded with 25 mg/mL peptide 
sample (4.4 mL) 
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 HPLC analysis, and physical description of the fractions generated from prep HPLC 
4.3.7.1 Physical appearance of lyophilised peptide fractions (liver) 
The physical properties of the lyophilised fractions from run 1 and the collected samples from runs 2 to 
5 showed some variation between the fractions.  Fraction 1 for both samples appeared denser in that 
there was a greater mass to the pellet than the other fractions collected.  The pellet was also noticeably 
more hygroscopic than the other fractions.  The samples from fraction 2 appeared visually much less 
dense and paler in colour.  It was noticeable that fraction 2 samples were charged which caused them 
to be attracted to the plastic container and made handling of this sample difficult.  Fraction 4 from run 
1 was extremely hygroscopic.  The solid contents of this fraction quickly turned into a liquid when 
exposed to air.  This was observable to the eye, the solid changed form a pale colour to a dark brown 
liquid.  The volume of the sample also reduced in size considerably. 
4.3.7.2 HPLC analysis of fractions 
The fractions generated form the prep HPLC (section 4.3.6.2) were further analysed using an analytical 
C18 column specifically designed for peptides and small proteins (Ascentis® Express Peptide ES-C18).  
The gradients of acetonitrile, and flow rates used were scaled from the data gained from the prep HPLC. 
 
The data shown in (Figure 4-21) highlight the difference between fractions F2R1 and F2R2.  Fraction 
F2R2 had a prominent peak at 4.4 minutes, which was not present in F2R1.  This peak is likely a result 
of the disappearance of the large peak that is present in the chromatogram for run 1, where the amplitude 
of the peaks that eluted between 3 and 5 minutes (Figure 4-20 b to e) are greater in comparison to the 
peaks at a similar retention time (Figure 4-20 a).  There is also a difference in the composition of F1R1 
and F1R2, though not quite so pronounced.  The most obvious difference is the small peak at 4.117 
minutes present in F1R2 (Figure 4-22 b1/b2).  The larger peaks also show a difference.  There 
appeared to be more compounds in F1R1 than F1R2.  Maybe the same process that caused the 
disappearance of the peaks at 9.1 minutes in F1R4 is also responsible for this change. 
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Fraction F4R1 was analysed using the method used for the previous two (Figure 4-23 a1/a2), and with 
a method used to mimic the acetonitrile gradient profile of the prep column (Figure 4-23 b1/b2).  This 
resulted in a different gradient (therefore concentration) of acetonitrile at any given time point.  The 
chromatograms both have a very sharp peak at around 4.3 minutes.  These peaks show similarities to 
the peak described in Figure 4-20 (at 4.4 minutes).  It cannot be determined if these are the same 
compound as of yet.  These samples would have to be analysed with MS/MS to investigate this.  What 
can be said about the peaks at 4.3 minutes in Figure 4-23 is that they have similar retention times 




Figure 4-21 Comparison of analytical high performance liquid chromatography (HPLC) chromatograms of fractions F2R1 (a1), and F2R2 (b1) with areas of interest highlighted (F2R1 peaks 




Figure 4-22 Comparison of analytical high performance liquid chromatography (HPLC) chromatograms of fractions F1R1 (a1), and F1R2 (b1) with areas of interest highlighted (F1R1 peaks 




Figure 4-23 Comparison of analytical high performance liquid chromatography (HPLC) chromatograms of fractions F4R1a (a1), and F4R1b (b1) with areas of interest highlighted (F4R1a peaks 
indicated in a2, and F4R1b peaks indicated in b2) 
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4.3.7.3 MTT assay of lyophilised peptide fractions (liver) 
The results for the MTT assay (Figure 4-24 and Figure 4-25) indicate the percentage of MTT 
metabolism by the cells in the presence of the different fractions, with the results for the control group 
used as the baseline.  The data suggests that there is no significant difference between most of the 
fractions in regards to cell viability (P>0.05).  The two results that show significant differences from 
the others are from fractions F1R2, and F2R2.  F1R2 appears to result in a reduction in cell viability at 
200 µg/mL, whereas F2R2 causes an increase (P<0.05). 
 
Figure 4-24 Cell proliferation data derived from (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) assay 
for the fractions collected from prep high performance liquid chromatography (HPLC):  Liver hydrolysate (L2) (a), F1R1 (b), 




Figure 4-25Cell proliferation data derived from (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) assay 
for the fractions collected from prep high performance liquid chromatography (HPLC):  F2R1 (a), F2R2 (b), and F4R1 (c) 
4.3.7.4 Scratch Assay of lyophilised peptide fractions (liver) 
The results of the scratch assay (Figure 4-26 and Figure 4-27) indicated that there was no significant 
difference in chemotaxis between the fractions.  The full hydrolysate did show the greater closure 
overall however.  When the rates of closure for the samples were analysed (Figure 4-28) it was found 




Figure 4-26 Percentage wound closure for each sample over time showing the error bars for no peptide (c1) (a), full 









Figure 4-28 Rate (µm2/h) of wound closure for negative control (C1), liver hydrolysate (L2) (Full), and the fractions generated 
from preparative high performance liquid chromatography (prep HPLC) (F1R1, F1R2, F2R1, and F2R2). 
4.3.7.5 DPPH Radical Scavenging Assay of lyophilised peptide fractions (liver) 
For the samples prepared at 0.8 mg/mL the fraction with the greatest RSA was F2R2.  A Tukey test 
(HDS = 5.71) indicated that F2R2 was significantly different to F1R1, F1R2, and F2R1, but not the full 
hydrolysate, and that the full hydrolysate was also significantly different to F1R1, and F1R2.  For the 
samples prepared at 0.4 mg/mL, the fraction with the greatest RSA was F2R2.  A Tukey test (HSD = 
5.99) indicated that F2R2 was significantly different to all other samples in the group.  For both the 0.8 
and 0.4 mg/mL concentrations, the full hydrolysate showed the second greatest RSA.  The fraction with 
the greatest RSA for the samples prepared at 0.2 mg/mL was the full hydrolysate, with F2R2 being 
second (no significant difference) (Tukey test HDS = 3.99).  F1R2 showed a significant difference to 
the full hydrolysate but not F2R2.  F1R1, and F2R1 both a significantly lower RSA than the other 
samples; there was no significant difference between these two samples.  The RSA data for the 




Figure 4-29 Radical Scavenging activity (RSA) of lyophilised liver peptide fractions measured by the 1, 1-diphenyl-2-
picrylhydrazyl (α,α-diphenyl-β-picrylhydrazyl (DPPH) assay 
 Stability studies of full hydrolysates 
The data for the stability studies are presented in Figure 4-30 to Figure 4-33.  The MTT data is 
represented as cell proliferation with 0% being the control group.  The data from the stability studies 
indicate that hydrolysates are stable in solution over the period of time that the study was performed.  
This can be seen in the chromatograms in Figure 4-31, and Figure 4-33, and the cell proliferation 




Figure 4-30 Cell proliferation data derived from 1, 1-diphenyl-2-picrylhydrazyl (α,α-diphenyl-β-picrylhydrazyl (MTT) assay:  
placenta 0-160330-1500 (P2) 0h after preparation (a), placenta 0-160330-1500 (P2) 24h after preparation (b), placenta 0-
160330-1500 (P2) 48h after preparation (c), placenta 0-160330-1500 (P2)72h after preparation (d), placenta 0-160330-1500 






Figure 4-31 High performance liquid chromatography (HPLC) data obtained using an Ascentis® Express Peptide ES-C18, 2.7 
Micron HPLC Column, showing data for placenta 0-160330-1500 (P2) in supplemented Dulbecco’s Modified Eagle Medium 




Figure 4-32 Cell proliferation data derived from 1, 1-diphenyl-2-picrylhydrazyl (α,α-diphenyl-β-picrylhydrazyl (MTT) assay:  
liver 160126-0700 (L2)0h after preparation (a), liver 160126-0700 (L2) 24h after preparation (b), liver 160126-0700 (L2) 48h 
after preparation (c), liver 160126-0700 (L2) 72h after preparation (d), liver 160126-0700 (L2) 96h after preparation, liver 





Figure 4-33 High performance liquid chromatography (HPLC) data obtained using an Ascentis® Express Peptide ES-C18, 2.7 
Micron HPLC Column, showing data for liver 160126-0700 (L2) in supplemented Dulbecco’s Modified Eagle Medium (DMEM) 
0h after preparation (a), 96h after preparation (b), and 168h after preparation (c) 
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 ACE inhibition assay 
Three hydrolysates (Placenta (P2), Liver (L2), and Liver (L3)) were tested for anti-ACE activity. All 
the hydrolysate showed ACE inhibitory activity.  P2 demonstrated the greatest activity with 
significantly more inhibition than either of the liver samples (p<0.05).  There was no significant 
difference between the liver samples L2, and L3 (Error! Reference source not found.).  All peptides t
ested showed significantly less ACE inhibition activity than captopril (0.02 µg/mL of captopril showed 
a percentage reduction of ACE activity of 98.7%; data not shown). 
 
Figure 4-34:  Percentage inhibition of angiotensin II converting enzyme (ACE) by the hydrolysates placenta 0-160330-1500 





 Antioxidant activities of the whole hydrolysates 
The investigation into the possible bioactivity of the hydrolysates began with researching their 
antioxidant activity in relation to four different antioxidant assays.  The antioxidant assays were chosen 
because they each concentrate on a different mechanism of action.  Testing the samples using different 
types of assays is important to gain a more complete picture of antioxidant activity exhibited by the 
hydrolysates. 
 
The DPPH assay works by the protonation of the stable radical DPPH·, into DPPH therefore the greater 
the proportion of proton donors present in a sample being analysed, the greater the radical scavenging 
activity.  The Biofac hydrolysates are composed of a mixture of peptides, which are themselves 
composed of various examples of amino acids with charged side chains.  Amino acids with charged 
side chains can be either proton donors or proton acceptors.  The proton donating amino acids are 
glutamic acid and aspartic acid; the proton accepting amino acids are arginine, lysine, and histidine.  
Histidine is not charged at values above pH 6, therefore under the assay conditions (pH 7.2) histidine 
is neutral, and has no bearing on the RSA of the hydrolysates.  The pKa values for the charged amino 
acids (not histidine) are Aspartic acid 3.9, glutamic acid 4.2, lysine 10.5, and arginine 12.5.  This value 
will affect the radical scavenging activities of the peptides at pH values lower than 4.2 and at values 
greater than pH 10.5, only positively charged side chains will be available.  This would likely lead to 
no radical scavenging activity for this particular assay.  This limits the pH range in which this assay is 
useful.  The proportion of charged amino acids in the hydrolysates (  
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Table 4-5) can be used to explain the RSA performance of each hydrolysate.  The RSA results as a 
whole demonstrated that the liver hydrolysates exhibited the greatest antioxidant activity, followed by 




Table 4-5 Percentage of net proton donors present in the Biofac hydrolysates 
 Net Proton Donors (%) 
  H1 L1 L2 L3 P1 P2 
With His 8.2 11 10.8 10.3 5.7 5.7 
Without His 10.3 13.8 13.4 13 6.8 6.8 
The net proton donating groups found in the liver hydrolysates (L1, L2, and L3) are comparable, with 
each other (L1 10.8, L2 10.8, L3 10.3) and the placenta hydrolysates (P1, and P2) both exhibit 5.7 % 
(for full amino acid composition data see appendix I).  The net proton donor groups in the liver 
hydrolysates are 49.3 - 52.3% greater than both placenta hydrolysates and 20.8 - 25.4 % greater than 
H1.  The distribution of the charged amino acids that make up the hydrolysates can be related to their 
relative RSA.  This explains most of the results, however there is a large difference in the RSA of the 
two placenta hydrolysates (P1, and P2) with P1 exhibiting the lowest RSA of all the tested hydrolysates 
(over 100 fold lower than L1).  P2 exhibits a RSA that is approximately 2 fold lower than L2 (which is 
similar to the difference in the proportion of net proton donors).  This large difference cannot be just 
based on the relative proportion of charged side chains because the proportion of net proton donors 
present in P1 and P2 is the same.  There must be another property of P1 that causes it to perform much 
worse than the other hydrolysates, including P2.  The production method to generate P2 utilises a step 
to remove components of the hydrolysates that are > 5 kDa in molecular weight.  It is suggested in this 
study (see chapter 5), and in the literature that small peptides (especially dipeptides) are likely to exhibit 
bioactivity, including antioxidant activity.  It was also noted that the placenta hydrolysates had in 
general a greater proportion of small peptides than those of the liver.  Therefore, the molecular cut-off 
of the P2 hydrolysate relative to P1 would increase the proportion of smaller peptides, and therefore 
increase the antioxidant activity. 
 
The ORAC assay was selected as a means to determine the oxygen radical absorbing activities of the 
hydrolysates because it is a relatively simple assay that is widely used in related literature.  The ORAC 
assay uses the water-soluble azo compound AAPH as the source of reactive oxygen species, and sodium 
fluorescein as the fluorescent probe.  The ability of experimental samples to protect the fluorescent 
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probe (or absorption of oxygen radicals) is directly measured by comparing the fluorescence of a control 
with no sample with that of the experimental sample.  AAPH is a commonly used in antioxidant assays 
as a free radical generator because it will decompose into molecular nitrogen, and two carbon radicals 
through thermal decomposition, with the majority of the carbon radicals then reacting with oxygen, 
resulting in the production of peroxyl radicals (Niki, 1990). 
 
The general trend of the data from the ORAC assays performed on all of the hydrolysate samples follow 
that of the DPPH assay, in that the liver hydrolysates (L1, L2, and L3) show slightly more activity than 
the low molecular weight placenta hydrolysate (P2), with the original placenta hydrolysate (P1) being 
significantly less antioxidant than all the other samples.  The significant lack of activity demonstrated 
by P1 in comparison to the other hydrolysates in relation to the DPPH, and the ORAC assay are likely 
to be related.  The pattern of antioxidant activities exhibited by the liver hydrolysates in the ORAC 
assay follow that of the DPPH assay, where L1 had the greatest activity, followed by L2, and then L3.  
The proportion of proton donating groups in the hydrolysates may interact with the carbon radicals 
produced from the decomposition of AAPH, this in turn would inhibit the production of peroxy radicals.  
The hydrolysates may also interact with the peroxy radicals directly to reduce the oxidation of the 
fluorescent probe. 
 
The data generated for lipid peroxidation reduction showed that all the samples significantly reduced 
autoxidation in the linoleic acid system.  There was no significant difference between the hydrolysates 
used in this assay (L1, H1, and P1).  The reduction in lipid peroxidation is interesting because the same 
mechanism of oxidative stress demonstrated with this model could be related to the oxidative damage 
caused to cell membranes.  Lipid peroxidation occurs when oxidants attack lipids, which contain carbon 
double bonds.  The presence of carbon double bonds found in phospholipids that make up the cell 
membrane, means that lipid peroxidation is biologically relevant (Ayala, 2014).  In the lipid 
peroxidation assay performed for this study, linoleic acid was used as a model for lipids found in cell 
membranes.  This assay was only performed on L1, H1, and P1 because it was decided that developing 
a cell-based assay would be more biologically relevant, and give an indication of how these samples 
134 
 
affect the whole cell instead of just one mechanism, and that the L2, L3, and P2 batches were received 
from Biofac after this decision was made.  However, the results of this assay were interesting because 
they did not follow the trend demonstrated by the DPPH, and the ORAC assays.  This is because the 
mechanism of autoxidation of lipids, which drives this assay, is not relevant to the DPPH and ORAC 
assays. 
 
The hydrolysates analysed using the lipid peroxidation assay (L1, H1, and P1) all exhibited relatively 
good antioxidant activity, whereas when L1, and P1 were analysed using the DPPH, and ORAC assay 
L1 demonstrated greater activity. This is likely because the mechanisms of the assays are different and 
therefore relate to different mechanisms of antioxidant activity.  The ability of P1 to reduce lipid 
peroxidation in the linoleic acid system is unrelated to its lack of activity for the DPPH, and the ORAC 
assay.  Because P2 shows a relatively large increase in activity over P1 in the DPPH, and ORAC assays, 
it was decided to discontinue the analysis of P1 in further studies. 
 
The hydrolysates assayed using the CAA assay were samples L2, and P2.  The antioxidant activity was 
significantly less than the Trolox control used for this assay, but there was some activity.  The 
mechanism of this assay is the conversion of DCFH to DCF through oxidation by the initial oxidation 
by AAPH.  DCFH is formed by the cleavage of DCFH-DA by cellular enzymes and because DCFH 
cannot pass through the membrane and out of the cell, any production of DCF will be intracellular.  This 
would suggest that some of the peptides present in the hydrolysates are either entering the cell, where 
they can counter the oxidative action of AAPH, or interacting with the membrane thus preventing some 
of the oxidation of the membrane lipids by AAPH.  Any reactive oxygen species that are produce 
through normal cell metabolism can be discounted because the activity is calculated from the negative 
control. 
 
What these data do indicate is that the assay is a useful one in relation to bioactivity.  Whereas the non-
cell based assays also showed robust data, they utilised pathways that are not necessarily biologically 
relevant.  This assay also indicates the bioavailability of the samples being tested.  Compounds may 
135 
 
demonstrate good antioxidant properties, but if they cannot get to the target site of action, then this 
activity may not be useful (Sánchez-Rivera et al., 2014).  The samples L2, and P2 do therefore contain 
elements that have antioxidant properties that are biologically available.  Bearing in mind that the crude 
hydrolysates may contain potent antioxidant peptides, just in low concentration, a pure sample of one 
of a synthesised peptide derived from the hydrolysates could show high activity.  
 
In general, the hydrolysates assayed all showed antioxidant activity, over a number of assays, which 
are based on different mechanisms.  These different methods demonstrated that an example of a high 
activity in one assay does not indicate that a similar result will be seen in another assay.  P1 prevented 
the autoxidation of linoleic acid as well as L1, and H1, but it was significantly less active in the DPPH, 
and ORAC assays.  This reinforces the need to use multiple antioxidant assays when assessing 
antioxidant activity. 
 Cell proliferation and wound healing 
Potential wound healing properties of the hydrolysates were initially investigated using two methods; a 
cell counting method that compared the DT, and the PDL, and the MTT assay where absorbance values 
related to the metabolism of MTT were used to quantify cell number.  3T3 fibroblasts were selected as 
the cell model due to the important role fibroblasts play in the wound healing process.  3T3 cells are 
frequently used in wound healing models because they undergo chemotaxis when a simulated wound 
is created in a cell monolayer.  As well as exhibiting chemotaxis, they also deposit collagen, which is 
important in the wound healing process (Fronza et al., 2009, Lipton et al., 1971, Peterkofsky, 1972).  
Fibroblasts migrate to the area of a wound between 16 and 24 hours post damage, and express COL1A1.  
Over the next 6 days the expression of this gene, and subsequent production of type I collagen increases, 
this contributes to the formation of granulation tissue at the wound site (Scharffetter, 1989).  The use 
of 3T3 cells for the cell proliferation assays centred on whether the addition of hydrolysate samples 




The results for the proliferation assays performed on the hydrolysates (L1, and P1) varied greatly 
between the two different methods.  The cell counting method showed very little difference in the 
proliferation of cells, whereas the MTT assay showed that in high concentrations, the peptides caused 
cell proliferation to be drastically reduced.  However, at lower concentrations, both peptides 
significantly increased proliferation.  The initial hypothesis for this event suggested that this could have 
be caused by the decomposition of longer peptide chains, releasing smaller active peptides.  The idea 
that decomposition was responsible arose because the same hydrolysate preparations were used for both 
assays, however, there was a week between the assays (with the week old preparations used in the MTT 
assay, and the fresh preparations used in the cell counting method).  This hypothesis is supported in the 
literature, where there are multiple references to active sequences bound within longer chains (Ahmed 
et al., 2015, Corrêa et al., 2014).  This lead onto work investigating the stability of the peptides, within 
the hydrolysates (discussed later in chapter 5), which indicated that the peptides were in fact stable over 
a longer period than seven days.  The data collected from analysis of the hydrolysates from later batches 
would indicate that the apparent change in bioactivity was either related to a lack of stability within the 
peptides contained within L1, and P1, or that there was some other element present within the samples 
that had an effect on the cell proliferation. 
 
Further investigation into the original hydrolysates (L1, and P1) was not carried out as priority was 
given to the newer batches L2 and P2, which had added filtration step during production to remove 
particles with molecular weights (MW) greater than 5 kDa.  Whilst the investigation into the first batch 
was progressed further, it did provide important data, which influenced the direction of the research.  
The apparent break down of the peptides to release shorter bioactive sequences was the basis for the in 
silico work described in chapter 5. 
 HPLC analysis of hydrolysates and fractionation of liver hydrolysate L2 
The method of producing the hydrolysates uses the cysteine enzyme papain to hydrolyse the raw 
material.  The fact that papain is a relatively unspecific enzyme (see chapter 1) with regards to where it 
hydrolyses peptide bonds means that it is likely that there will be multiple peptides of different 
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sequences and length.  This will result in a complex mixture of peptides, and amino acids that constitutes 
the hydrolysates.  This complex nature is a problem when it comes to analysing the hydrolysates for 
bioactive properties as it is possible to identify if the samples show activity but it is difficult identify 
particular peptides responsible.  To analyse the activity in the hydrolysates further, two methods were 
used.  The first method used analytical reverse phase HPLC to separate the peptides in the samples to 
the greatest resolution possible, before the using the method developed to scale up the fractionation by 
prep HPLC.  The fractions were then collected and freeze-dried prior to use in bioactivity assays.  The 
only hydrolysate sample to be analysed using this method was L2.  The second method concentrated 
on the identification of peptides in the hydrolysates using de novo sequencing and in silico analysis 
(described in chapter 5). 
 
The initial analytical HPLC analysis of the hydrolysates L2, and P2 (Figure 4-18, and Figure 4-19) 
indicated that the hypothesis that the samples were made up of a complex mixture of peptides was 
correct.  The majority of peptides eluted from the column in the first 4 minutes.  The column used to 
analyse the samples was C-18 reverse phase, this means that compounds are separated through 
hydrophobic interactions, and size of the molecule.  It can therefore be said that the majority of the 
peptides eluting from the column, for both L2, and P2 were small, though there are a greater number of 
peaks in the P2 sample in the fraction eluted before 4 minutes.  There was a significant peak present in 
the L2 samples at 5.6 minutes, and it appears like there is a smaller corresponding peak in the P2 sample 
at 5.78 minutes.  The similarities between the samples could be because of the unspecific nature of 
papain, which would result in many small peptides, however, the exact composition of these small 
peptides found in each sample could differ greatly.  The significant group of peaks present in both L2 
and P2 samples that eluted from the column between 22 and 28 minutes, (using a high proportion of 
acetonitrile in the mobile phase), were likely to be conjugates of peptides and other impurities that have 




The liver hydrolysate sample L2 was selected for further analysis using prep HPLC.  This was chosen 
because the liver hydrolysate samples generally had greater bioactivity, and the HPLC data (Figure 
4-18) suggested that there was a greater heterogeneity in peaks. 
 
In total, five prep HPLC runs of L2 were performed.  There was a clear difference between the 
chromatogram for liver peptide run 1 compared to runs 2 to 5.  The significant peaks present in fraction 
4 (9.1-13 min) are not evident in the chromatograms for subsequent runs (Table 4-4, and Figure 
4-20).  Another obvious difference between the chromatograms is the magnitude of the peaks 
represented in fractions 1 and 2.  The peaks from run 1 have approximately half the absorbance as the 
peaks from runs 2 to 5.  In addition to this observation, the peaks from run 5 appear different to the ones 
form previous runs, though it could be argued that runs 2 and 5 are more similar.  A possible explanation 
for the differences between the chromatograms could be that the peptides hydrolysed in the time 
between the first run and the subsequent runs.  This could be the reason for the disappearance of the 
peaks with a greater retention time, and the doubling in intensity for the peaks with a lower retention 
time (larger peptides breaking down to smaller ones).  There was, however, no evidence of this in the 
stability studies (section 4.3.10). Therefore, the most likely explanation was that the peptides were 
aggregating and then dispersing, which would affect the chromatography of the peptides. 
 
The fractions from runs 2 to 5 generated from the prep HPLC were combined whereas the fractions 
from run 1 were kept separate.  The fractions were then lyophilised resulting in solid samples.  While 
the fractions taken from the prep HPLC were from poorly resolved peaks (this being an apparent 
limitation of the column used), they did exhibit markedly different physical properties.  The samples 
from fraction 1 (F1R1, and F1R2) appeared to be much denser than those samples from fraction 2 
(F2R1, and F2R2), which were much less dense, and were obviously charged with clearly visible static 
electrical interactions with plastic containers.  The high density of peaks that eluted from the analytical 
column for both L2, and P2, could be the reason that lyophilised samples were denser than the fractions 
taken after 4 minutes (where the density of peaks is much lower).  The sample derived from fraction 4 
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(F4R1) was stated as being extremely hygroscopic.  The physical properties of this sample could not be 
analysed because the sample quickly liquified within seconds of exposure to the air. 
 
The samples generated from the lyophilised fractions (F1R1, F1R2, F2R1, F2R2, and F4R1) were 
dissolved in the aqueous running buffer for analysis using the Ascentis® Express Peptide ES-C18 
column.  Equivalent fractions from each run were compared to assess the differences between the runs.  
The chromatograms for F2R1, and F2R2 (Figure 4-21) demonstrated a noticeable difference between 
the two runs for this fraction.  All of the significant peak in F2R1 eluted from the column before 2.75 
minutes, and the peaks had significantly lower areas than those found in the F2R2 fraction.  There was 
a significant peak at 4.28 minutes found in F2R2, which is completely absent from F2R1.  Considering 
that there was a considerable peak that eluted from run 1 that was not present in runs 2 to 5, the peak at 
4.28 minutes in F2R2 is likely related to this fact.  This is corroborated by the chromatograms of F4R1 
(Figure 4-23).  When this sample was analysed there was only one peak observed, which eluted at 
similar times (4.37, and 4.27 minutes) to the peak found in F2R2 (Figure 4-21b1/b2).  It is likely that 
the difference between the two fractions can be explained by the absence of a peak in fraction 4 for runs 
2 to 5.  The chromatograms for F1R1, and F2R1 (Figure 4-22) follow a similar pattern to the fraction 
2 samples in that they the peaks have a greater amplitude in the samples from runs 2 to 5.  The peaks 
themselves are more similar to each other in comparison to the chromatograms representing fraction 2 
peaks.  The fact that the peaks in F1R2 have a greater amplitude (with a similar fold change) is probably 
related to the peak found in F4R1. 
 
The fractions generated from the prep HPLC were analysed using the MTT assay, scratch assay, and 
their radical scavenging activity was analysed using the DPPH assay.  The results presented in Figure 
4-24 are the percentage of MTT metabolism by the cells in the presence of the different fractions with 
the results of the control group used as the baseline.  These data suggest that on the whole there is no 
significant difference between most of the fractions in regards to cell metabolism .  The two results that 
showed significant differences from the others were from fractions F1R2, and F2R2.  F1R2 appeared 
to result in a reduction in metabolism at 200 µg/mL, whereas F2R2 caused an increase.  Both these 
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results were significant according to the data.  The fact that it is fraction F2 from the second run that 
showed the greatest positive result is interesting.  Maybe there is a peptide, or multiple peptides that 
were present in this fraction generated from the breakdown, or de-aggregation of the fraction F4 from 
run 1.  The increase/decrease in metabolism over the full peptide could be explained by the peptides in 
the fractions are at a greater concentration than in the full liver hydrolysate.  It should also be noted that 
the peaks found in the fractions from run 2 had a greater amplitude, suggesting that they contained more 
peptides than those found in the fractions from run 1. 
 
The results of the scratch assay indicated that there was no significant difference between the fractions 
in regards to a change in chemotaxis in both the percentage wound closure over time (Figure 4-26), 
and the rate of wound closure (Figure 4-28).  These data taken alongside the MTT data for the fractions 
derived from L2 indicate that there is likely to be no wound healing properties exhibited by either the 
full hydrolysate, or the fractions.  This follows on from the earlier cell proliferation data generated from 
samples L1, and P1, where proliferation was not affected in either a negative or positive manner. It can 
therefore be surmised that the Biofac hydrolysates do not show bioactivity related to wound healing.  
This does not necessarily mean that there will not be any potential peptides that influence wound healing 
in the samples, just that they are in too low a concentration (if they are there at all) to show an effect.  
This is further analysed using the synthetic peptides in chapter 5. 
 
The results of the DPPH assay on the fractions (Figure 4-29) showed a similar relationship between 
activity and concentration as the assays performed on the full hydrolysates (the greater the 
concentration, the greater the radical scavenging activity).  The activity of F2R2 at 0.8 mg/mL and 0.4 
mg/mL were both significantly greater than the other fractions.  The greater activity in comparison to 
the full sample at these concentrations could be due to more active components in the full sample being 
in a greater concentration in this fraction, however, this does not explain the equalisation of the activities 
at 0.2 mg/mL.  The mechanism for the DPPH assay relies on the availability of proton donors.  It would 




 Stability Studies 
The data from the stability studies indicated that hydrolysates were stable in solution over the period of 
time that the study was performed.  This can be seen in the chromatograms presented in Figure 4-31, 
and Figure 4-33, and the cell proliferation graphs in Figure 4-30, and Figure 4-32.  These data 
show that the peptides that are present in the hydrolysates were stable in solution up to 168 hours.  This 
discounts theories that more active peptides are released from larger peptides over time. 
 ACE inhibition assay 
A large proportion of bioactive peptides that have been reported in the literature show anti-angiotensin 
converting enzyme (ACE) activity.  It was this reason the anti-ACE activity of the hydrolysates was 
investigated. The method used was developed based on the synthetic ACE substrate HHL, using the 
known ACE inhibitor Captopril as the positive control.  The ability of the enzyme to cleave HHL was 
determined by the decrease in the product HA. 
 
The placenta hydrolysate (P2) demonstrated significantly more anti-ACE activity than the liver 
hydrolysates (L2, and L3) (Error! Reference source not found.).  Looking at bioactive peptide d
atabases, a common feature of peptides that show anti-ACE activity is that they are di-peptides. The 
data generated from HPLC analysis of the P2 hydrolysate indicated that there was a greater proportion 
of di-peptides in the sample than the liver hydrolysates.  The majority of known bioactive peptides that 
exhibit anti-ACE activity are di-peptides.  This would explain why the placenta hydrolysate showed 
significantly greater activity than the liver samples. 
4.5 Summary 
The assays performed on the Biofac hydrolysates indicated that there are bioactive peptides present in 
the samples.  The antioxidant assays showed that there was a wide range of antioxidant activity in all 
the samples assayed, except for P1, which only showed significant activity (relative to the other 
samples), in the lipid peroxidation assay.  Batch to batch variation (L1, L2, L3, and P1, P2.) was also 
apparent.  This was clearly evident in the dramatic difference observed in the DPPH assay for the liver 
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hydrolysates, and the ORAC activity demonstrated by the both the placenta and liver hydrolysates.  
These batch-to-batch variations can be attributed to the production method used.  The data generated 
from the ACE inhibition assay highlights interesting possibilities in the discovery of potent anti-
hypertension peptides present in the hydrolysates.  This data was encouraging, highlighting the 




 Generation of and bioactivity analysis of synthetic 
peptides derived from hydrolysates 
5.1 Introduction 
As discussed in previous chapters, bioactive peptides can be released from precursor proteins by 
proteolytic enzymes.  Some common proteases that are used in the hydrolysis of proteins include 
digestive enzymes that can be found in the gastrointestinal tract, these include trypsin, and pepsin, while 
others can be derived from microorganisms and plants.  Papain, and bromelain are two widely used 
proteases, used in meat tenderisation that are derived from plants (papain from papaya, and bromelain 
from pineapple) (Rawlings and Barrett, 1994, Zatul et al., 2014).  The hydrolysates generated from 
these protein digests can be further processed using techniques such as FPLC, and RP-HPLC; the 
fractions generated can then be assayed for any bioactive properties.  Active fractions identified through 
assays are then further separated using HPLC to isolate individual peptides, and sequenced using 
MS/MS and de-novo sequencing (Ahmed et al., 2015) (Corrêa et al., 2014).  Sequences that are 
identified through de-novo sequencing can be cross checked with a number of databases that act as a 
depository of known bioactive peptides.  Multiple studies have been undertaken where sequence data 
is obtained in this manner.  The desired result is to discover new bioactive peptides, and determine what 
biological function they affect.  This approach can be structured as follows: Digestion – separate – assay 
– separate – sequence – synthesis - assay. 
 
HPLC coupled with MS/MS and de-novo sequencing can be used to identify peptides that show 
bioactivity, but data generated from this process can also be used to identify the host protein from which 
particular peptides was derived.  Identifying a host protein from samples such as those produced by 
Biofac is a useful method to understand the composition of the hydrolysates.  The raw material for each 
product is known, but it is not known exactly what proteins, and in what proportion they contribute to 
the bulk hydrolysates.  Having an understanding of the source proteins can be used to perform in silico 
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digests, using online tools such as BIOPEP (Minkiewicz et al., 2008) to generate a list of peptides that 
could be released as a result of the production method. 
 
In the case of the Biofac hydrolysates papain digestion was used, however, different proteases have 
differing specificity concerning where they cleave a protein.  Therefore, it is possible to perform in 
silico digests of the target protein with various proteases, that will cleave at different sites producing 
multiple peptide fragments, that demonstrate different modes of bioactivity (Jang and Lee, 2005).  The 
theoretical peptides generated using this method can then be analysed for possible bioactivity.  This 
method will produce a large amount of theoretical peptides.  To identify peptides that could be bioactive, 
the structures require analysis to single out interesting peptides, which not only have a high chance of 
demonstrating bioactivity, but also are novel peptides, in that they have not been previously reported in 
the literature.  For this study the online bioactivity prediction tool Peptide Ranker, developed by 
Bioware was used (Mooney et al., 2012).  This program assigns a rank to the likelihood of a peptide 
sequence being bioactive (0.0 being highly unlikely, 1.0 being highly likely).  The Peptide Ranker tool 
works by analysing the sequence of peptides, and relating them to known bioactive peptides.  Mooney 
et al (2012) noted that bioactive peptides that demonstrate different functional classes have certain 
attributes alike.  Therefore, these similarities can be used to predict if a peptide is likely to be bioactive, 
without indicating what sort of bioactivity will be displayed.  In developing the tool, they noted that 
elements that confer bioactivity differs in relation to the size of the peptide.  For example, it was reported 
that short peptides (< 20 amino acids) that scored highly were likely to contain phenylalanine (F).  The 
difference in the physical attributes that confer bioactivity between large, and small peptides is likely 
to be the ability of longer peptides to form tertiary structures (Mooney et al., 2012). 
 
This project was based on investigating the bioactive properties of hydrolysates of porcine liver, and 
placenta provided by the company Biofac, which were generated through papain hydrolysis.  Therefore, 
the focus of this section of work was on peptides generated through in silico hydrolysis with papain.  
However, this method could also be applied to different enzymes, in doing so it would be possible to 
identify peptides generated from different production methods prior to hydrolysis. To demonstrate this 
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it was decided to perform  in silico digestion on the precurser proteins using the gastic enzymes trypsin 
and pepsin at pH 1.3 (levels found in the stomach), and the pineapple derived enzyme bromelain.  The 
rationale behind using these particlar enzymes is that they have all been used in similar projects (Lafarga 
et al., 2014, Chatterjee et al., 2015), and that they are commerically available from companies such as 
Merck/Sigma-Aldrich.  These enzymes are also more specific than papain, so it is likely that they will 
generate larger peptides from the digestion (Minkiewicz et al., 2008). 
 
As has been mentioned, the methodology of the studies investigating the bioactivity of peptides 
generally follow a similar stratergy:  Separate the peptides in the hydrolysate; assay the fractions; isolate 
indivdual peptides in active fractions; synthesis of the peptides and repeat the assay.  The work carried 
out for this chapter focused on using in silico methods for identification of the host proteins that were 
hydrolysed to produce the peptides and identification of the peptides that would likely be produced by 
the particular enzyme used in the hydrolysis.  These peptides could then be analysed for the likelyhood 
of bioactivity and then manufactured and used in assays. 
 
This chapter will primarily investigate four synthetic peptides derived from hydrolysates of porcine 
liver, and placenta, supplied by Biofac. These peptides were selected after in silico analysis of sequence 
data derived from the hydrolysates that had been separated using HPLC.  The synthetic peptides selected 




5.2 Materials and methods 
 Isolation of individual fractions for MS analysis 
L2, and P2 hydrolysate solutions (5 mg/mL) were prepared in the aqueous HPLC running buffer 
(ultrapure water, acetonitrile (0.2 %), TFA (0.01 %)) and filtered using 0.2 µm syringe filters.  This was 
loaded onto an analytical HPLC column (Ascentis® Express Peptide ES-C18) using a 20 µL loading 
loop at a flow rate of 1 mL/min.  The concentration gradient of acetonitrile for all samples went from 
5% to 29% in 10 minutes followed by 29% to-95% in 5 minutes.  Samples were collected manually and 
tested by running the collected peak through the same HPLC setup to ensure that they only contained 
the desired peak.  Sample L2a was derived from the liver hydrolysate L2 and was collected from the 
fraction containing the peak at 6.017 minutes.  Sample L2b was collected from a similar fraction, from 
the same hydrolysate (L2) but on a different run.  This was done to evaluate the reproducibility of the 
method.  Sample P2a was derived from the placenta hydrolysate P2 and was collected from the fraction 
containing the peak at 6.1 minutes.  The concentration of the peptides in the samples isolated from the 
peak at 6.1 minutes were estimated using a standard curve.  Liver peptide solutions (80, 40, 20, and 10 
µg/mL) were prepared using the aqueous buffer with 5% acetonitrile.  The samples were analysed using 
a UV-Vis spectrophotometer at 220 nm that was blanked with the same buffer.  This method estimates 
the concentration of the peptide in relation to the amount of peptide bonds. 
 Peptide Sequencing Using MS/MS 
The three samples that were collected (L2a, L2b, and P2a), were shipped on dry ice to the Metabolomics 
& Proteomics Lab at the University of York for peptide sequencing using LC-MS/MS using a Bruker 
maXisHD mass spectrometer interfaced to a 50 cm PepMap column with a Bruker CaptiveSpray ion 
source.  Peptides were eluted from the column over a 35 min gradient at 300 nL/min.  Eluting peptides 
were selected for MS2 fragmentation using top speed data dependent acquisition, a dynamic 7-25 Hz 
acquisition rate and 1 s cycle time. Product ion spectra were searched against the porcine subset of the 
UniProt database (The UniProt Consortium, 2017) using Mascot, with no enzyme specificity.  Search 
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results were filtered to require expect scores of 0.05 or lower, this means that sequence matches have a 
equal to or less than a 1 in 20 chance of being a false positive, and therefore incorrect. 
 In silico digestion, and activity prediction 
In silico enzyme digestion were carried out on the protein sequences derived from the UniProt searches 
(cytosol aminopepsidase, haemoglobin subunit alpha, and type VI collagen alpha-1 chain), using the 
analysis tool available on the BIOPEP website (Minkiewicz et al., 2008).  Sequences were generated 
using papain, bromelain, pepsin (pH 1.3), and trypsin.  Generated sequences were then cross-referenced 
against a number of bioactive peptide databases to find any active sequences that have been previously 
reported.  Peptide sequences that had not been reported were then analysed using the Peptide Ranker 
tool by Bioware (Mooney et al., 2012).  Peptide Ranker predicts the likelihood of a peptide sequence 
being bioactive (0.0 being highly unlikely, 1.0 being highly likely). 
 Peptide synthesis and preparation 
Based on the in silico activity prediction, four synthetic peptides were ordered from Peptide Synthetics 
(Protein Peptide Research Ltd. Bishops Waltham, UK).  They were supplied as 10 mg aliquots of 
lyophilised powder.  The synthetic peptides were dissolved in deionised water to produce 10 mM stock 
solutions: 
• FWG:  In 10 mg/mL = 0.024 M = 24.48 mM.  10 mM = 10 mg/2.448 mL 
• MFLG:  In 10 mg/mL = 0.021 M = 21.43 mM.  10 mM = 10 mg/2.143 mL 
• SDPPLVFVG:  In 10 mg/mL = 0.011 M = 10.75 mM.  10 mM = 10 mg/1.075 mL 
• FFNDA:  In 10 mg/mL = 0.016 M = 16.32 mM.  10 mM = 10 mg/1.632 mL 
The dissolved peptides were aliquoted and stored at -20°C. 
 ORAC Assay 
The Oxygen Radical Absorbance Capacity of the synthetic peptides were analysed using the ORAC 
assay as described in section 4.2.2 with some alterations.  The synthetic peptides were used to generate 
stock solutions (100 µM) by diluting the specific synthetic peptide sample (10 mM) in 10 mM potassium 
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phosphate buffer (pH 7.4).  The stock solutions were used to prepare a concentration gradient ranging 
from 12.5 µM to 3.25 µM.  An off the shelf dipeptide Leucine-Glycine (LG) was used as another 
example of a synthetic peptide.  It was prepared in the same concentrations as the other peptides. 
 Cellular Antioxidant Activity Assay 
The CAA assay used to assess the antioxidant activity of the synthetic peptides followed the same 
method that was described in section 4.2.4.  Sample media used in the CAA was prepared by adding 
DCFH-DA to supplemented DMEM (10% FBS, 2% L-Glutamine (220 mM), 1% PenStrep) to a 
concentration of 5 µM.  The synthetic peptides were added to the sample media to generate 
concentrations of 25 and 50 µM.  Negative controls contained only DCFH-DA. 
 MTT assay 
A 96 well plate was seeded at 5 x 104 cells/mL (5 x 103 cells/well) using 3T3 fibroblasts cultured in 
supplemented DMEM (10% FBS, 2% L-Glutamine (220 mM), 1% PenStrep) approximately 24 hours 
prior to the addition of the synthetic peptides.  Peptide preparations (containing 100 – 3.25 µg/mL of 
synthetic peptide) were added to the plate and incubated at 37°C at 5% CO2 for 46 hours before 20 µL 
of MTT in PBS (5 mg/mL) was then added to each well. The plate was then incubated at 37°C at 5% 
CO2 for a further 4 hours, after which, the media was aspirated and 150 µL of DMSO was added.  The 
absorbance was then measured at 540 nm using a plate reader (applying a 5 second shake to ensure the 
samples were suitably mixed prior to the measurement).  Data were displayed as percentage 
proliferation, where the mean data for the control group was used as the base line for the experimental 
groups. Therefore, less proliferation than the control is displayed as a negative value, and more 
proliferation than the control is displayed as a positive value.  The percentage proliferation was 
calculated using equation 4.8. 
 Scratch assay 
To investigate potential wound healing activity of the synthetic peptides a scratch wound assay was 
performed. Briefly, 6 well plates were prepared as reported in section 4.2.10.2.  Synthetic peptides were 
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added to CGM (10 mL) to produce sample preparations.  Each sample preparation was then sterile 
filtered using 0.22 µm syringe filters.  The concentration for the preparations was 100 µM.  The 
procedure from this point followed that of section 4.2.10.2.  Wound closure rate (μm2/h) was calculated 
using equation 4.11 and percentage wound closure was calculated using equation 4.12. 
 Angiotensin converting enzyme (ACE) inhibition assay 
To assess the anti-ACE activity of the synthetic peptides, they were analysed using the ACE inhibition 
assay as described in section 4.2.12.  Synthetic peptide samples were prepared by diluting the 10 mM 
stock solutions using milli-q water to produce samples at 2 mM, 1 mM, and 0.1 mM. 
 Statistical analysis 
Data were analysed using one-tailed t-tests with equal variances assumed.  Statistical analyses were 
performed on triplicate data using Microsoft Excel with a p value < 0.05 considered significant. 
Standard deviation derived from the mean values were indicated with error bars. Where relevant, p-
values obtained in t-tests were included in the data to highlight significant differences, or where there 





 Isolation of individual peaks for MS analysis 
Three samples from fractions eluted from individual peaks were collected; L2a (Figure 5-1a) and L2b 
(data not shown) from the liver hydrolysate (L2) (peak at 6.017 minutes), and P2a (Figure 5-2a) from 
the placenta hydrolysate (P2) (peak at 6.1 minutes).  Samples of the collected fractions were analysed 
using HPLC using the same method used in the initial separation to check the purity of the aliquots 
(Figure 5-1b, and Figure 5-2b).  The chromatograms in Figure 5-1b, and Figure 5-2b indicate that 
the aliquots were pure.  The small peak at 1.117 minutes can be attributed to the solvent peak. 
 
Figure 5-1 Chromatograms indicating the fraction that was collected for Liver 160126-0700 (L2) (peak at 6.017 min) (a), and 




Figure 5-2 Chromatograms indicating the fraction that was collected for placenta 0-160330-1500 (P2) (peak at 6.100 min) 
(a), and the collected fraction loaded onto the column again to check for purity (peak at 6.250 min) (b) 
 Peptide Sequencing Using MS/MS 
The following peptides were identified in the samples:  
L2a:  TPANEMTPTR + Oxidation (M) – expect = 0.0033, mass error = 0.45 ppm 
L2b:  SAADKANVKAA – expect = 0.01, mass error = -0.43 ppm 
P2a:  YSGTGQQQPER – expect = 0.00048, mass error = -1.98 ppm, and NVINGGSHAGNK – 
expect = 0.0034, mass error = -0.02 
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The predicted peptides were cross-referenced using the UniProt database to find the host protein.  The 
structure of the peptides are shown in Figure 5-3 to Figure 5-6. 
TPANEMTPTR + Oxidation (M)  
Thr – Pro – Ala – Asn – Glu – Met – Thr – Pro – Thr – Arg 
 
Figure 5-3 Structure of the peptide TPANEMTPTR with methionine sulfoxide 
The host protein of this peptide was determined as cytosol aminopeptidase; an enzyme that can be found 
in the liver of mammals that facilitates the removal of N-terminal amino acid from peptides.  It can also 
cleave the N-terminal of amides and arylamides.  The peptide sequence is highlighted within the host 
protein sequence below: 
Amino Acid Sequence of Cytosol aminopeptidase (Sus scrofa) 
  1 mfllplpaaa rvavrqlsvr rfwgpgpdaa nmtkglvlgi yskekeddap qftsagenfd 
 61 klvsgklrei lnisgpplka gktrtfyglh edfssvvvvg lgkkgagvdd qenwhegken 
121 iraavaagcr qiqdleipsv evdpcgdaqa aaegavlgly eydelkqkkk vvvsaklhgs 
181 gdqeawqrgv lfasgqnlar hlmetpanem tptrfaevie knlksasskt dvhirpkswi 
241 eeqemgsfls vakgseeppv fleihykgsp dasdpplvfv gkgitfdsgg isikasanmd 
301 lmradmggaa ticstivsaa kldlpinlvg laplcenmps gkankpgdvv rakngktiqv 
361 dntdaegrli ladalcyaht fnpkviinaa tltgamdial gsgatgvftn sswlwnklfe 
421 asietgdrvw rmplfehytk qivdcqladv nnigkyrsag actaaaflke fvthpkwahl 




Ser – Ala – Ala – Asp – Lys – Ala – Asn – Val – Lys – Ala – Ala 
 
Figure 5-4 Structure of the peptide SAADKANVKAA 
The host protein of this peptide was determined as haemoglobin subunit alpha.  The peptide sequence 
is highlighted within the host protein sequence below: 
Haemoglobin subunit alpha (Sus scrofa) 
  1 mvlsaadkan vkaawgkvgg qagahgaeal ermflgfptt ktyfphfnls hgsdqvkahg 
 61 qkvadaltka vghlddlpga lsalsdlhah klrvdpvnfk llshcllvtl aahhpddfnp 
121 svhasldkfl anvstvltsk yr 
YSGTGQQQPER 
Tyr – Ser – Gly – Thr – Gly – Gln – Gln – Gln – Pro – Glu – Arg 
 
Figure 5-5 Structure of the peptide YSGTGQQQPER 
The host protein of this peptide was determined as Type VI collagen alpha-1 chain.  The peptide 
sequence is highlighted within the host protein below: 
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Type VI collagen alpha-1 chain, partial (Sus scrofa) 
1 fsspaditil ldgsasvgsh nfdttkrfak rlaerfltag rtdpahdvrv avlqysgtgq 
61 qqperaalqf lqnytvlast vdamgffnda tdvtdalgyv trfyreassg aakkkl 
NVINGGSHAGNK 
Asn – Val – Ile – Asn – Gly – Gly – Ser – His – Ala – Gly – Asn – Lys 
 
Figure 5-6 Structure of the peptide NVINGGSHAGNK 
The host protein of this peptide was likely to be enolase.  The peptide sequence is highlighted within 
the host protein below:  This sequence was not analysed for this project because it was not identified 
until after the practical work was completed. 
1 msiekiware ildsrgnptv evdlytakgl fraavpsgas tgiyealelr dgdkqrylgk  
61 gvlkavdhin ttiapalvss glsvveqekl dnlmldldgt enkskfgana ilgvslavck  
121 agaaerdlpl yrhiaqlagn sdlilpvpaf nvinggshag nklamqefmi lpvgaesfrd  
181 amrlgaevyh tlkgvikdky gkdatnvgde ggfapnilen sealelvkea idkagyteki  
241 vigmdvaase fyrdgkydld fkspadpsry itgdqlgaly qdfvrdypvv siedpfdqdd  
301 waawskftan vgiqivgddl tvtnpkrier aveekacncl llkvnqigsv seaiqackla  
361 qengwgvmvs hrsgetedtf iadlvvglct gqiktgapcr serlakynql mrieeelgde  
421 arfaghnfrn psvl   
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 In silico digestion, and activity prediction 
5.3.3.1 Known bioactive peptides 
All known bioactive peptides found using this method were dipeptides.  They fell within the following 
categories:  dipeptidyl peptidase IV inhibitors, ACE inhibitors, renin inhibitors, CaMPDE inhibitors, 
stimulating vasoactive substance release, regulating the stomach mucosal membrane activity, and 
antioxidant peptides.  In total there were 34 dipeptides found in the databases (Table 5-1 to Table 
5-5).  These peptides were entered into the Peptide Ranker tool as a test to assess how it would report 
known active sequences.  All the peptides were reported to have a high probability of bioactivity.  
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Table 5-1 Known bioactive peptides that were predicted from the in silico digest of cytosol aminopepsidase with papain.  
Data taken from the BIOPEP database 
Sequence Name Function Activity  
PG  
peptide regulating the 
stomach mucosal 
membrane activity 




- - antithrombotic 
prolyl endopeptidase 
inhibitor 
inhibitor of prolyl 
pndopeptidase (PEP) 
(EC 3.4.21.26) 









dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
VA  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
Peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
MA  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
Peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
FA  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
Peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 















inhibitor of renin (EC 







(abbrev. CaMPDE) (EC 
3.1.4.17). 
inhibitor 
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 






Table 5-2 Known bioactive peptides that were predicted from the in silico digest of cytosol aminopepsidase with papain.  
Data taken from the BIOPEP database cont. 
Sequence Name Function Activity  
LH  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 









peptide from soybean 
protein isolates: beta-








dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 









DA  ACE inhibitor 
inhibitor of angiotensin-
converting enzyme 





dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
SG  ACE inhibitor - ACE inhibitor 
TG  
ACE inhibitor - ACE inhibitor 
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
NG  
ACE inhibitor - ACE inhibitor 
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
VR  
ACE inhibitor from k-CN 
(fr. 67-68) 
Inhibitor of angiotensin-
converting enzyme (EC 
3.4.15.1) (MEROPS ID: 
XM02-001) 
ACE inhibitor 
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 






Table 5-3 Known bioactive peptides that were predicted from the in silico digest of cytosol aminopepsidase with papain.  
Data taken from the BIOPEP database cont. 
Sequence Name Function Activity  
QK  
ACE inhibitor from pea 
vicilin 
- ACE inhibitor 
NK  
ACE inhibitor from 
wakame 
- ACE inhibitor 
LY  
peptide from soybean 
protein isolates: beta-
conglycinin and glycinin 
- antioxidative 









dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
IH  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
MG  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
ACE inhibitor - ACE inhibitor 
NE  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
PK  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
QA  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
QE  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
SK  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
TK  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 






Table 5-4 Known bioactive peptides that were predicted from the in silico digest of Haemoglobin subunit alpha with papain.  
Data taken from the BIOPEP database 
Sequence Name Function Activity  
VA  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 










dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
TY  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
antioxidant peptide  antioxidative 
DA  ACE inhibitor 
inhibitor of angiotensin-
converting enzyme 





dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 














Table 5-5 Known bioactive peptides that were predicted from the in silico digest of Type VI collagen alpha-1 chain, partial 
with papain.  Data taken from the BIOPEP database 
Sequence Name Function Activity  
LA  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 











converting enzyme (EC 




ACE inhibitor  ACE inhibitor 
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
FA  
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
FY  ACE inhibitor 
inhibitor of angiotensin-
converting enzyme 




SG  ACE inhibitor  ACE inhibitor 
LG  ACE inhibitor 
inhibitor of angiotensin-
converting enzyme (EC 




dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 
dipeptidyl peptidase IV 
inhibitor 
TG  
ACE inhibitor  ACE inhibitor 
dipeptidyl peptidase IV 
inhibitor (DPP IV 
inhibitor) 
inhibitor of dipeptidyl 
peptidase IV (EC 
3.4.14.5) (MEROPS ID: 
S09.003) 






5.3.3.2 Predicted activity of peptides derived from simulated digests 
The Peptide Ranker results for the peptides generated from the simulated papain digest of cytosol 
aminopeptidase are presented in (Table 5-6 and Table 5-7).  The most potent peptide predicted was 
found to be FWG (1).  This also is an example of a peptide that had not been previously described in 
the literature.  The Peptide Ranker results for the peptides generated from the simulated papain digest 
of Haemoglobin subunit alpha are presented in Table 5-8.  The dipeptide WG (0.98) showed the 
greatest predicted bioactivity and the greatest predicted activity from a peptide that had not been 
reported was shown by MFLG (0.98).  The Peptide Ranker results for the peptides generated from the 
simulated papain digest of Type VI collagen alpha-1 chain, partial are represented in (Table 5-9).  The 
reported dipeptide FY (0.98) demonstrated the greatest predicted bioactivity (Minkiewicz et al., 2008, 
Mooney et al., 2012).  FFNDA (0.77) was the peptide that had yet to be reported that showed the greatest 
bioactivity. 
 
The majority of the fragments from all the simulated digests were single amino acids, with glycine 
representing the greatest predicted bioactivity (0.89).  Glycine is known to function in several roles as 
a neurotransmitter (Lopez-Corcuera et al., 2001).  All the simulated digests had the same single amino 
acids present, these were G, R, Y, H, A, K, and E.  
 
Simulated digests of the same protein were also carried out using the proteases trypsin, bromelain, and 
pepsin (at pH 1.3) (full data set in appendix IIa - IIl).  Predicted peptides with a predicted rank > 0.5 for 
all the digests (proteases and proteins) are represented in Table 5-10.  Selected peptides from this 




Table 5-6 Peptide Ranker scores for predicted papain digestion of cytosol aminopeptidase (1) 
Sequence    Score    Sequence    Score    Sequence    Score    Sequence    Score    
FWG 1 LG 0.72 SPDA 0.36 A 0.21 
WA 0.96 LG 0.72 MDIA 0.34 A 0.21 
FA 0.96 MFLLPLPA 0.71 LH 0.34 A 0.21 
MG 0.94 DMG 0.71 LH 0.34 A 0.21 
G 0.89 TFY 0.7 VPY 0.33 A 0.21 
G 0.89 MA 0.69 PK 0.33 A 0.21 
G 0.89 NMDLMR 0.66 PK 0.33 A 0.21 
G 0.89 PPLK 0.62 IR 0.33 A 0.21 
G 0.89 PPVFLE 0.6 PDA 0.32 A 0.21 
G 0.89 VDPCG 0.58 IY 0.32 A 0.21 
G 0.89 LR 0.57 SFLSVA 0.31 A 0.21 
G 0.89 LR 0.57 PTR 0.31 A 0.21 
G 0.89 VFTNSSWLWNK 0.55 PQFTSA 0.31 A 0.21 
G 0.89 R 0.55 LA 0.31 A 0.21 
G 0.89 R 0.55 MTPTR 0.3 A 0.21 
G 0.89 R 0.55 DR 0.29 A 0.21 
G 0.89 R 0.55 FSQDSA 0.28 A 0.21 
G 0.89 R 0.55 LILA 0.27 A 0.21 
  G 0.89 R 0.55 FVTH 0.25 A 0.21 
G 0.89 LY 0.52 VLG 0.24 A 0.21 
G 0.89 NMPSG 0.51 ITFDSG 0.24 A 0.21 
G 0.89 LFE 0.51 CTA 0.24 A 0.21 
G 0.89 VLFA 0.48 TPA 0.23 A 0.21 
G 0.89 Y 0.44 QIVDCQLA 0.23 A 0.21 
G 0.89 Y 0.44 LVLG 0.23 TG 0.19 
PG 0.88 Y 0.44 LME 0.23 TG 0.19 
PG 0.88 Y 0.44 H 0.23 QNLA 0.19 
CR 0.87 TFNPK 0.42 H 0.23 LDIA 0.19 
FLLR 0.86 SWIE 0.42 H 0.23 LK 0.17 
WQR 0.84 PLCE 0.42 H 0.23 ILNISG 0.17 
FLK 0.81 SG 0.41 NIR 0.22 NMTK 0.15 
NWH 0.78 SG 0.41 DFSSVVVVG 0.22 SA 0.14 
SDPPLVFVG 0.75 SG 0.41 IH 0.21 SA 0.14 
MPLFE 0.75 LDLPINLVG 0.41 A 0.21 SA 0.14 
VWR 0.73 NG 0.39 A 0.21 QLSVR 0.14 





Table 5-7 Peptide Ranker scores for predicted papain digestion of cytosol aminopeptidase (2) 
Sequence    Score    Sequence    Score    
NLK 0.14 K 0.06 
LVSG 0.14 K 0.06 
TR 0.13 K 0.06 
ISIK 0.13 K 0.06 
DVNNIG 0.13 K 0.06 
DDA 0.13 K 0.06 
DA 0.13 K 0.06 
DA 0.13 TLIE 0.05 
QA 0.12 TDVH 0.05 
VR 0.11 DQE 0.05 
TLTG 0.11 VVVSA 0.04 
IPSVE 0.1 VIE 0.04 
VIINA 0.09 VDDQE 0.04 
SSK 0.09 TIQVDNTDA 0.04 
VMTNK 0.08 SE 0.04 
TICSTIVSA 0.08 QE 0.04 
SIE 0.08 DE 0.04 
SK 0.07 DE 0.04 
DVVR 0.07 TK 0.03 
VA 0.06 NE 0.03 
VA 0.06 E 0.02 
QK 0.06 E 0.02 
NK 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 
K 0.06 E 0.02 




Table 5-8 Peptide Ranker scores for predicted papain digestion of Haemoglobin subunit alpha 
Sequence    Score    Sequence    Score    
WG 0.99 A 0.21 
MFLG 0.96 A 0.21 
FPH 0.94 A 0.21 
G 0.89 A 0.21 
G 0.89 A 0.21 
G 0.89 A 0.21 
G 0.89 A 0.21 
G 0.89 A 0.21 
FLA 0.89 A 0.21 
LR 0.57 LLSH 0.2 
R 0.55 VG 0.17 
R 0.55 VG 0.17 
PDDFNPSVH 0.5 LSA 0.17 
Y 0.44 MVLSA 0.16 
LDDLPG 0.44 SLDK 0.14 
FNLSH 0.42 DA 0.13 
VDPVNFK 0.41 QA 0.12 
FPTTK 0.34 TY 0.11 
LSDLH 0.27 SDQVK 0.11 
H 0.23 LTK 0.07 
H 0.23 VA 0.06 
H 0.23 QK 0.06 
H 0.23 NVSTVLTSK 0.06 
H 0.23 LE 0.06 
H 0.23 K 0.06 
CLLVTLA 0.22 K 0.06 
A 0.21 DK 0.06 
A 0.21 NVK 0.04 
A 0.21 E 0.02 




Table 5-9 Peptide Ranker scores for predicted papain digestion of Type VI collagen alpha-1 chain, partial 
Sequence    Score    Sequence    Score    
FY 0.98 A 0.21 
FA 0.96 A 0.21 
MG 0.94 A 0.21 
G 0.89 A 0.21 
FFNDA 0.77 TDPA 0.2 
LG 0.72 TG 0.19 
FSSPA 0.65 SH 0.16 
LL 0.62 SVG 0.15 
R 0.55 SA 0.14 
R 0.55 VLQY 0.12 
R 0.55 QQQPE 0.12 
R 0.55 DVR 0.12 
R 0.55 VA 0.06 
R 0.55 TVLA 0.06 
FLTA 0.51 STVDA 0.06 
Y 0.44 K 0.06 
SG 0.41 K 0.06 
LQFLQNY 0.33 K 0.06 
LA 0.31 K 0.06 
SSG 0.25 VTR 0.05 
H 0.23 TDVTDA 0.04 
DITILLDG 0.23 E 0.02 
NFDTTK 0.21 E 0.02 





Table 5-10 Predicted peptides with a predicted rank > 0.5 for all the digests (proteases and proteins).  Green highlighted 
peptides were selected for synthesis, yellow highlighted peptides are repeats, and red highlighted peptides have been 
reported in the literature as bioactive peptides 
Cytosol aminopepsidase derived peptides 
Papain Bromelain Pepsin Trypsin 




FLLR (0.86) FLK (0.81) MRADMGGAATICSTIVS
AAKL (0.83) 
SAGACTAAAFLK (0.74) 
WQR (0.84) SDPPLVFVG (0.75) CYAHTF (0.73) LDLPINLVGLAPLCENMP
SGK (0.74) 
FLK (0.81) LCY (0.73) YGL (0.72) VWR (0.73) 
NWH (0.78) MFLLPLPA (0.71) APL (0.7) ASANMDLMR (0.72) 
SDPPLVFVG (0.75) DMG (0.71) WNKL (0.69) GMAGR (0.61) 
MPLFE (0.75) PPLK (0.62) SVRRF (0.68)   
VWR (0.73)   NISGPPL (0.64)   
LCY (0.73)   HGSGDQEAWQRGVL 
(0.63) 
  




DMG (0.71)   ADVNNIGKYRSAGACTA
AAF (0.61) 
  
TFY (0.7)       
PPLK (0.62)       
PPVFLE (0.6)       
Haemoglobin subunit alpha derived peptides 
MFLG (0.96) FLA (0.86) PHF (0.94) AAWGK (0.66) 
FPH (0.94) FPHFNLSHG (0.76) ERMF (0.78)   
FLA (0.86) LERMFLG (0.66) PGAL (0.71)    
  DKF (0.66)    
  AAHHPDDF (0.64)    
  LSHCL (0.62)   
Type IV collagen alpha-1 chain partial derived peptides 
FFNDA (0.77) RFA (0.87) GYVTRF (0.64) FYR (0.94) 
FSSPA (0.65) FFNDA (0.77) ASTVDAMGF (0.6) FAK (0.62) 





5.3.3.3 Synthesised peptides 
The following peptides were selected to be synthesised and analysed (the host protein and the Peptide 
Ranker score are also reported):  FFNDA type VI collagen alpha-1 chain (0.77) (Figure 5-7), FWG 
cytosol aminopeptidase (1.00) (Figure 5-8), SDPPLVFVG cytosol aminopeptidase (0.75) (Figure 
5-9), and MFLG haemoglobin subunit alpha (0.96) (Figure 5-10).  These peptides were chosen 
because they all elicit a relatively high score from the Peptide Ranker tool, and have not been reported 
in the literature as being bioactive.   
 
Figure 5-7 The molecular structure of the peptide FFNDA 
 
 




Figure 5-9 The molecular structure of the peptide SDPPLVFVG 
 
Figure 5-10 The molecular structure of the peptide MFLG 
 
 ORAC assay 
The ORAC TE data for the synthetic peptides plus LG (Figure 5-13), that was derived from the data 
represented in the fluorescent traces (Figure 5-11 and Figure 5-12), indicated that FWG had a greater 
oxygen radical scavenging activity than Trolox (12.5 µM of FWG is equivalent to 19.2 µM of Trolox).  
For MFLG, 12.5 µM is equivalent to 6.47 µM of Trolox.  Both these peptides were soluble in aqueous 
solutions.  The other synthetic peptides plus LG gave a negative value at these concentrations; this 
indicated that at these concentrations they do not perform as oxygen radical scavengers.  TE (Table 













Figure 5-13 ORAC Trolox standard curve with the activity of the peptides at 12.5 µM plotted on the curve showing equivalence 
to Trolox concentration 








 Cellular antioxidant activity assay (CAA) 
The initial results for the CAA of the synthetic peptides indicated that they all demonstrated antioxidant 
activity, which is concentration dependant.  All the test samples demonstrated some protection of the 
DCFH when oxidative stress was introduced (slower rate of fluorescence increase than the control) 
(Figure 5-14).  FWG demonstrated the greatest antioxidant activity at 50 µM, this was significantly 
greater than FFNDA, and SDPPLVFVG, however, the difference with MFLG was not significant.  At 
25 µM, there was no significant difference in antioxidant activity between the samples (Figure 5-15). 
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Trolox control was assessed alongside the hydrolysate samples (section 4.3.4).  The concentration of 
Trolox was reported in mg/mL (data not shown).  To compare it to the synthetic peptides, 50 µM of 
Trolox is equal to 12.5 µg/mL, 6.25 µg/mL (25 µM) gave a CAA of 34.1%.  This is in a similar range 
as the synthetic peptides 
 
 
Figure 5-14 Fluorescence over time for synthetic peptides.  The cellular antioxidant activity (CAA) of each sample is derived 
by comparing the area under the curve (AUC) of the samples to the AUC of the negative control (c) 
 
Figure 5-15 Cellular antioxidant activity (CAA) (%) of synthetic peptides with significant results highlighted  
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 MTT Cell proliferation assay 
The MTT results used to generate cell proliferation data indicated that there was no significant increase 
in cell proliferation for the peptide treated samples.  Moreover, FWG, and SDPPLVFVG treated 
samples appeared to reduce proliferation at when treated at a concentration of 100 µM, Figure 5-16 a, 
and c. 
 
Figure 5-16 Cell proliferation data derived from (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) assay 
(percent proliferation relative to the control group) for synthetic peptides FWG (a), MFLG (b), SDPPLVFVG (c), and FFNDA (d) 
 Scratch assay 
The potential wound healing properties of the peptides were investigated using the scratch assay.  The 
data generated from the assay were used to calculate the rate of wound closure over 32 hours (all wounds 
had closed up by 38 hours).  The rate of wound closure (µm2/h) (Figure 5-17) for the samples treated 
with the synthetic peptides FWG, MFLG, and FFNDA were significantly less than the control groups.  
This indicates that at the concentrations used for this assay these peptides reduced cell taxis.  




Figure 5-17 Rate of scratch wound closure over 32 hours with control groups (c1, and c2) (no peptide); FWG, and MFLG with 




 ACE inhibition assay 
The synthetic peptides, and the hydrolysates had some inhibitory activity on ACE, which was 
concentration dependant.  Figure 5-18 shows the percentage inhibition on ACE of the synthetic 
peptides.  MFLG, and FWG showed a greater inhibitory effect than SDPPLVFVG, and FFNDA.  
SDPPLVFVG, (FFNDA was not assayed at 2 mM because there was not enough sample to prepare this 
concentration).  All synthetic peptides tested showed considerably less ACE inhibition activity than 
captopril (0.1 µM of captopril showed a percentage reduction of ACE activity of 98.7%, and 0.01 µM 
showed a percentage reduction of 88.7% data not shown). 
 
Figure 5-18 Percentage inhibition of angiotensin II converting enzyme (ACE) by the synthetic peptides FWG, MFLG, 





The aim of this section of the project was to develop a method that could identify bioactive peptides 
that were likely present within the Biofac porcine liver, and placenta hydrolysates.  Other studies have 
used similar techniques to analyse bioactive peptides but they generally start from peptides that have 
been isolated from active fractions (Lassoued et al., 2015, Lafarga et al., 2014, Cheung et al., 2009).  
This method was designed as a more high-throughput approach.  By sequencing straight after the initial 
separation, and using the BIOPEP database and Peptide Ranker utilities, it is possible to identify 
bioactive peptides before bioactivity assays are performed.  That being said, it has been reported that 
there are significant differences in the predicted bioactive peptides, and actual peptides found using 
empirical methods (Chatterjee et al., 2015).  This can be explained by the incomplete nature of these 
bioactive peptide databases, however, as the aim was to identify bioactive peptides that were not already 
in the databases, this was not a concern.  There is therefore, a chance that the peptides released from 
experimental enzyme digestion could be different to the predicted peptides. This could be the result of 
miss-cleavage because of varying quality of the enzymes used (Burkhart et al., 2012).  There is likely 
to be non-specific cleavage associated with the experimental process, therefore the complexity of the 
peptide profile of the hydrolysates cannot be just accreted to the specific enzyme used (in this case 
papain) (Picotti et al., 2007). However, if it is likely that a predicted peptide will be present, as in the 
case of this investigation, the overall complex nature of the hydrolysate is not a major concern. 
 
The method of using the host protein as a starting point for in silico enzymatic cleavage was developed 
because the chance of identifying a bioactive peptide from the HPLC MS/MS process is slim.  It does 
not appear to be an efficient way of uncovering bioactive peptides directly through HPLC, and 
sequencing.  All the peptides that were reported from the MS/MS data when processed by the BIOPEP 
data base showed no similarities with reported bioactive peptides, and when they were analysed using 
the Peptide Ranker tool by Bioware all the peptides were predicted to have a low probability of being 
bioactive.  While it was likely that no potential bioactivity was present in the peptides identified through 
MS/MS (section 5.3.2), the information about the host proteins was used in the in silico analysis in the 
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hunt for possible bioactive peptides.  The Biofac hydrolysate are produced in a certain way using the 
same type of raw material.  While it cannot be said that all the samples will be homogeneous, it is likely 
that a similar process will produce comparable results.  By identifying the host protein, it can be argued 
that a particular bioactive peptide is likely to be present in the hydrolysate.  Further analysis of the 
hydrolysates can then uncover further host proteins, ultimately generating a full-predicted profile for 
the product. 
 
The assays used to analyse the synthetic peptides were selected because they were used for the analysis 
of the crude hydrolysates, however, this method could be used to tailor assays to the 
peptides/hydrolysates rather than blindly selecting an assay based on what may be useful.  An example 
of this is the prevalence of ACE inhibitors identified in the hydrolysates.  The basic structure of ACE 
inhibitors, and how they work are well known (Wu et al., 2006, Vulupala et al., 2018).  This information 
therefore, can be used to select un-reported peptides that score highly on the peptide ranker tool, that 
have similar attributes to known ACE inhibitors. 
 
The data generated from the antioxidant assays (ORAC, and CAA) indicated that the prediction of 
bioactivity using the peptide ranker tool could supply useful results.  As mentioned previously, the 
group that developed Peptide Ranker discovered that in small peptides (< 20 amino acids), the presence 
of phenylalanine (F) was linked with bioactivity (Mooney et al., 2012).  All the peptides selected to be 
synthesised contained phenylalanine.  This could be related to the bioactivity demonstrated by FWG, 
and MFLG.  The ORAC assay indicated that the two peptides that ranked the highest, FWG (1), and 
MFLG (0.96), were significantly more potent antioxidant compounds than FFNDA (0.77), and 
SDPPLVFVG (0.75).  The Trolox equivalent value for FWG was 0.43. This means that for the peptide 
to exhibit the same ORAC value as 1 g of Trolox, 0.43 g of FWG would be required, indicating that 
FWG is a more potent antioxidant than Trolox.  MFLG demonstrated a TE of 0.94, therefore, has a 
similar antioxidant capacity to Trolox.  The TE for FFNDA, and SDPPLVFVG were 7.19, and 7.14 
respectively.  These scores are both relatively high, so they may exhibit some other bioactivity that is 
not related to the ORAC assay.  This method does indicate that the bioactivity prediction for FWG and 
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MFLG is related to antioxidant activity, but this does not mean that these peptides could not demonstrate 
any other bioactivity.  The CAA data showed that all the peptides demonstrated antioxidant activity that 
were similar to Trolox, with only FWG at 50 µM showing significantly more activity between the 
peptides.  All other samples were not significantly different (Figure 5-15).  The data from the 
antioxidant assays demonstrate that the predicted bioactivity is in some part related to antioxidant 
activity.  The differences between the two antioxidant assays can be explained by the antioxidant 
mechanism of each assay.  There is a great variety in mechanisms of oxidative stress, and antioxidant 
activity, and this is reflected in the types of in vitro assays used to for analysis.  Two different assays 
may use completely different mechanisms, and compounds may generate different results.  Therefore, 
compounds can only be determined as antioxidant in relation to a particular mechanism.  For example, 
FWG and MFLG displayed potent antioxidant properties when measured using the ORAC assay, but 
all four of the synthetic peptides tested were potent antioxidant peptides when analysed using a more 
complex system.  This would indicate that the mechanism of antioxidant activity is different for FWG 
and MFLF from FFNDA, and SDPPLVFVG. The CAA assay is therefore a good method to test 
antioxidant activity because it uses cells, and their entire metabolism to assess activity (López-Alarcón 
and Denicola, 2013). 
 
All samples tested reduced the activity of ACE.  There were significant differences between two groups 
of the synthetic peptides.  FWG and MFLG showed greater activity than SDPPLVFVG, and FFNDA.  
At the lowest concentation tested (0.1 mM), MFLG showed significantly more activity than FWG, this 
was not shown in the other concentrations (1 mM and 2 mM).  SDPPLVFVG and FFNDA were not 
assayed at 2 mM because there was not enough of these peptides to generate data at that concentration.  
Both FWG and MFLG were freely soluble in aqueous conditions whereas SDPPLVFVG and FFNDA 
were not as soluble.  This may be linked with the lower anti-ACE activity demonstrated with these 
peptides.  This could also be the reason that FFNDA, and SDPPLVFVG, did not show activity relative 




When the data from the synthetic peptides were compared to the anti-ACE activity of the hydrolysates 
from which they were derived (data not shown), it was clear that the placenta hydrolysate out performs 
the synthetic peptides in inhibition of ACE.  It would appear that because the placenta hydrolysate 
contains a large proportion of di-peptides, it has a greater effect on ACE inhibition. 
 
Captopril is by some margin a more potent ACE inhibitor than any of the samples tested here with 0.1 
µM able to cause a reduction in ACE activity of 98.7%, and even at a concentration of 0.01 µM showed 
a percentage reduction of 88.7%.  The fact that the synthetic peptides are less potent than captopril is 
not surprising when looking at the structure of the synthetic peptides in comparison to designed ACE 
inhibitors.  The synthetic peptides were not selected because they were likely to be potent anti-ACE 
compounds, but due to potential bioactivity.  It is clear that while they do show anti–ACE activity, it is 
not very high in comparison to other ACE inhibitors therefore the prediction of activity is unlikely to 
be associated with ACE inhibition. To compare the synthetic peptides used in this study to peptides 
used in similar investigations from the literature, the IC50 (Inhibitory Concentration at 50 %) values of 
each were calculated (Table 5-12).  It is useful to express these data as IC50 because it can be difficult 
to determine the point at which a substance is 100 % effective. 
Table 5-12 Inhibitory Concentration at 50 %(IC50) values for the synthetic peptides 






The review by Vercruysse et al. (2005), aimed to investigate ACE inhibitory peptides derived from 
animal muscle protein.  Selected data from this review (Table 5-13) shows the peptides that were 
generated from porcine muscle.  The ACE inhibitory IC50 values of these peptides ranged from 34 to > 
1000 µM.  The peptides synthesised in the present study mostly fall within this range, with MFLG (70 
µM) showing the greatest activity.  Another example of an ACE inhibitory peptide reported in the 
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literature reviewed for this thesis was the study carried out by Himaya et al (2012).  The peptide 
(LLMLDNDLPP) was derived from pacific cod skin gelatin.  The IC50 value was reported to be 35.7 
µM, with the authors suggesting that the prolines at the carboxyl end being important to the activity of 
the peptide. 
Table 5-13 Examples of angiotensin II converting enzyme (ACE) Inhibitory Concentration at 50 % ( IC50) values for peptides 
derived from porcine muscle.  Data in the review ‘ACE Inhibitory Peptides Derived from Enzymatic Hydrolysates of 
Animal Muscle Protein’ (Vercruysse et al., 2005) 
Peptide Parent Protein Enzyme ACE inhibition IC50 µM 
ITTNP myosin thermolysin 549 
MNPPK myosin thermolysin 945.5 
MNP myosin synthesized 66.6 
NPP myosin synthesized 290.5 
PPK myosin synthesized >1000 
ITT myosin synthesized 678.2 
TTN myosin synthesized 672.7 
TNP myosin synthesized 207.4 
RMLGQTPTK troponin C pepsin 34 
RMLGQTP troponin C pepsin 503 
  
The data sets reported here, from these two separate studies indicate that the peptide MFLG is 
comparable in terms of ACE inhibition.  The method used to select the synthetic peptides could be used 
to focus on peptides that are more likely to have anti-ACE activity.  The hydrolysate itself could be 
further investigated by using HPLC to create fractions, which could then be tested using this assay, as 
it is likely that there are potent anti-ACE peptides within the hydrolysate.   
 
Data generated for the investigation into wound healing (cell proliferation (MTT), and chemotaxis 
(scratch assay)) indicated that the synthetic peptides show no effect.  Both sets of data show that cells 
treated with the peptides did not propagate, or migrate differently to untreated cells.  The predicted 




The work carried out on the identification of potential bioactive peptides shows that it is possible to 
identify active peptides using the method developed in this study.  The results indicated that the 
predicted bioactivity of the synthetic peptides would likely include antioxidant activity.  FWG and 
MFLG showed activity better or comparable to Trolox in the ORAC assay, while all the peptides 
showed comparable activity to Trolox in the CAA assay.  Of the other assays used in this project, the 
ACE assay demonstrated that the predicted bioactivity could be related to ACE inhibition, and that there 
is no evidence to support wound healing activity. 
 
The information on the anti-ACE, and antioxidant activity of the peptides that were synthesised, and 
the examples of peptides that have been reported in bioactive peptide databases, indicate that there are 
multiple active peptides within the Biofac hydrolysates.  Further analysis of the samples could lead to 
better profiling of the hydrolysates, so the approximate amounts of the active peptides can be predicted 
for the individual products.  A good example is the large proportion of active dipeptides in the placenta 




 General Discussion, Future Work and Conclusions 
6.1 Original Project Aims 
The original aim of this project was to investigate the physicochemical properties, and bioactivity of 
hydrolysates derived from porcine heart, liver, and placenta.  These hydrolysates were produced by 
Biofac as commercial products to add monetary value to material that would otherwise be disposed of 
as waste.  This not only generates income from the sales of the product, but also removes the cost of 
processing the waste.  With a view to increasing the value of the hydrolysates, this project aimed to 
identify, and assign specific bioactivities of the peptides within the hydrolysates.  The methods used to 
analyse the hydrolysates were selected because they represented common bioactivities investigated in 
other studies recorded in the literature, namely antioxidant activity, anti-ACE activity, and wound 
healing.  Other potential bioactivities that have been previously reported in the literature for similar 
peptides that were not investigated in this study are antimicrobial, and immunomodulating activity.  The 
assessment of these particular bioactivities would be a logical extension to the work carried out in this 
thesis. 
 
The overall findings of the investigation into the bioactivity profiles of the hydrolysates were that the 
liver samples (L1, L2 and L3) demonstrated greater antioxidant activity than the placenta samples (P1 
and P2) (section 4.4.1), and that the placenta samples outperformed the liver in anti-ACE activity 
(section 4.4.5).  For reasons discussed previously, the investigation into the heart hydrolysate was not 
continued beyond the antioxidant activity (assayed using the DPPH, and lipid peroxidation method).  
The difference in antioxidant activity between the liver, and placenta hydrolysates was attributed to the 
greater proportion of proton donor residues within the liver hydrolysates compared to the placenta 
(section 4.4.1).  The diverse mechanisms of antioxidant activity, as discussed, do not all rely on this 
particular facet but proportion of proton donors present is definitely a reason behind the difference.  
Despite the greater activity demonstrated by the liver samples overall, the placenta samples did perform 
similarly to the liver in the lipid peroxidation (section 4.3.3), and the CAA assays (section 4.3.4).  
Indeed, the results for the CAA assay indicated that the placenta samples (P2) performed better than the 
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liver (L2).  The reason for this can be attributed to the greater proportion of smaller peptides within the 
placenta hydrolysates (section 4.3.6).  One of the most important factors in bioactive peptides (and all 
pharmaceutics in general) is the ability of the target compound to be able to reach the desired area in 
the body (bioavailability).  Where the chemical based assays do not have this limitation, the CAA assay 
does, whereby the peptides need to either interact with the membrane, or pass through the membrane 
into the cytoplasm.  Large molecules such as peptides do not readily diffuse across cell membranes, but 
small, hydrophobic peptides should pass through more easily.  An example of a cellular mechanism that 
allows small peptides (di, and tri-peptides) is the oligopeptide transporter PepT1 (Yang and Hinner, 
2015). 
 
The greater proportion of small peptides in the placenta hydrolysate (P2) can also be attributed to the 
greater anti-ACE activity demonstrated by P2 when compared to the liver hydrolysate L2 (section 
4.3.9).  The performance of P2 in the ACE inhibition assay suggests that it is the multitude of di-peptides 
that are likely to be present (section 4.3.7.2).  The databases of known bioactive peptides, which have 
anti-ACE activity (such as BIOPEP) consist mainly of di-peptides.  The in silico work carried out for 
this project identified a number of known di-peptides derived from the host proteins with anti-ACE 
activity (Table 5-1, Table 5-2, Table 5-3, Table 5-4, and Table 5-5), therefore, it is likely that 
similar sequences are present in the full hydrolysate. 
6.2 High throughput screening method development 
Over the course of this study, the analysis of the bioactivity of the hydrolysates shifted from screening 
the full hydrolysates to the identification of active components contained within the hydrolysates.  This 
is a common theme in the literature where research is aimed at identifying specific sequences isolated 
from fractions of hydrolysates that were found to be bioactive.  For this study a method that used a 
different tactic was developed, favouring a more theoretical approach that identified peptides that were 




The rationale behind this was to develop a high throughput screening method that could be used to 
determine a good source of bioactive peptides without performing some or all of the steps reported in 
the literature.  In the case of the Biofac hydrolysates, de-novo sequencing was performed to discover 
the host protein of an isolated peptide, but this step could be removed when analysing possible protein 
sources, of which the constituent protein is known (chickpeas for example, see section 6.4).  The de-
novo sequencing step could also be removed from subsequent analysis of the Biofac hydrolysates, 
however, this would require further work to confirm that common proteins found in the starting material 
(porcine organs) relate to the peptides found in the finished product. 
 
The peptides that were synthesised from the data generated through this method were analysed using 
the same techniques that were applied to the full hydrolysates.  The results indicate that the use of 
activity prediction algorithms did result in bioactive peptides.  Like the full hydrolysates, only 
antioxidant activity, and anti-ACE activity were found in the peptides.  FWG, and MFLG showed the 
greater antioxidant activity overall (FFNDA, and SDPPLVFVG performed poorly in the ORAC assay 
(section 5.2.5) but showed similar activity in the CAA assay (section 5.5.6)).  They also showed the 
greater activity in the anti-ACE assay (5.3.7).  It is likely that there is other activity, which these peptides 
will show, however, one of the limitations of the method is the inability of the Peptide Ranker algorithm 
to predict the specific type of activity.  There are other algorithms that can be found that concentrate on 
specific activities, for example, AHTpin is an anti-ACE peptide predictor (Kumar et al., 2015), AntiCP 
is an anti-cancer peptide predictor (Tyagi et al., 2013), and AntiBP is an anti-microbial predictor (Lata 
et al., 2007).  The use of these, alongside a robust range of assays that cover a wider range of 
bioactivities would be a way of improving the discovery of novel bioactive peptides. 
6.3 Future Work 
The investigation into the bioactivity of the hydrolysates supplied by Biofac began with researching the 
full hydrolysates along with the physicochemical properties of the powders.  The study progressed onto 
the molecular make-up of selected peptides that constitute the hydrolysates and subsequently, led to the 
development of the method described in section 5.2.3.  Future work that could be carried out following 
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on from this investigation would likely follow a similar direction as described in this thesis.  This would 
likely involve the further investigation into the physicochemical attributes, the continuation of 
bioactivity assays on the full hydrolysates, and extending the work carried out on the screening methods 
developed in chapter 5.  The method could also be applied to new sources of peptides, that could be of 
interest to Biofac. 
 
The investigation into the physicochemical properties of the hydrolysates was performed to gain a basic 
understanding of the materials physical behaviour and was not designed to be a comprehensive study 
applied to a specific functionality. This therefore, leaves scope to investigate these properties in relation 
to production methods (are the drying processes the ideal methods), and maybe more interestingly 
formulation of potential dosage forms.  If a certain bioactivity can be associated with the current or 
future products, understanding how they can be developed to successfully administer the products 
would also be worthwhile. 
 
The range of bioactivities that were used during this study could be extended to include the study of 
activities not investigated for this project such as antimicrobial, and immunomodulation as discussed in 
chapter 1, and investigate activities such as antioxidative, and anti-ACE using different assays to gather 
a more complete picture of bioactivity of the hydrolysates. 
 
The synthetic peptides that were derived from the work carried out for chapter 5 were analysed to a 
certain degree, but there are more assays that could be used to analyse bioactivity that have not been 
used in this study.  An important factor that was not investigated in this study was the structure activity 
relationship (SAR) of the synthetic peptides in relation to their bioactivity.  While the presence of 
phenylalanine in the peptides was an indication that they were bioactive, the relationship to the other 
amino acids in the sequence was not studied (Mooney et al., 2012).  The SAR of bioactive peptides can 
be demonstrated by the activity of the peptide being compared with a mixture of its component amino 
acids.  This was demonstrated by Chen et al (2015) where they analysed the antioxidant activity of 
peptides derived from defatted walnuts; when they analysed the amino acids that constituted these 
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peptides, no activity was found (Chen et al., 2015).  This finding suggests that the sequence of amino 
acids in a peptide are vital to activity (Zou et al., 2016).  The sequence of the amino acids in the peptides 
investigated in this project could explain the differences in activity in conjunction with other factors 
such as solubility, and the peptide being amphiphilic (Zou et al., 2016).  Another important factor with 
sequence is how the amino acids interact with its adjacent partner.  Bamdad et al (2015) demonstrated 
that if a glutamic acid is next to a tyrosine, the second carboxyl side chain can cause a proton to be 
released from the phenolic hydroxyl in tyrosine.  This change in the the tyrosine residue, facilitated by 
its conjunction with glutamic acid increases the antioxidant activity of the peptide (Bamdad et al., 2015).  
Future investigation into the peptides generated in this project, and those that could be derived through 
in silico digests using different enzymes would benefit from studying possible SARs of said peptides. 
 
The investigation into the theoretical bioactive peptides from the in silico protease digestions only used 
synthesised peptides that were the product of papain digestion, however, other enzymes were used 
(bromelain, trypsin, and pepsin).  The data gathered from these enzymes could also be investigated 
using the same method.  More importantly, this method could be applied to different sources of proteins 
such as the one described in section 6.4 that looks at the possibilities of using chickpeas as the protein 
source.  Using a less complex hydrolysate, or isolating proteins from the raw material prior to 
hydrolysation, would be a logical step in proving the concept of the screening method.  Finally, the use 
of more specific peptide activity prediction algorithms, like the ones discussed in section 6.2, after the 
initial use of Peptide Ranker could refine the method, and increase the chance of identifying a novel 
bioactive peptide. 
6.4 Theoretical digestion of proteins found within chickpeas 
Chickpeas are a prominent target for bioactive peptide research.  Numerous studies have been 
undertaken on peptides isolated from chickpea hydrolysate, some of which have been discussed in this 
study (Xue et al., 2012, Xue et al., 2015).  Three important globulin proteins present in chickpeas are 
legumin 11S, vicilin 7S, and convicilin 15S (Schwenke, 2001).  For this demonstration of the method 
developed here, legumin 11S was selected as the protein of interest, and trypsin chosen as the enzyme.  
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The known sequences identified as bioactive by the BIOPEP database (Table 6-1) follow the trend 
found in the digestions performed for the proteins derived from the Biofac hydrolysates, namely being 
short (2 to 3 residues), and demonstrating anti-ACE activity.  The peptides sequences that have not been 
reported on the BIOPEP database are represented in Table 6-2.  
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Table 6-1 Know bioactive peptides generated from trypsin digest of chickpea legumin 11S 
Sequence Name Function Activity 
PR ACE inhibitor 
Inhibitor of Angiotensin-Converting 
Enzyme (ACE) (EC 3.4.15.1) 
(MEROPS ID: XM02-001) 
ACE inhibitor 
LHR synthetic peptide  antioxidative 
LR ACE inhibitor 
Inhibitor of Angiotensin-Converting 
Enzyme (ACE) (EC 3.4.15.1) 
(MEROPS ID: M02-001) 
ACE inhibitor 
GR ACE inhibitor 
Inhibitor of Angiotensin-Converting 
Enzyme (ACE) (EC 3.4.15.1) 




from k-CN (fr. 
67-68) 
Inhibitor of angiotensin-converting 








Inhibitor of Dipeptidyl Peptidase IV 











Inhibitor of Dipeptidyl Peptidase IV 














Inhibitor of Dipeptidyl Peptidase IV 










Table 6-2 Un-reported peptides generated from trypsin digest of chickpea legumin 11S 
 
 
The sequences generated from the in silico tryptic digest of chickpea legumin 11S, alongside MFLG, 
FFNDA, and SDPPLVFVG, were analysed using Peptide Ranker (Mooney et al., 2012), and the 
AHTpin tool (Kumar et al., 2015), which predicts the likelihood of a peptide sequence demonstrating 
anti-ACE activity. The predicted scores (Table 6-3) indicate that the peptide 
MAAPPSMLWLLLLALLVLGVR from legumin 11S would have a 98% chance of being bioactive, 
with a 72% chance of demonstrating anti-ACE activity.  For comparison, the three synthetic peptides 































tested that were made for this study ranked lower.  Interestingly, MFLG ranked lower than FFNDA, 
which is a contradiction to the data generated in this study (the greater solubility of MFLG is the likely 
reason for this).  This highlights the importance of empirically testing the peptides as well as running 
the simulation. 
Table 6-3 The probability of general activity (using Peptide Ranker (Mooney et al., 2012)), and anti-angiotensin II converting 
enzyme (ACE) activity of Selected peptides from the tryptic digest of chickpea legumin 11S , and three of the synthetic 
peptides produced for this study (yellow highlighted)  using the AHTpin is an anti-ACE peptide predictor (Kumar et al., 2015) 
Peptide Activity prediction anti-ACE prediction 
MAAPPSMLWLLLLALLVLGVR 0.98 0.72 
GAGR 0.56 0.3 
MFLG 0.98 0.61 
FFNDA 0.77 0.69 
SDPPLVFVG 0.75 0.58 
 
This example demonstrates that in a relatively short period of time, a large amount of sequences can be 
identified, and screened.  The use of the general ranking algorithm, Peptide Ranker indicated that 
MAAPPSMLWLLLLALLVLGVR is extremely likely to be bioactive.  The type of activity has then 
been narrowed down using a more specific programme.  The peptide of interest can then be synthesised, 





The Biofac hydrolysates all exhibited antioxidant activity to a certain extent, depending on the 
mechanism of action of the assay used for analysis.  All batches of hydrolysates tested with the lipid 
peroxidation assay for example reduced autoxidation in linoleic acid, there were however major 
differences between the batches demonstrated in the other antioxidant assays.  In general, it can be said 
that liver hydrolysates performed better than placenta, the overall order being L1 > L2 > L3 > P2 > P1.  
The other significant area of bioactivity demonstrated in the hydrolysates was anti-ACE.  Here the 
placenta hydrolysate P2 outperformed the liver hydrolysates L2, and L3, which had very similar 
activities.  It should be noted that the levels of activity were much lower than that of the ACE inhibitor 
captopril, but the complex nature of the hydrolysates might lead to the active components (most likely 
dipeptides) being greatly diluted.  These sets of data indicate that there is evidence that the hydrolysates, 
can be protective against oxidative stress, and hypertension, however, in-vivo studies would be required 
to ensure the peptides are bioavailable and to determine whether the activity was at therapeutic levels. 
 
The data generated through the characterisation, and identification of the peptides within the 
hydrolysates indicate that there is a possibility to further refine the hydrolysates to isolate more active 
components.  This information could be used to either extend the manufacturing process at Biofac to 
create a product with greater value, or be used by the customers of Biofac in their own use of the 
products. 
 
Finally, the method used to predict the presence of bioactive peptides within hydrolysates utilising de-
novo sequencing, and in silico analysis tools shows promise in the discovery of new bioactive peptides.  
This method could identify interesting potential targets before the time consuming process of 
discovering them empirically.  The time constraints on this study led to only a small number of peptides 
being investigated in this fashion, but it is likely there are multiple undiscovered bioactive peptides 
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Appendix I:  Amino Acid Composition of the Biofac Hydrolysates 
Heart 150615-1900 (H1) 
Amino Acids g % 
Serine 3.3 4.6 
Glutamic Acid 10.7 14.8 
Proline 4.1 5.7 
Glycine 5.7 7.9 
Alanine 5.3 7.3 
Valine 4.3 5.9 
Isoleucine 3.1 4.3 
Leucine 6.5 9.0 
Tyrosine 2.3 3.2 
Phenylalanine 3.2 4.4 
Threonine 3.3 4.6 
Arginine 4.2 5.8 
Lysine 6.1 8.4 
Hydroxyproline 1.1 1.5 
Histidine 1.5 2.1 
Aspartic Acid 7.0 9.6 
Ornitine 0.6 0.9 




Placenta 0-150625-1700 (P1) Placenta 0-160330-1500 (P2) 
Amino Acids g % Amino Acids g % 
Serine 2.8 3.7 Serine 2.8 3.7 
Glutamic Acid 9.18 12.0 Glutamic Acid 9.18 12.0 
Proline 8.44 11.0 Proline 8.44 11.0 
Glycine 15.4 20.1 Glycine 15.4 20.1 
Alanine 7.17 9.4 Alanine 7.17 9.4 
Valine 2.59 3.4 Valine 2.59 3.4 
Isoleucine 1.42 1.9 Isoleucine 1.42 1.9 
Leucine 3.5 4.6 Leucine 3.5 4.6 
Tyrosine 0.887 1.2 Tyrosine 0.887 1.2 
Phenylalanine 2.01 2.6 Phenylalanine 2.01 2.6 
Threonine 1.92 2.5 Threonine 1.92 2.5 
Arginine 5.77 7.5 Arginine 5.77 7.5 
Lysine 3.43 4.5 Lysine 3.43 4.5 
Hydroxyproline 5.93 7.7 Hydroxyproline 5.93 7.7 
Histidine 0.906 1.2 Histidine 0.906 1.2 
Aspartic acid 5.26 6.9 Aspartic acid 5.26 6.9 
Ornitine 0.05 0.1 Ornitine 0.05 0.1 




Liver 150615-1900 (L1) Liver 160126-0700 (L2) Liver 170127-0815/33155 (L3) 
Amino Acids g % Amino Acids g % Amino Acids g % 
Serine 3.1 5.1 Serine 3.43 5.3 Cystein+Cystein 0.662 1.1 
Glutamic Acid 8.61 14.1 Glutamic Acid 9.16 14.2 Methionin 1.46 2.5 
Proline 3.52 5.8 Proline 3.54 5.5 Lysine 4.05 6.8 
Glycine 4.05 6.6 Glycine 4.35 6.7 Threonine 3.15 5.3 
Alanine 4.19 6.9 Alanine 4.54 7.0 Isoleucine 3.02 5.1 
Valine 4.29 7.0 Valine 4.85 7.5 Leucine 5.25 8.8 
Isoleucine 3.21 5.3 Isoleucine 3.49 5.4 Histidine 1.58 2.7 
Leucine 6.04 9.9 Leucine 6.58 10.2 Phenylalanine 3.35 5.6 
Tyrosine 0.812 1.3 Tyrosine 0.886 1.4 Tyrosine 0.825 1.4 
Phenylalanine 3.12 5.1 Phenylalanine 3.58 5.6 Valine 4.48 7.5 
Threonine 3.1 5.1 Threonine 3.45 5.4 Alanine 4.39 7.4 
Arginine 1.38 2.3 Arginine 1.17 1.8 Arginine 0.808 1.4 
Lysine 5.12 8.4 Lysine 5.11 7.9 Aspartic Acid 5.15 8.7 
Hydroxyproline 0.326 0.5 Hydroxyproline 0.05 0.1 Glutamic Acid 7.42 12.5 
Histidine 1.68 2.8 Histidine 1.75 2.7 Glycine 3.97 6.7 
Aspartic Acid 6.3 10.3 Aspartic Acid 6.23 9.7 Hydroxyproline 0.193 0.3 
Ornitine 2.11 3.5 Ornitine 2.31 3.6 Ornitine 2.16 3.6 
Total 60.958 100 Tryptophane 1.06 1.6 Proline 3.19 5.4 
   
Cystein+Cystein 0.869 1.3 Serine 3.14 5.3 
   
Methionin 1.61 2.5 Tryptophane 1.19 2.0 
   





Appendix IIa:  In Silico Papain Digest of Cytosol Aminopepsidase Data 
 
 































































































































































































































Appendix IIb:  In Silico Bromelain Digest of Cytosol Aminopepsidase Data  
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Appendix IIc:  In Silico pepsin (pH 1.3) Digest of Cytosol Aminopepsidase Data  
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Appendix IId:  In Silico Trypsin Digest of Cytosol Aminopepsidase Data  
 
Sequence    Score 











































Sequence    Score 
























Appendix IIe:  In Silico Papain Digest of Haemoglobin Sub-unit Alpha Data  
 































































Appendix IIf:  In Silico Bromelain Digest of Haemoglobin Sub-unit Alpha Data  
 
















































Appendix IIg:  In Silico Pepsin (pH 1.3) Digest of Haemoglobin Sub-unit Alpha 
Data 
 





























Appendix IIh:  In Silico Trypsin Digest of Haemoglobin Sub-unit Alpha Data 
 

















Appendix IIi:  In Silico Papain Digest of Type VI collagen alpha-1 chain Data 
 



















































Appendix IIj:  In Silico Bromelain Digest of Type VI collagen alpha-1 chain 
Data 
 





































Appendix IIk:  In Silico Pepsin (pH 1.3) Digest of Type VI collagen alpha-1 
chain Data 
 




















Appendix IIl:  In Silico Trypsin Digest of Type VI collagen alpha-1 chain Data 
 
Sequence    Score    
FYR 0.94 
LL 0.62 
FAK 0.62 
R 0.55 
R 0.55 
FLTAGR 0.54 
FSSPADITILLDGSASVGSHNFDTTK 0.28 
TDPAHDVR 0.2 
EASSGAAK 0.16 
LAER 0.1 
VAVLQYSGTGQQQPER 0.08 
K 0.06 
K 0.06 
AALQFLQNYTVLASTVDAMGFFNDATDVTDALGYVTR 0.02 
 
